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Abstract 
 
 
Thyrotropin signalling links skin and thyroid disease 
 
Thyroid dysfunction is frequently associated with skin and hair diseases; however, the underlying 
pathogenic mechanisms are poorly understood. Pathological activation of the thyroid stimulating 
hormone receptor (TSHR) is the key feature of both hyper- and hypo-thyrodism. Expression of the 
(TSHR) has been reported in several extra-thyroidal locations including adipose tissue, bone and 
skin fibroblasts. TSHR expression may explain the association between the thyroid and skin 
disease. The TSHR can also be activated by a newly discovered glycoprotein hormone, known as 
thyrostimulin. This hormone is composed of a dimer of unique α 2 and β 5 subunits. Although 
thyrostimulin has not been detected in the circulation. However, both subunits have been shown to 
be expressed in different tissues including the skin. The aim of this study is to examine the 
expression of the TSHR and thyrostimulin in the skin. In addition, to investigate the expression of 
a variant form of the TSHR in human and mouse skin and, other mouse tissues. RT-PCR using 
primers specific for the full length receptor and the truncated variant revealed that although the 
variant was widely expressed in mouse tissues including skin, it was not found in human skin. The 
full length receptor and thyrostimulin were found to be co-expressed in eye, testis and skin. 
Immunohistochemistry of frozen skin and thyroid sections using commercially available antibodies 
against the extracellular (A9) and transmembrane domains (A7) of TSHR demonstrates that TSHR 
is not expressed in the epidermis but expressed in dermal fibroblasts and in myoepithelium around 
sweat glands.  A new β5 antibody was characterised by western blotting and 
immunohistochemistry for future investigation of β5 expression in the skin.  These data suggest a 
functional role for TSHR signalling possibly via thyrostimulin in the skin and that the variant form, 
although potentially present in some tissues, is unlikely to be important in human skin.  
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1. Chapter One 
 
1.1 Skin Biology 
1.1.1 Skin structure  
 
An insight into normal skin structure and differentiation is crucial for understanding the 
molecular biology of skin. The skin makes up approximately 15% of the total body weight 
and covers a surface area of about two square meters. Skin has several vital functions. Its 
most important functions are to form an effective barrier between the inside and the 
outside of the body, thermoregulation through sweating and protection against harmful UV 
rays via melanin synthesis (melanocytes)
1
. It also has an antimicrobial function and a 
major role in immunity (Langerhans and T-Cells).  Morphologically, the skin is composed 
of two layers, the outer epidermis and the inner dermis, underneath the dermis (but not part 
of skin) is the hypodermis or the subcutaneous layer. The epidermis and dermis are 
separated by a basement membrane. The skin has a number of appendages including 
pilosebaceous gland (hair follicles & sebaceous glands), nails, apocrine and eccrine sweat 
glands
2
. 
 
The epidermis is a stratified squamous epithelium and the dermis is a connective tissue 
consisting of fibroblasts and structural proteins such as collagens and fibronectin
3
. The 
dermal epidermal junction is undulating where ridges of the epidermis, known as rete 
ridges, project into the dermis. The basement membrane lies at this junction and provides 
mechanical support for the epidermis and acts as a partial barrier against exchange of cells 
and large molecules. Underneath the dermis is a fatty layer, the panniculus adipose tissue, 
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usually designated as ‘subcutaneous’ tissue 3. There are two main types of human skin. 
Glabrous skin (non hairy skin), found on the lips, palms and soles, is grooved on its 
surface and characterized by; thick epidermis, the presence of encapsulated sense organs 
within the dermis and, the lack of hair follicles and sebaceous glands. On the other hand, 
hair-bearing skin has both hair follicles and sebaceous glands but lacks the encapsulated 
sense organs
3
. 
 
1.1.1.1The epidermis 
The epidermis consists largely of differentiated stratified squamous epithelium. The main 
cell component of the epidermis is the keratinocyte. However, there are several other cell 
populations namely melanocytes which donate pigment to keratinocytes, Langerhans cells, 
which have immunological functions and Merkel cells are also present but in small 
numbers
1,3
. The main function of melanocytes is the production of pigment secreted in 
melanosomes and transferred to the keratinocytes, forming a supranuclear cap to protect 
nuclear DNA from UV radiation. Langerhans cells are important for immune surveillance 
and Merkel cells are transducers of fine touch stimuli
1,3
. 
 
In normal epidermis, the keratinocyte regenerate continuously by division and give rise to 
several layers as they move upwards, a process known as epidermal differentiation
3,4
.  Cell 
division occurs primarily in the basal layer where cells are attached to the basement 
membrane. Due to a poorly understood trigger, certain basal cells released from the 
basement membrane, lose their mitotic activity, stop dividing and begin to differentiate, 
stratify and change morphologically and biochemically. These triggered cells begin to 
synthesize a new set of structural proteins and enzymes that are characteristic of 
differentiation
1,4
. Histologically, the epidermis is divided into four layers; stratum basale 
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(basal layer), stratum spinosum (spinous layer), stratum granulosum (granular layer) and 
stratum corneum (horny layer) (figure 1.1)
5
.  
 
 Figure 1.1:  Skin cartoon showing cellular component of epidermis (adapted from 
Champion, R,1998)
5
  
 
The stratum basale is the lower most cell layer and contains the germinative cells and is 
attached to the basement membrane (basal lamina) which separates the dermal layer from 
the epidermis
4
. The small columnar or cuboidal cells are attached to the basement 
membrane at hemidesmosomes and to the surrounding cells by desmosomes
1,6,7
.  Keratin 5 
(K5) and keratin 14 (K14) are expressed in these mitotically active basal layer cells, and 
their expression is down-regulated as cells differentiate. The rate of basal cell proliferation 
is under the control of a variety of intrinsic and extrinsic factors
1,4
. The stratum spinosum 
is located immediately above the stratum basale layer and is named for the spine-like 
appearance of the cell border which is due to the presence of numerous desmosomes 
joining adjacent cells
3
. Morphologically the cells are more cuboidal than the basal cells 
with a rounded nucleus. The spinous cells are metabolically active. Here, the cells dedicate 
most of their protein synthesis to synthesize new keratins K1 and K10 which replace the 
pre-existing K5 and K14
1,3
. Involucrin is another important protein in terms of epidermal 
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differentiation which is expressed by the spinous cells and forms the initial scaffold 
adjacent to the inner aspect of the plasma membrane for cell envelope formation
2,4
. 
Furthermore, the lamellar granules are made at this stage, they are found in the upper 
spinous and granular layers adjacent to the cell membrane which will subsequently fuse 
with the plasma membrane and release lipids into the intercellular space of the granular 
layer and the stratum corneum
4
. 
 
The granular layer lies just above the spinous layer, so named due to the presence of 
keratohyalin granules. The keratohyalin granules are composed mainly of Profilaggrin 
which is a high molecular mass precursor of the protein filaggrin (FLG) an important 
structural protein essential for the formation of a functional environmental barrier
3,4
.  At 
this stage the cells stop generating keratin and envelope proteins, and start their final 
tailoring in protein synthesis, including production of filaggrin which aggregates the 
keratin filaments into tight bundles
4
.  Moreover, loricrin which is major structural protein 
component of the cornified envelope is also synthesized here at a later stage
8
. 
 
Additionally, lipid-filled lamellar granules or lamellar bodies are found in the upper 
spinous and granular layers adjacent to the cell membrane. The intercellular skin lipids are 
synthesised and stored in these lamellar granules, which fuse with the plasma membrane 
and release their lipid contents into the extracellular space in the upper granular layer 
during keratinisation
1
. Complex changes in lipid composition occur after the extrusion of 
the contents of the lamellar granules by enzymatic action of a group of acid hydrolases, 
which are also secreted into the extracellular space forming an important barrier to 
permeability
9,10
. Skin lipids play important roles in barrier function which help to avoid 
trans-epidermal water loss and intercellular cohesion within the stratum corneum
4,11
.  
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The stratum corneum or the cornified layer is the outermost layer of the epidermis and is 
composed of terminally differentiated keratinocytes sealed together by lipids
4
.  During the 
transition from the granular to cornified layer, the keratinocyte (now named corneocytes) 
loses its nuclei and cytoplasmic organelles. The cells become flattened and the keratin 
filaments align into disulphide cross-linked macrofibers, under the influence of filaggrin. 
This promotes the collapse of the cells into a flattened shape which is characteristic of 
corneocytes. The corneocytes also contain remnants of organelles, melanin pigment, and 
membrane profiles
1
. Together, keratins and filaggrin constitute 80-90% of the protein mass 
of mammalian epidermis and the series of changes whereby keratin filaments aggregates 
into bundles through the action of filaggrin is known as keratinisation (squame 
biogenesis)
12
.   
  
1.1.1.2 The basement membrane zone (BMZ) 
The basement membrane zone (BMZ) is a highly specialized structure located at the 
interface between the epidermis and the dermis
13
; it forms the junction between the lower 
epidermis and upper dermis and for that reason it is known as the dermal-epidermal 
junction (DEJ)
7,13
. The DEJ provides epidermal-dermal adherence, a mechanical support 
for the epidermis, and a barrier to the exchange of cells and of some large molecules across 
the junction, thus governing the overall structural integrity of the skin
1,13
. This zone 
contains supporting structures, which are critical for the integrity of the stable association 
between epidermis and dermis
14
. These structures are known as anchoring complexes, the 
anchoring complex consists of hemidesmosomes, anchoring filaments and anchoring 
fibrils
14
. 
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1.1.1.3 The dermis 
The dermis is an integrated fibrous, filamentous structure located underneath the epidermis 
and consisting of cellular connective tissue that accommodates the nerve and vascular 
networks and the epidermally derived appendages. In addition, it contains many resident 
cell types including fibroblasts, macrophages, mast cells and the transient circulating cells 
of the immune system
1,3
.  The function of the dermis is to provide pliability, elasticity, and 
tensile strength to the skin; it also supports the epidermis above and the appendages within 
it. Furthermore, it protects the body from the mechanical injury, binds water within the 
body and accommodates sensory receptors
3
. In addition, the dermis is a vascular layer 
which is necessary for thermoregulation and the supply of nutrients to the epidermis which 
has no blood supply
1
. The dermis sits on a cushion of subcutaneous adipose and a thin 
layer of muscle
3
.  
 
The dermis is divided into two regions, the upper papillary dermis and the reticular dermis. 
The upper papillary dermis undulates and forms rete ridges, which increases the surface 
area with the epidermis to provide better adhesion and allowing a greater exchange of 
nutrients by diffusion. The lower regions of the dermis are reticular and form the major 
portion
3
. The interlacing (reticular) structure of collagen and elastin fibres within the 
dermis provides resilience and elasticity to the skin. The dermis consists mainly of a 
supporting matrix or ground substances in which polysaccharides and proteins coexist and 
interact. The bulk of the dermis is composed of type I and type III collagen
3
. In addition, 
fibroblast, macrophage, and mast cells are considered the main cellular components of the 
dermis. These cells are usually located in the papillary dermis surrounding the subpapillary 
plexus (dermal vascular network). However, they may present in the reticular dermis  
mainly between collagen fibre bundles
1
.  
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The fibroblasts are the most predominant cells found in the loose connective tissue; they 
have a mesenchymal origin and have a spindle shape appearance.  These cells exist in 
different phenotypes even within the same tissue
1
.  These cells migrate through the tissues 
and are responsible for synthesis of all the dermal connective tissue elements or their 
precursors
15
. In addition, fibroblasts play a crucial role in wound healing and scaring by 
increasing their proliferative and synthetic activity
1
.  
 
There is a wide regional variation between different body sites. For example the scalp with 
its large hair follicles may be contrasted with the forehead which has only small vellus 
hair-producing follicles, although associated with large sebaceous glands. The axilla is 
distinguished because it has apocrine glands in addition to the eccrine sweat glands which 
are found throughout the body
3
. 
 
1.1.2 Skin appendages 
 
Skin appendages include sebaceous glands, sweat glands, hair follicles and nails.  
 
1.1.2.1 Sebaceous glands  
The sebaceous gland is a unilobular or multilobular structure that is usually associated with 
the hair follicle. The sebaceous gland and the associated hair follicle are known as the 
pilosebaceous unit
5,16
. This gland produces sebum, an oily liquid released by holocrine 
secretion, through a duct into the upper follicle, which lubricates the hair shaft and 
epidermis
16
. It is largest and most numerous on the face, scalp, trunk, in the external 
auditory canal (ceruminous glands) and on the anogenital surfaces, but not normally 
present on the palms or soles, and only sparsely on the dorsal surface of the hands and 
feet
3
. It is regulated by androgens and retinoids. However, other factors are also 
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involved
16
. Histologically, it consists of acini connected to a common excretory duct 
composed of stratified epithelium; the glands are composed of highly mitotic cuboidal or 
columnar sebocytes and of keratinocytes that line the sebaceous duct, the cells progress 
towards the middle of the duct and accumulate lipid droplets as they terminally 
differentiate 
16
.  When fully differentiated the sebocytes are full of lipids and lack all other 
cellular organelles. The sebaceous gland is surrounded by a connective tissue capsule 
composed of collagen fibres which provide physical protection to the gland
16
.  
 
1.1.2.2 Sweat Glands  
Two types of sweat glands had been recognised in humans, namely eccrine and apocrine 
sweat glands
3
. The eccrine sweat glands are smaller in size than the apocrine sweat glands 
and are distributed all over the body except the lips, external ear canal, clitoris or labia 
minora. Eccrine sweat gland secret hypotonic sweat consisting mostly of water and 
electrolytes, their main function is to control body temperature during exposure to hot 
environment or during physical exercise, failure to regulate body temperature under either 
of these conditions leads to hyperthermia and/or heat stroke.  Sweat lowers body 
temperature by dissipation of heat by evaporation. The average density of eccrine sweat 
gland varies according to race and anatomical site
17
. Histologically, it is a simple tubular 
epithelium consisting of a secretary portion and a ductal portion
18
. The coiled portion of 
the sweat gland is made up of the secretary coil and the proximal duct. The secretory coil 
is composed of three distinct cell types; clear (secretory), dark (mucoid), and 
myoepithelial
18
.  The dark cells are located near the apical or the luminal surface of the 
secretory tubules whereas, the clear cells are located either directly on the basement 
membrane or on the myoepithelial cells (Sato, 2001)
18
.  When two or more clear cells lies 
adjacent to each other they form an intercellular canalculi.  The canaliculi merge 
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immediately above the basement membrane or the myoepithelial cells and open directly 
into the lumen of the gland. Furthermore, the spindle shape myoepithelial cells are located 
adjacent to the clear cells, together with masses of myofilaments which lie on the basement 
membrane. The distal duct is relatively straight and connects the coil with the epidermis. 
Furthermore, the duct forms a spiral in the epidermis and the stratum corneum (forming 
the acrosyringium or intraepidermal sweat duct unit), and it opens directly onto the skin 
surface
17,18
. The clear cells are most likely responsible for making the sweat secretion, 
while the function of the dark cells is unknown. The myoepithelial cells are contractile 
cells with abundant filament and have a smooth muscle-like function
17,18
  
 
Apocrine sweat glands are different from eccrine sweat glands in structure and function
17
 
Apocrine sweat glands are larger in size than the eccrine ones and distributed on the 
axillae, areola and genital areas, they become active at puberty and secret proteinaceous 
viscous sweat which has unique odour
17
 . The apocrine sweat glands are composed of three 
segments: the secretory portion, the intradermal duct, and the intraepithelial duct. Ducts of 
apocrine sweat glands open to the hair follicle whereas ducts of eccrine sweat glands open 
to the surface of the skin through the epidermis. Furthermore, ducts of apocrine sweat 
glands enter pilosebaceous follicle in the infundibulum above the entrance of sebaceous 
duct. The ductal portion of apocrine sweat glands is composed of two layers of ductal cells 
while the secretory portion of apocrine sweat glands consists of a single layer of columnar 
secretory cells and a single layer of surrounding myoepithelial cells
1,17
. 
 
1.1.2.3 The hair follicle  
The hair follicle is one of the most complex mini organs of the human body. They vary 
considerably in size and shape, depending on their location, but they all have the same 
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basic structure. The hair follicles are sloped in the dermis, and the longer follicles extend 
into the subcutaneous layer
3
. An oblique muscle, the arrector pili muscle, runs from the 
mid region of the follicle wall to a point in the papillary dermis close to DEJ
19
. Above the 
muscle lies one or more sebaceous glands, and in some regions of the body an apocrine 
gland also, opens into the follicle
19
. Together, these structures form the so called 
pilosebaceous unit
3
. It is believed that the hair follicle has ectodermal-mesodermal 
origin
19,20
.  The epithelial components of hair follicle including the sebaceous gland and 
the apocrine gland are derived from the ectodermal hair follicle stem cells; while, the 
follicular dermal papilla and connective tissue sheath are originated from mesoderm 
derived cells. In addition the hair follicle pigmentary unit is derived from neural crest 
derived melanocyte
21,22
.  
 
The hair follicle is divided into a ‘permanent’ upper part, which does not cycle visibly, and 
a lower part, which is continuously remodeled in each hair cycle. The upper part of the 
hair follicle consists of the infundibulum, and the isthmus. The lower part of the hair 
follicle consists of suprabulbar and bulbar area (figure 1.2 A)
23
. The sebaceous gland duct 
joins the hair shaft at the lower end of the infundibulum, whereas, the arrector pili muscle 
is inserted at the proximal end of the infundibulum (figure 1.2 A)
23
.  
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Figure 1.2: Histomorphology of the hair follicle & hair bulb (adapted fromSchmidt-
Ullrich, 2005
19,24
.  A) Longitudinal section through a human scalp hair follicle (anagen 
VI) showing the main components of the hair follicle; the (infundibulum, isthmus), the 
suprabulbar and the bulbar region (B) High magnification image of the isthmus. The bulge 
region is shown in the dashed square. (C) High magnification image of the bulb. (D) 
Schematic drawing illustrating the concentric layers of the outer root sheath (ORS), inner 
root sheath (IRS) and shaft at the level of the bulb. The inner root sheath is composed of 
four layers: Companion layer (CL), Henle’s layer, Huxley’s layer, and the inner root 
sheath cuticle. (BM = basal membrane; APM=arrector pili muscle; CTS= connective tissue 
sheath; DP= dermal papilla; M= matrix; HS= hair shaft, IRS= inner root sheath; ORS= 
outer root sheath; SG=sebaceous gland) 
24
.  
 
 
 
In cross-section the hair follicle epithelium forms a cylinder with at least nine different 
concentric layers, each one expressing a distinct pattern of keratins 
23
. Starting from the 
outermost to innermost, these layers include the connective tissue sheath (CTS), the outer 
root sheath (ORS), the inner root sheath (IRS), the hair shaft cortex, hair shaft medulla, the 
hair cuticle, the each layer is characterized by the expression of hair follicle specific 
keratins. Furthermore, the IRS is made of three concentric rings of epithelia: the outermost 
Henle’s layer, the central Huxley’s layer and the inner most is the inner root cuticle. The 
companion layer is a single layer of tiny cells derived from the matrix. It is in close cell-
cell contact with Henle’s layer, it provides a slippage plain between ORS and IRS25(figure 
1.2.D). 
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In adult humans, there are two major hair types: the terminal hairs which are heavily 
pigmented, found on the scalp, and other sites e.g. beard. The vellus hairs, are non-
pigmented and most abundant e.g. in facial and truncal skin. The follicles grow deep into 
subcutaneous layer in terminal scalp hairs and only penetrate the dermis in the case of 
vellus hair producing follicles
1
.   
 
1.1.2.4 The nail & the nail bed 
The finger nail is made up of the nail plate which is the horny dead product, and four 
specialized epithelia; the proximal nail fold, the nail matrix, the nail bed, and the 
hyponychium
26
. The nail plate is a semi-transparent horny structure lying on the dorsal 
surface of the terminal phalanx and surrounded proximally and laterally by a fold of skin 
(nail folds)
27
. The proximal nail fold is a skin fold that has two surfaces, dorsal and 
ventral; at the junction of the two, the cuticle projects distally onto the nail surface
26
. The 
nail matrix is a specialized epithelial region underneath the proximal nail and above the 
mid portion of the distal phalanx. It produces the major part of the normal nail plate, and is 
subdivided into dorsal (ventral aspect of the proximal nail fold), intermediate (germinal 
matrix) and ventral (nail bed) sections
28.  The lunula or “half moon” is white in colour and 
represents the most distal region of the matrix
27
. The nail bed extends from the distal 
margin of the lunula to the onychodermal band and it is completely visible through the nail 
plate
26
. The hyponychium is the anatomical area that lies between the nail bed and the 
distal groove, where the nail plate attaches with the dorsal digit
15
. 
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1.1.3 Hair follicle Biology  
 
1.1.3.1 Hair cycle 
The hair follicle is a dynamic structure. It undergoes continuous cycles of growth, 
involution and rest throughout the life of a mammal. It is strongly believed that the mouse 
is an excellent model system for studying the hair cycle for the following reasons; firstly, 
the mouse has a short hair cycle, about three weeks compared to humans; the time for each 
stage is a lot shorter making it easy to study. Secondly, the mouse hair cycle is 
synchronised whereas in human each hair follicle cycles independently of each other. 
Thirdly, the stages of hair cycle have been well characterized in the mouse
29
. Moreover, 
there is no evidence to suggest that the mouse hair cycle differs structurally in any way 
from that of the human. Finally, because, cycling hair follicles cannot be maintained for 
any length of time in culture 
30
,  most of the knowledge about the hair follicle cycle is 
obtained from the studies of spontaneous or genetically engineered mouse hair loss 
mutants
31
. The main stages of the hair cycle are anagen (growth phase) and catagen 
(regression phase) and telogen (resting phase) (figure 1.3)
31
. 
28 
 
 
 
Figure 1.3 Schematic representation of different stages of mouse hair cycle (adapted 
from Porter, 2003)
31
. 
 
1.1.3.1.1Anagen phase 
Anagen is the growth phase of hair cycle. In mice, the duration of anagen phase is ~ 1-4 
weeks
29
. In human, the length of anagen controls the length of the hair shaft and this 
allows a wide diversity of different hairs in different body sites
29
. Anagen is divided into 
six different stages defined by specific morphological criteria (i.e. increasing the size of 
dermal papilla from anagen I to VI).  The main characteristic feature of this phase is a 
rapid proliferation in the bulb to form the inner root sheath and hair shaft
29
.   
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1.1.3.1.2 Catagen phase 
Catagen (regression phase) is the dynamic transition phase between the anagen and 
telogen, in mice it lasts ~ 2 days (starts at day 16 and completed on day 17 after birth), in 
human it lasts ~ 2-3 weeks
29
. During catagen, the lower part of hair follicle undergo rapid 
regression by apoptosis of the matrix, inner root sheath and outer root sheath (ORS) while 
the stem cells in the bulge, the sebaceous gland and infundibulum remain. Eventually, the 
lower part of the hair follicle is reduced to an epidermal strand which brings the dermal 
papilla (DP) up into close proximity with the bulge. The old hair shaft (also known as the 
club) normally remains in its canal even while the new hair erupts through the same orifice 
29
.  
 
1.1.3.1.3 Telogen phase 
Telogen phase is referred to as the resting phase due to relative quiescence of the cells 
during this stage. In mice, it lasts about 11 days 
29, whereas in humans, the telogen phase 
lasts up to three months before the hair follicles restart anagen phase and the cycle is 
repeated again. A signal for the next anagen stage is thought to pass between the dermal 
papilla and the stem cells in the bulge to initiate the next anagen stage and down growth of 
the hair follicle epithelium. The enlarged dermal papilla is soon encapsulated by epithelial 
cells and the production of inner root sheath and hair shaft lineages begins while the 
follicle is still growing down into the subcutaneous adipose tissue in the case of terminal 
hairs and mouse pelage but not vellus hairs
29
. 
 
 
As shown above (figure 1.2), the hair production originates from proliferating germinative 
epithelial cells located in the hair follicle bulb, which is under the control of the dermal 
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papilla.  Complex cell signalling between the germinative cells of the hair follicle bulb and 
the dermal papilla instructs lineage restricted differentiation
19,20
. 
 
1.1.4 Common types of hair Loss 
 
Hair loss (Alopecia) is a common problem that affects up to 50%  of both sexes throughout 
their lives
32
. This condition can occur anywhere on the body but it is more common on the 
scalp where patients are presented mainly for cosmetic concerns
32
. Hair loss is broadly 
divided into focal or diffuse hair loss (table1.1)
33
. Focal hair loss is further sub-divided 
into scarring or non-scarring depending on the underlying cause. The main cause of non 
scarring focal alopecia is tinea capitis or alopecia areata. Whereas, patchy hair loss is 
caused by traction alopecia or trichotillomania. Scarring alopecia is a rare condition and 
mainly caused by discoid lupus erythematosus
33
.  
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
Table 1.1 Common types and clinical feature of hair loss (adapted from Mounsey, 
2009) 
33
. 
 
Type of hair loss 
 
Subtype 
 
            Clinical feature  
 
 
 
 
 
 
    Diffuse  
Female pattern hair loss Hair thinning 
Intact frontal hair line  
Negative pull test 
Male pattern hair loss Hair thinning 
Frontal line involved (M pattern) 
Negative pull test 
Diffuse alopecia areata More patchy distribution  
Positive pull test 
Alopecia totalis or 
universalis 
Total scalp hair loss  and/ or body 
Telogen effluvium  30-50% hair loss, three months after 
precipitating event 
Positive pull test 
Anagen effluvium  90%  of sudden hair loss two weeks 
after chemotherapy 
 
 
Focal, Non 
scarring 
Alopecia areata (AA) Normal scalp with surrounding 
exclamation point hair  
Tinea capitus Scaly Scalp, Positive KOH test 
(fungus visible on KOH 
examination) 
Traction alopecia  Patchy, +/- scaring,  related to hair 
practice 
Trichotillomania Patchy, +/- scaring, associated 
psychological disturbance 
      
Focal, scarring 
 
Cicatricial alopecia Scaring, atrophy of the scalp  
(e.g. DLE, discoid lupus 
erythematosus) 
 
Alopecia areata (AA) is defined as non scaring sudden hair loss that ranges from a single 
oval patch to multiple patches that become confluent. It can occur at any age and both 
sexes are equally affected. Studies showed that there is genetic predisposition to AA with a 
polygenic pattern of inheritance
34
.  Alopecia areata is considered as an organ specific auto 
immune disease most probably mediated by autoreactive T cells which affect the hair 
follicle and the surrounding area
35
. It is commonly associated with other autoimmune 
diseases such as autoimmune vitiligo, thyroid disorders, type 1 diabetes, rheumatoid 
arthritis and discoid lupus erythematosus
33
. 
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On the other hand, diffuse hair loss (generalized hair loss) is also known as telogen 
effluvium. It occurs when an increased number of hairs enter the telogen (resting phase) of 
the hair cycle from the anagen (growing) phase and these hair are lost about three months 
later
33
. Telogen effluvium may be precipitated by severe illness, infection, injury, surgery, 
childbirth thyroid disorders, psychological stress, iron deficiency anaemia and drugs. 
However, in about third of patients, no cause can be found
36
.  Thyroid disorders including 
both hypo and hyper thyroidism can cause telogen effluvium; it is usually reversible when 
the thyroid status is corrected. The patient presents with increased numbers of hair in their 
hair brush or shower, they may also present with thinning of hair in the scalp, axillary, and 
pubic area. A detailed history and a careful examination may indicate the cause of hair 
loss
36
.  
 
1.2 Normal Thyroid Biology 
1.2.1 Anatomy, histology and morphogenesis 
“The thyroid gland develops from a tubular invagination of the embryonic pharynx, and 
migrates towards the neck where it develops into a thyroid gland. The thyroid is composed 
of two lateral lobes joined across the midline by an isthmus; a pyramidal lobe of varying 
size extends upward from the isthmus and represents the point of attachment with the 
thyroglossal duct. The thyroid is closely attached to thyroid cartilage and to the upper end 
of the trachea, and thus moves on swallowing
37,38
.  
 
Macroscopically, the thyroid is firm, reddish brown in colour, smooth and surrounded by a 
fibrous capsule that bonds together with the deep cervical fascia, and weighs between 20-
25g
37
. Microscopically, the thyroid is composed of closely packed follicles, which are 
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separated by a rich vascular supply and a little intervening stroma. These follicles are lined 
by cuboidal epithelioid cells and contain colloid; a proteinaceous material composed 
mainly of thyroglobulin (TG) and provides the matrix for thyroid hormone biosynthesis 
and a vehicle for its subsequent storage
39
. The gland has a rich blood supply from superior 
and inferior thyroid arteries. Dispersed between the thyroid follicles are the parafollicular 
or C cells, and these secrete calcitonin, a hormone involved in the regulation of circulatory 
calcium
39
 The thyroid follicular cells co-express the three thyroid specific transcription 
factors. Thyroid transcription factor1 (TTF1 also known as NKX2.1), thyroid transcription 
factor 2 TTF2 (also known as FOXE1), and Pax8 (a member of the paired box family of 
DNA binding proteins), which are all required for the thyroid morphogenesis. In the 
absence of the mentioned factors, morphogenesis is thoroughly impaired
40,41,42
. 
 
1.2.2 The Thyroid function 
 
The thyroid plays a vital role in the intermediary metabolism of virtually all tissues, and is 
of fundamental importance for the normal growth, mental and sexual maturation
43
. The 
main function of thyroid hormones is to control the overall metabolic turnover. Moreover, 
it plays a crucial role in the growth and development of the nervous system of the 
developing fetus and the new born
43.  The widespread effects of the thyroid result from the 
biosynthesis and secretion of two rather unique iodine-containing hormones, 
triiodothryonine (T3) and thyroxine (T4)
44
. 
 
The thyroid hormones modify the enzyme systems that affect the intermediary metabolism 
of carbohydrate, lipid, protein and the rate of terminal oxidative metabolism by direct and 
indirect mechanisms. The net effects of thyroid hormone actions are therefore to increase 
the cell’s metabolism by enhanced turnover of the carbohydrate, protiens and lipids thus 
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regulating body weight, maintaining the core body temperature by production of metabolic 
heat, and the regulation of calcium metabolism of bone
45
. In addition, thyroid hormones 
are of particular importance in the long term adaption to stress, including prolonged 
exposure to cold
43,45
. 
 
1.2.3 Regulation of thyroid function 
 
The anterior pituitary thyroid stimulating hormone (TSH) is the major stimulus of thyroid 
hormone secretion
46
. TSH secretion in turn is controlled by the hypothalamus which 
produces thyrotropin releasing hormone (TRH) (a positive regulator) and somatostatin (a 
negative regulator)
46
. The secretion of TRH and TSH are regulated via a negative feedback 
loop (hypothalamic pituitary thyroid axis) responding to the amounts of the thyroid 
hormones circulating in the blood and intra-hypothalamic and intra-pituitary T3 levels
46
 . 
 
TSH is a pulsatile secreted hormone with a marked circadian rhythmicity with a 
characteristic nightly surge
43
. Activation of the sympathetic branch of the autonomic 
nervous system directly stimulates the thyroid gland while, somatostatin and cortisol 
inhibit TSH secretion, whereas, iodine (I) directly inhibits growth of the thyroid gland. At 
physiological levels by negative feedback mechanism, the thyroid hormones reduce TSH 
secretion. T3 binds to the anterior pituitary nuclear receptors, and because most of the 
intracellular T3 is derived from circulating free T4, the pituitary gland is more sensitive to 
changes in plasma T4 than to T3 concentration
46
. 
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1.2.4 Thyroid hormones biosynthesis and secretion 
 
Thyroid hormones are synthesized in the thyroid gland by iodination and coupling of two 
molecules of the amino acid, tyrosine (Tyr). The pituitary thyrotropin (TSH) level controls 
the rate, and all steps of thyroid hormone synthesis in the blood. TSH also induces an 
increase in the number and size of thyroid follicular cells, this is achieved by its binding to 
the thyroid stimulating hormone receptor (TSHR) and activating downstream signal 
cascades, mainly cAMP 
45
.  The synthesis of thyroid hormones is fundamentally dependent 
on the adequate iodine (I) supply. TSH is the principle factor determining the rate of (I) 
uptake by the thyroid and as a result thyroid hormone secretion
44
.    
 
Iodide transport into the thyroid cytoplasm is an active transport process against an 
electrochemical gradient carried out by the sodium iodide symporter (NIS). The NIS 
couples the inward “downhill” translocation of Na+ with the inward uphill translocation of 
iodine
47
. The driving force of this process is the inwardly directed Na
+
 gradient generated 
by the Na
+
/K
+
 adenosine triphosphatase (ATPase). Once inside the cell, the I
-
 is then 
passively trans-located through the putative I
-
 channels across the apical membrane into 
the colloid, in the follicular lumen (I
-
 efflux) where it is oxidized by thyroid peroxidase 
(TPO), to a higher state (TPOI) as a result transforming into an effective iodinating 
agent
47
.  Within the thyroid follicular lumen, the thyroid hormones are then formed in a 
two stage process. Firstly; the tyrosine molecule on TG are singly or doubly iodinated to 
form monoiodotyrosine (MIT) or diiodotyrosine (DIT).  Subsequently, Triidothyronine 
(T3) is formed by joining MIT and DIT and similarly, Thyroxin is formed by joining two 
DIT (figure 1.4).  
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The iodination and coupling of iodotyrosyl precursors are mediated by TPO, and the 
thyroid hormones (still incorporated in TG) are stored within the colloid of the thyroid 
follicle
44
. When required, the thyroid hormones are retrieved by endocytosis and both T3, 
T4 are released by cleavage, with the proteolytic enzymes allowing the hormones to enter 
the circulation. The I
-
 is then released from MIT and DIT and is re-circulated
44
.  
 
 
Figure 1.4:  Chemical structure of Triiodothryronine (T3) and Thyroxine 
(T4)(adapted from Carrasco, N. et al, 1993)
44
.  
 
1.2.5 Thyroid hormone transport and metabolism 
 
When released into the circulation, the thyroid hormones are immediately bound to plasma 
proteins. More than 99% of plasma T3 & T4 are bound to plasma proteins
48
. The thyroxine 
binding globulin (TBG) carries about 70% of T3 & T4 because of its high affinity for both 
hormones, while about 15-20% are bound to para-albumin and about 10-15% are bound to 
transthyretin or "thyroxine-binding pre-albumin" (TTR or TBPA) which has a lower 
affinity binding, thus allowing the thyroid hormone to disassociate more rapidly. This 
fraction is responsible for much of the immediate delivery of T3 & T4
48
.  
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Thyroid hormone receptors (THr) are located in the nuclei of the cells and, the affinity of 
the receptors to T3 is higher than that of T4. In the peripheral tissues ( liver and kidney), 
the majority of the secreted T4 is deiodinated (removal of an iodine atom from the outer β 
ring) to a more active form T3 and approximately 80% of plasma T3 is formed in this way. 
The remaining 20% is secreted by the thyroid gland. Deiodination of the inner α ring of the 
T4 produces reverse T3 (rT3) that is inactive. While T4 has independent capability, T3 
binds more avidly to thyroid receptors and is the main active form
48
. 
 
 
1.3 Disorders of thyroid gland 
The most common clinical presentations of thyroid disorders are as a result of excessive 
hormone secretion (Hyperthyroidism), deficient hormone secretion (Hypothyroidism) and 
Goitre (diffuse or nodular) in which case there may or not be abnormal thyroid hormone 
secretion
49
. Normal level of thyroid hormones is variable, different testing laboratories 
may have different reference ranges. 
 
1.3.1 Hypothyroidism 
 
Hypothyroidism is a medical condition characterized by low levels of thyroid hormones 
(T3 and T4) and high levels of TSH causing a general slowing of the BMR (basal 
metabolic rate), which manifests itself clinically as weight gain, cold intolerance, fatigue, 
lethargy, depression, hoarseness of voice, dry skin, decreased appetite and menstrual 
disturbances
49
. It is classified as primary, due to a decrease in thyroid hormone levels 
resulting from a disease process in the thyroid gland or secondary resulting from failure of 
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pituitary TSH secretion. A reduction of thyroid hormone synthesis and secretion at birth is 
known as cretinism, while myxedema in adults
49
.  
 
Congenital hypothyroidism (Cretinism) is an uncommon disease of childhood (1-4000 live 
births), it is screened for in all newborns (Guthrie test) as early diagnosis and immediate 
treatment by thyroxin administration is crucial in order to avoid irreversible developmental 
defects. The main causes of congenital hypothyroidism include: 1) thyroid gland 
dysgenesis: ectopy, agenesis, hypoplasia, hemiagenesis 2) failure of thyroid hormone 
synthesis due to severe dietary iodine deficiency (maternal during pregnancy or after 
birth); 3) failure due to the presence of dietary substances (goitrogens) that block hormone 
synthesis: 4) failure of synthesis due to autosomal recessive enzyme deficiency (sporadic 
cretinism)
49
 .   
Hypothyroidism in adults is caused by: 1) Hashimoto autoimmune thyroiditis; 2) 
secondary hypothyroidism due to pituitary failure; 3) hypothyroidism due to anti thyroid 
drugs or ablation of the gland by surgery or radiation; 4) failure of hormone synthesis due 
to extreme dietary iodine deficiency. This is usually compensated by hyperplasia of the 
thyroid gland via the TSH feedback mechanism and the enlarged gland maintains adequate 
hormone secretion
49
.   
 
1.3.1.1Cutaneous manifestation of Hypothyroidism  
The skin manifestations vary and depend on the extent, duration of the disease and the 
ethnicity. The skin is cold, pale, due to cutaneous vasoconstriction and reduced core 
temperature, patients may have, dry, thick, rough, hyperkeratotic skin
50
. The most striking 
skin changes are due to dermal accumulation of mucopolysaccharides causing diffuse 
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generalized myxedema
51
. However, the hands and periorbital region of the legs are more 
commonly affected. Unlike the pretibial myxedema of Graves’ disease, the generalized 
myxedema of hypothyroidism is fully reversible with thyroid hormone therapy
52,53
. 
 
The facial changes are almost pathognomonic; nonpitting swelling or puffiness around the 
eyes with a very characteristic loss of the outer third of the eyebrows (Madarosis), 
drooping of eye lids. Furthermore, malar flush and yellow discolouration of skin especially 
palms, soles and naso-labial folds. The scalp hair may be thin, dull, coarse and brittle 
resulting in a diffuse, partial alopecia (alopecia areata),  axillary and pubic hair may be 
sparse
34
. The nails are thin, brittle and striated with both longitudinal and transverse 
grooves
51
.  
 
1.3.2 Hyperthyroidism  
It is a medical condition characterized by high levels of thyroid hormones (T3 and T4) and 
supressed TSH.  The most common causes of hyperthyroidism are Graves’ disease (GD) 
and toxic thyroid adenomas, both causes produce continuous activation of the TSHR 
(figure 1.5)
54
.  
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Figure 1.5: Consequences of activation of TSHR. The TSHR is coupled mainly via the 
G protein S to the cAMP cascade. The cAMP cascade positively regulates thyroid 
hormone production and thyroid epithelial cell proliferation and thereby mediated 
hyperthyroidism as well as the formation of thyroid adenoma (adapted from Paschke et al, 
1996
54
). 
 
GD is diffuse autoimmune thyroid hyperplasia characterized by the presence of IgG auto-
antibodies which stimulate each thyrocyte in the gland to produce excess thyroid 
hormones. These thyroid stimulating antibodies (TSAbs) mimic the effects of the TSH on 
the thyrocytes causing inappropriate production of cAMP with subsequent hyperfunction 
and goitre
55
. 
 The toxic thyroid adenoma is a circumscribed benign tumour with monoclonal origin. 
This condition is characterized by an inappropriate production of cAMP started in a single 
cell, which often harbours an activating TSHR mutation and then experiences clonal 
expansion leading to the generation of the hyper-functioning nodule. When the thyroid 
TSH receptor 
G alpha S
Function Proliferation 
Hyperthyroidism Thyroid adenoma 
Cyclic adenosine monophosphate cascade 
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hormone production by this nodule exceeds the normal daily production, the normal tissue 
surrounding the adenoma is put at rest as a consequence of suppressed TSH levels
54
. Other 
causes of hyperthyroidism include: 1) Toxic Multi-nodular goiter (MNG); 2) TSH 
secreting pituitary adenoma (known as pituitary hyperthyroidism); 3) Sub-acute thyroiditis 
(De Quervian’s) 4) Germline tumors such as chorio-carcinoma or teratoma 5) An active 
follicular carcinoma (rarely) 
49
. 
 
1.3.2.1Cutaneous manifestation of Hyperthyroidism  
The skin manifestations vary and can include; warm, moist erythematous, silky texture, 
and frequently pruritic skin
56
.  The warmth is caused by increased blood flow and 
peripheral vasodilatation may be responsible for episodic facial flushing and palmer 
erythema
56
. The epidermis is thin but not atrophic with generalised hyperhydrosis which is 
more prominent in palms and soles
51
. Diffuse or localized hyper- pigmentation and vitiligo 
of a variable degree can occur and the latter is seen especially with Graves’ disease, it is 
thought to be part of the autoimmune response. Diffuse hair loss occurs in about 20-40% 
of patients with hyperthyroidism and the severity of the loss is not directly related to the 
severity of the disease. Loss of axillary, pubic, eyebrows in addition to alopecia areata may 
be seen
51
. The nails become soft, shiny, rapidly growing and friable 
26,57
. Onycholysis 
occurs in many patients, it is a distal separation of nail plate from its underlying bed with 
upward curvature; so called Plummer’s nail 26,57. Onycholysisis is not specific to 
hyperthyroidism, it may be observed in patients with hypothyroidism, psoriasis, contact 
dermatitis and trauma
26,57
. 
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1.3.3 Autoimmune thyroid disease 
Graves’ disease (GD) is the most common autoimmune thyroid disorder and is 
characterized by the presence of thyroid stimulating auto antibodies (TSAbs) which mimic 
the effects of the TSH leading to stimulation of the thyroid follicle via the TSHR to 
produce excess thyroid hormone
49,55
. Hashimoto autoimmune thyroiditis is the cause of 
most cases of primary hypothyroidism, and is the result of an auto immune destruction of 
the thyroid by a cytotoxic T-cell-mediated hypersensitivity reaction
49
.   
 
1.3.3.1Cutaneous manifestation of autoimmune thyroid disease (Thyroid 
Dermopathy) 
The dermatologic manifestations of Graves’s disease are thought to be due to autoimmune 
mediated reaction rather than elevated thyroid hormones levels
51,58
.   In addition to the fore 
mentioned cutaneous features of hyperthyroidisim, patients with Graves’ disease have 
distinctive cutaneous manifestation such as pretibial myxedema and acropachy
51
. Table 1.2 
summarizes the clinical presentation of thyroid disease.  
 
Pretibial myxedema is also known as thyroid dermopathy and usually occurs in 
hyperthyroid patients. However, it can also occur in euthyroid patient
59,60
. It is 
characterized by dermal fibroblast proliferation resulting in immune reaction and the 
release of local glycosaminoglycans and cytokines which causes mild to moderate skin 
thickening
50
. The most common site of myxedema is the anterior tibia and dorsa of feet. 
However, other areas of the body can be affected such as face, pre-radial area, scalp, neck 
extremities and torso
59,60
. It was suggested that local physical and anatomical factors such 
as local trauma, oedema on a background of a usually subclinical, systemic, connective 
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tissue inflammation may aggravate pretibial myxedema 
61
.  It is diagnosed clinically by its 
characteristic features; the early lesions may be unilateral or bilateral, non-pitting, scaly, 
firm, with a peau d’ orange51. The lesions may coalesce to form hyperkeratotic or 
verruocus plaques, and may appear pink or purple, hyperhidrosis and hypertrichosis may 
be present. It is usually non progressive and may partially or completely regress in time
62
. 
Biopsies in general should be avoided as the lesions may not heal. Histologically, staining 
with hematoxylin and eosin shows mucin production in the lower dermis and a reduction 
in elastic tissue. Acropachy is characterized by a clinical triad consisting of digital 
clubbing, soft tissue swelling of the hands and feet and periosteal new bone formation, it 
occur in 0.1-1% of patients and it almost always occurs in association with 
ophthalmopathy and pretibial myxedema
51
.  
 
Table 1.2 Summary of clinical presentation of thyroid disease. (Adapted from Safer, 
JD, 2011
63
). 
Low T3,T4 and High TSH  HighT3,T4 and low TSH Autoimmune  reaction 
Cold intolerance Heat intolerance Heat intolerance 
Pallor Warm skin Acropachy 
Dry,  scaly skin Increased sweating 
(hyperhydrosis) 
Urticaria, pruritis  
Generalized myxedema  Pretibial myxedema 
Diffuse alopecia  
Loss of hair of  lateral eye 
brow  
 
Hypertrichosis Alopecia areata 
Purpura Erythema  Vitiligo 
Drooping of upper eyelid Hyperpigmentation Pernicious anaemia  
Nerve entrapment 
syndromes 
Telengictasia Bullous disorders 
Eczema 
Connective tissue 
disease.  
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 1.3.3.2 Treatment of thyroid dermopathy  
Generally, localized lesions of pretibial myxedema are asymptomatic and most patients 
require no treatment. The indications for treatment are cosmetic concern, functional 
impairment or local discomfort
64
. Topical application of corticosteroids is the preferred 
therapy; however, as the extent of the lesion increases the likelihood of successful 
treatment is decreased and the severe elephantiasic forms may lead to significant limb 
enlargement and impair function
64
. Surgical treatment should be avoided because scarring 
may aggravate the dermopathy, and the benefits are equivocal. Compression wraps or 
stockings that provide 20-40 mm Hg of pressure can be useful as an adjunctive
65,66
.   
Systemic steroids or other immunosuppressive therapy is not indicated for patients 
presenting with only localized myxoedema, it is indicated when presented with both 
ophthalmopathy and myxedematous lesion
62,67
. 
 
 The long term outcome for patients with localized myxedema varies.  It is not known to 
what extent treatment promotes remission of the lesions
64
 . Long term remission appears to 
depend on the severity of the initial disease rather than the effect of the therapy
65
. The 
available therapeutic modalities are palliative at best and a better and safer means of 
immune modulation are needed to treat this extra thyroidal manifestation of autoimmune 
thyroid disease.  
 
1.3.4 Inflammatory thyroid disease 
Sub acute thyroiditis is an uncommon inflammatory condition of the thyroid; the most 
likely cause is viral origin, histologically characterized by extensive destruction and 
fibrosis of the thyroid follicles with aggregation of macrophage and giant cells around the 
fragments of colloid
49. Riedel’s disease is a rare chronic condition, not involving thyroid 
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auto-antibodies, associated with fibrosing lesions of mediastinum and retroperitonium.  It 
is suggested that this condition may be a systemic disease involving the fibroblast
49
.  
Other forms of thyroid dysfunction are: Diffuse non-toxic, Multinodular goiter (MNG) 
represents a compensatory thyroid hyperplasia as a result of the accumulation of mild 
deficiency of thyroid hormone production. Hyperplasia corrects the hormone deficiency 
and maintains the euthyroid state. Endemic goiter is the result of iodide deficiency and 
sporadic goiter is usually due to increase of physiologic demand for thyroxine during 
pregnancy or at puberty
49
. 
 
1.4 Effect of thyroid hormones on different parts of the 
skin 
It is commonly believed that most of thyroid associated skin symptoms are related to 
autoimmune reaction rather than disturbance of thyroid hormone level
58
. This section 
describes the effect of thyroid hormones on different parts of the skin which are 
summarized in (table 1.3). 
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Table 1.3 Summary of effect of thyroid hormones on different parts of skin. (Adapted 
from Safer, JD, 2011
63
). 
 Skin changes  Low T3,T4 and high TSH High T3, T4 and low TSH 
Epidermal 
changes 
Coarsened, thin, scaly skin  Smooth, thin skin 
Dermal changes  
 
Non pitting oedema (myxedema) 
Oedema (hands, face, eyelids) 
Carotenemia 
Pallor 
 
Hair and nail 
changes 
Dry, brittle, coarse hair 
 Alopecia 
Loss of lateral third of eye brows 
 Coarse, dull, thin, brittle nails 
Fine hair (loses waves), 
hypertrichosis 
Shiny, soft, friable nails 
(Onycholysis, Plummer’s 
nails) 
Sweat gland 
changes 
Dry skin (xerosis) 
Decreased sweating 
Excessive sweating. 
 
 
1.4.1 Epidermal effect 
 
High levels of T3 and T4 causes thinning of the epidermis (not atrophic). However, one 
report showed epidermal thickening in skin biopsies from thyrotoxic subjects
68
. Tissue 
culture studies show that T3 stimulates growth of both epidermal keratinocytes and dermal 
fibroblasts
69,70
. However, thyroid hormone mediated inhibition of keratinocyte growth has 
been observed when the keratinocytes were co-cultured with dermal fibroblasts
71
.  
 
In addition, in vitro keratinocyte studies have demonstrated that depletion of T3 causes 
elevation of transglutaminase level, which is involved in the formation of the cornified 
envelope. Moreover, it was also observed that T3 depleted keratinocytes have reduced 
levels of plasminogen activator, an enzyme involved in the corneocyte shedding process
72
.   
Low levels of thyroid hormones in hypothyroid status may affect the epidermal barrier 
function. Studies of thyrodiectomized rats have suggested that sterol synthesis (which is 
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associated with scaling dermatoses) is altered in epidermal keratinocytes deprived of 
thyroid hormone
73
. It is believed that thyroid hormones accelerate the barrier formation of 
the skin by enhancing the enzyme activities in the cholesterol sulphate cycle
74
. It was also 
suggested that hypothyroid status may affect the development of the lamellar granules, 
which are vital for the development of normal stratum corneum in fetal mice
75
.  
 
Thyroid hormones have a direct control over keratin genes, which encode the intermediate 
filaments and make up about 30% of the protein of the epidermis, at a nuclear level 
through hormone response element in their upstream promoters
75,76
. It stimulates the 
expression of proliferation associated keratin genes (K6a,K16,K17) both in vivo and 
vitro
77
. However, only negative thyroid response elements have been identified for these 
genes
78
.  
 
1.4 .2 Dermal effects 
 
Most of the dermal changes in hyperthyroid patients are derived from autoimmunity rather 
than direct thyroid hormone action while most of the dermal changes in hypothyroid 
patients are thought to be because of low thyroid hormone rather than autoimmune 
reaction
58
. In hypothyroid patients, pale skin is due to dermal mucopolysaccharides and 
water content. However, a prominent yellow hue of palms, soles and nasolabial fold is 
caused by dermal carotene
63
.  The main causes of thyroid dermopathy (myxedematous 
state) are accumulation of hyaluronic acid, the extravascular albumin accumulation (due to 
increase of its trans-capillary escape) and an inadequate lymphatic drainage
79
. Hyaluronic 
acid (HA) is the major glycosaminoglycan that is produced by 3 synthase enzymes and 
accumulates in myxedema, its hygroscopic nature allows it to swell when it is hydrated 
80,81
.  
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The effect of thyroid hormones on dermal fibroblast is a debatable issue. Tissue culture 
studies showed that thyroid hormones stimulate the proliferation of dermal fibroblast
71,82
. 
However, other groups showed inhibiting synthesis of hyaluronic acid, fibronectin and 
collagen in cultured fibroblast
83,84
. Moreover, animal studies using rat treated with 
triiodothyronine (T3) administrated topically or intra-peritoneally suggested increased 
dermal thickness
69,71
. Another study reported increased collagen thickness in mice treated 
topically with the thyroid hormone analog, tri-iodothyroacetic acid (Triac)
85
. 
 
1.4 .3 Effect on wound healing  
 
It is believed that topical thyroid hormone may have a useful effect to accelerate wound 
healing rate. Safer JD et al demonstrated that topical application of supra-physiological 
does of T3 accelerate wound healing in normal mice
86
. Another clinical report showed that 
human wound healing formulation requires T4 in addition to growth hormone and 
insulin
87
.  
 
1.4 .4 Effect on hair and nail 
Studies show that thyroid hormone affects the hair cycle. Animal treated by intra-
peritoneal administration of T4 showed decreased telogen (resting phase) and anagen 
phases (growth phase) of hair cycle
88
.  In vitro studies suggested increased hair growth rate 
in Hyperthyroidism; DNA flow cytometry of dissected anagen hairs from thyrotoxic 
patients compared with follicles taken from euthyroid controls demonstrated a 30% 
increase in the S and G2+M phases of the cell cycle
89
. Moreover, a pilot study showed 
topical application of T4, insulin and growth hormone enhances hair growth over 6 months 
in male patients with androgenic alopecia
90
. Another animal study revealed that topical 
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application of T3 for short periods produced increased hair counts whereas, animal made 
thyrotoxic with systemic T3 showed decreased hair counts
69,71
. 
On the other hand, in hypothyroidism the hair is coarse, dry, brittle and slow growing 
(diffuse alopecia) and with localized hair loss (similar to AA)
91
. The hypothyroidism 
related alopecia may be mediated by hormonal effect initially as well as the duration of 
hair growth. However, there is evidence that associated autoimmunity and thyroid 
dysfunction may be involved
92
. Therefore, tests to detect thyroid autoantibodies are 
relevant in alopecia areata patients
92
. Nail changes are characterized by concave contour 
associated with distal onycholysis (Plummer’s nails)26. 
 
1.4.5 Effect on sweat glands 
 
In hypothyroidism, the skin is dry due to decrease in eccrine gland secretion. The 
mechanism of deceased sweat gland secretion is not clear yet.  Histological analysis shows 
atrophy of the sweat glands. Moreover, it was suggested that accumulation of periodic 
acid-Schiff (PAS) positive material may play a role
93
.   
 
Hyperthyroidism is associated mainly with generalized hyperhydrosis which is usually 
more prominent in palms and soles. It is believed that hyperhydrosis is a reflection of the 
underlying metabolic status; the other suggested causes are increased sympathoadrenal 
activity caused by synergistic action between catecholamines and thyroid hormones
94
. 
Localized hyperhydrosis has been documented in patients with pretibial myxedema, it is 
caused by inappropriate stimulation of the sympathetic nerves by perineural infiltration of 
mucin
95
. 
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1.5 The glycoprotein hormones family 
Glycoproteins are proteins that contain oligosaccharide chains (glycans) covalently 
attached to polypeptide side-chains. The carbohydrate is attached to the protein in a 
cotranslational or posttranslational modification. This process is known as glycosylation. 
Secreted extracellular proteins are often glycosylated. The glycoprotein hormones family 
involves human thyrotropin (TSH), follitropin (FSH), lutropin (LH), and chorionic 
gonadotropin (CGH). TSH, FSH and LH are synthesized and stored in a specific group of 
cells in the anterior pituitary and are released in response to a specific releasing hormone 
secreted by the hypothalamus, whilst CGH is produced predominantly by the placenta 
during pregnancy
48
.  These glycoprotein hormones form the basis of the classic pituitary 
peripheral target feedback mechanism and, TSH, specifically, plays a crucial role in 
metabolism and physiological function of virtually all tissues via its regulation of T4/T3 
production, while, the CGH is important during pregnancy
96,97
. Structurally the 
glycoprotein hormones are classified as part of the cysteine-knot growth factors (CKGF) 
super family of structurally related proteins with important biological activities
98
. 
Furthermore, the glycoprotein hormones are heavily glycosylated heterodimers comprised 
of non-identical subunits coupled by noncovalent interactions, glycoprotein hormone α1 
subunit (GPHα1) which is common to all members of this family and a glycoprotein 
hormone specific β subunit (GPHβ) which is unique and confers biological specificity to 
each hormone, the formation of α/β dimers is necessary for their biological function99, 
96,100
.  
As mentioned above, an important structural component of glycoprotein hormones is their 
N-linked oligosaccharides or their carbohydrate moiety. The N-linked glycosylation is the 
attachment of a sugar molecule (a process known as glycosylation) to a nitrogen atom in 
an amino acid residue in a protein. The N-linked oligosaccharides of these hormones are 
51 
 
necessary for proper folding, assembly, secretion, metabolic clearance and biological 
activity
101
. The common α- subunit has two asparagines (N)-linked oligosaccharides, and 
the β-subunit has one (in TSH and LH) or two in (CG and FSH)102,103. 
 
The heterodimers of glycoprotein hormones are stabilized by a unique segment of the β 
subunit termed “seat belt” segment because it wraps around α subunit long loop. The 
human TSH-β subunit has three disulfide bridges from cysteine-knot motif that determines 
the core structure, two of the disulfide bridges are involved in the seat belt formation and 
the third one links the two β- hairpin loops104. This additional stabilization by the seat belt 
results in doubling of the subunit interface. Moreover, these hormones are also shown to 
activate specific G protein–coupled receptors in the thyroid and gonads by activating the 
thyrotropin receptor (TSHR) and FSH and LH/ CG receptors respectively
96,105
. 
 
1.5.1 TSH structure 
 
The thyroid stimulating hormone (TSH) is a member of glycoprotein hormone family, it is 
28- to 30- kDa glycoprotein produced in the thyrotroph cells (basophil cells) of the anterior 
pituitary gland
100,105
. Its synthesis and secretion is stimulated by thyrotropin releasing 
hormone (TRH) and inhibited by thyroid hormones T3 & T4 in a classic negative feedback 
mechanism
100,105
. Both TSH subunits are synthesized from separate mRNAs encoded on 
different chromosomes, the common human α1 subunit and TSH-β subunit are encoded by 
genes located on chromosome 6 and 1 respectively
100. The α1 subunit gene is 9.4 kb in 
length, consists of four exons and three introns whereas, the TSH-β subunit gene is 4.9 kb 
in length, consists of three exons and two introns
99
. 
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1.5.2 TSH Function 
 
The TSH controls thyroid growth and function upon its interaction with the G protein-
coupled TSH receptor (TSHR)
43
. The physiological role of TSH includes the stimulation 
of different thyroid functions, such as iodide uptake and organification, the release of 
thyroid hormones from thyroid gland, and promotion of thyroid growth
106
. It also plays a 
critical role as a thyrocyte survival factor and protects the cells from apoptosis
107
.   
 
1.6 Thyroid stimulating hormone receptor (TSHR) 
1.6.1 Structure of TSHR 
 
The TSHR is a G-protein coupled receptor (GPCR) characterized by large glycosylated 
extra cellular domain (residues 21-415) and N-amino terminus responsible for high affinity 
binding of TSH
45,108,109
. The TSHR shares with other GPCR a common molecular 
architecture of seven trans-membrane segments (three extracellular loops and three 
intracellular loops plus the carboxyl terminus) responsible for the G coupling and the 
signal transduction
108,110
(figure 1.6). 
 
At protein level, the human full length TSHR is made up of amino acids 21-764 amino 
acids. The TSHR contains six putative glycosylation sites and the first 20 amino acids are 
the signal peptide
109
. It contains two subunits; A subunit, corresponding to the extracellular 
domain (ECD) (residues 21-415) and, the B subunit, is mainly the transmembrane domain 
(TMD) (residues 416-764)
111-114
.  
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Post translation proteolysis splits the TSHR into two subunits (A and B subunits) linked to 
each other by disulfide bonds
115
.  These A and B subunits are formed by intermolecular 
cleavage of the C peptide and formation of S-S bridges between cysteines, apparently at 
two sites (site1 & site 2)
115
 with removal of an intervening polypeptide segment of 
approximately 50 amino acids known as the “hinge” region113,114,116(figure 1.6).   
  
Figure 1.6: Structure of TSHR protein: showing seven trans-membrane spanning loops, 
intra and extra cellular domain.(Adapted from Rapoport, B,1998)
109
.  
 
Furthermore, the extra cellular domain consists mainly of nine leucine-rich repeats (LRRs) 
and an N-terminal tail forming the binding domain for TSH. Whereas, the seven trans-
membrane domain are joined intracellularly by connecting loops that interact with G 
proteins when the receptor is activated
117
. Each LRR consists of 20–24 amino acids (aa), 
which combine to form a horseshoe-like structure with a concave inner surface which 
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determines its ligand specificity
118
.  The LRRs are characteristic to the subgroup of GPCRs 
such as TSHR, LH-R, FSH-R
45,109
.  
 
Unlike the other members of this subgroup of receptors, the extra cellular domain of the 
TSHR has two very unique regions. These regions are in the N-terminus of the ectodomain 
~10 amino acids (residues 38-45) and, in the C-terminus of the ectodomain ~ 50 amino 
acid (residues 316-366)
109
.  It is believed that the cysteine clusters in this N-terminus is 
important for appropriate folding and intercellular trafficking of the receptor. While, 
cysteine clusters at the C-terminus of the ectodomain serve in disulfide bond formation 
after intermolecular cleavage which produce the receptor’s A and B subunits109.  
 
 1.6.2 Genomic structure of TSHR 
 
At the genomic level, the full length TSHR is located on chromosome 14q3
110
 , sequence 
reference number (NM_000369). It spans over 60 kilobases (kb) which is split into 10 
exons. It consists of two subunits generated by cleavage of a single gene product, linked by 
disulphide bridges
119
. The A subunit (A), corresponding to the extracellular domain 
(ECD), is encoded by exons 1-9 plus the first 300 base pairs (bp) of exon 10, and a B 
subunit (B), which is a trans-membrane domain region (TMD), important for signal 
transduction via cAMP, encoded by the remaining 1000bp of exon 10
120
(figure 1.7).  
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Figure 1.7 Structure of Human TSHR gene (adapted from Paschke, R et al,1996)54. Blue 
boxes indicate the translated region (exons1-10), Black horizontal line indicates introns, 
and grey boxes represent untranslated regions. 
 
 
 
1.6.3 Cleavage and shedding of TSHR 
 
As mentioned above, the TSHR comprises two subunits held together by di-sulphide 
bonds. These two subunits are formed by intermolecular cleavage from a large precursor, 
apparently at multiple sites
114,115
. This cleavage is associated with the loss of an 
intervening C peptide segment corresponding approximately to 50 amino acids (amino 
acids 316-366) that are uniquely present in the TSHR and not LH and FSH receptors, 
(figure 1.6)
109
. The fact of TSHR cleavage into 2 subunits is thought to explain why the 
TSHR is so easily activated by autoantibodies and mutations
109
. 
 
Under certain conditions the disulphide bonds holding the A and B subunits are reduced 
most probably by protein disulfide isomerise leading to release of the A subunit from the 
membrane bound receptor 
116,121
and possibly progression of B subunit degradation towards 
the membrane
113
. This phenomenon of releasing of A subunit is referred to as receptor 
shedding and it produces a soluble form of ligand binding protein
122
.   
TSHR RNA
5́ UTR
Start codon
  UTR
Stop codon
1 2-8 9 10
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1.6.4 Post-translational TSHR modifications  
 
The recombinant full length glycosylated TSHR determined by SDS-PAGE appears to be 
~ 100-120 Kilo Dalton (kDa), this mature glycosylated form of TSHR receptor is 
expressed on the plasma membrane and undergoes cleavage
109
. The molecular weight of 
the un-glycosylated TSHR deduced from the amino acid sequence corresponding to ~ 84 
kDa
109
.  
 
1.6.5 Activation of TSHR  
 
The thyrotropin receptor basically acts as a transducer molecule whereby ligand binding 
(TSH or TSAbs) triggers the activation of the G protein (guanine –nucleotide –binding 
protein). The N-terminus of the ECD contributes to TSH binding but the trans-membrane 
spanning region and the carboxyl terminus are responsible for G protein coupling and 
signal transduction
123
.  When the TSHR is preferentially coupled to the α subunit of the 
stimulatory G protein (Gs α), it activates the adenylate cyclase and increases the 
accumulation of cyclic AMP (cAMP) (figure 1.8)
55
.  
 
Figure 1.8: Schematic figure showing activation of adenylate cyclase by TSHR 
activation.   
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Both the growth and function of the thyroid are stimulated by cAMP
55
. This second 
messenger indirectly regulates the expression of the thyroglobulin (TG) and thyroid 
peroxidase (TPO) genes, whose promoters contain binding sites for the transcription 
factors TTF-1 and TTF-2 and Pax8
124
. Therefore, continued stimulation of the cAMP 
pathway (as occurs in patients with Graves’ disease) causes hyperthyroidism and thyroid 
hyperplasia
124
.  TSH has been documented to induce not only cAMP activation but also to 
the induce protein kinase C pathway in thyroid cells
125
.  
 
1.6.6 TSHR expression in the skin  
 
It is well known that skin development and function are regulated by thyroid hormones. 
However, thyroid dysfunction can cause alteration in skin architecture and 
haemostasis
50,126
.  For example thyroid hormone dysfunction can effect fetal epidermal 
differentiation, barrier formation, hair growth, sebum production, wound healing, 
epidermal oxygen consumption, keratinocyte proliferation, and keratin gene expression 
127,128,77,126,129-131
. Traditionally the skin/skin appendages conditions associated with thyroid 
dysfunction have all been attributed to the effects of too much or too little thyroid hormone 
and several thyroid hormone responsive genes have been identified in the skin
53
. However 
a role for TSH and autoantibodies has also been suggested but this would require the 
presence of the TSHR in the skin. More recently, elements of the hypothalamic- pituitary –
thyroid axis genes
53
 have been demonstrated in the skin with TSHR expression shown to 
occur in different cell types, including the epidermal keratinocytes, dermal papillae 
fibroblasts
132
, hair arrector pili muscle, sweat glands, sebaceous gland cells, vascular 
endothelial cells, Schwann cells
133
. 
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1.7 TSHR variant 
 
A number of TSHR splice variants or isoforms of variable length have been described for 
the TSHR
134
, LH/hCG receptor
135,136
 and FSH receptor
137, 138
.  TSHR variants have also 
been described in other vertebrates including mouse (NM_001113404.1), dog
139
 and 
embryonic chicken thyroid
140
. The pathophysiologic importance of these variants is not 
clearly known
141
. Graves and his team were able to clone and sequence a 1.3kb TSHR 
variant namely TSHR isoform 2 precursor which codes for amino acid residues (21-253) 
(NM_001018036.1)
134
 and, found that it comprised exons 1-8 and a new “tail sequence”. 
This transcript variant encodes the extracellular ligand binding domain but lacks the trans-
membrane domain and is therefore not capable of signalling
134
. Furthermore, another 
TSHR variant with deletion of exon 3 has been described
139
 with deletion of exon 3 known 
as TSHR isoform 3 precursor which codes for amino acid residues 21-274 
(NM_001142626.1)
139
. The isoform variants differ in the 3' UTR and coding sequence 
compared to isoform 1. The resulting protein variants have a shorter and distinct C-
terminus compared to isoform 1
134
. 
 
The splice variants for the glycoprotein hormone receptors family described in the 
literature so far comprise nearly the entire extracellular domain of the receptors
134,138
, and 
parts of the carboxyl terminal intracellular domain
135,136
. Therefore, studies trying to detect 
full length TSHR by PCR should be undertaken with primers spanning exons 1-10. Studies 
trying to detect full length TSHR using primers spanning shorter segment could carry a 
considerable risk of amplifying the TSHR variant instead of the full length receptor as 
these short segment primers could not distinguish between the full length form and the 
variant form
141
.      
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The level of expression of these receptors varies depending on the functional state of the 
target tissue for LH and FSH
142,143
. Using primer specific for human 1.3kb variant 
transcript described by Graves and his team in 1992
134
 in a reverse polymerase chain 
reaction and southern blotting analysis
134
, Paschke and his team were able to demonstrate 
the presence of 1.3kb variant transcript in many locations including normal thyroid tissue, 
Graves’ thyroid, peripheral blood mononuclear cells (PBMC) and also in extra ocular 
muscles and to a lesser extent in fat and cultured ocular and dermal fibroblasts
141
. 
However, it is not known whether TSHR variants actually exert a physiological role in the 
body. Similarly, the exact cellular location of TSHR variant expression is also not known 
yet. In addition to the possible modulatory effects of TSHR variants on TSH/TSHR 
interactions is still not clear.  
 
1.8 Thyrostimulin 
1.8.1 Thyrostimulin discovery 
 
A new glycoprotein hormone known as thyrostimulin or corticotroph-derived glycoprotein 
hormone has been described
144
. Based on Genbank search, Nakabayashi et al, 2002144, 
identified two novel human glycoprotein hormone-like genes The first one was named 
GPHα2 due to its structural similarity to the common glycoprotein α-subunit and, the 
second one was named GPHβ5 as the potential fifth member of glycoprotein hormone β-
subunit family, accession numbers for α2 and β5 are AF403384 and AF403430, 
respectively
144
 . This new hormone was named thyrostimulin. 
 
Human α2 is located on chromosome 11q13 and β5 is located on chromosome 12145.  Both 
α2 and β5 subunits were capable of activating TSHR in vitro and in vivo with an affinity 
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similar to that of thyroid stimulating hormone (TSH). However, they have limited effect on 
LHR and FSHR
144
. The pathophysiological role of thyrostimulin is still unclear. However, 
its expression in the anterior pituitary suggests a paracrine signaling mechanism
144,146
. 
 
1.8.2 Structure of Thyrostimulin 
 
Thyrostimulin consists of non-covalent heterodimers of a novel α subunit and unique β 
subunit
144
. Unlike other glycoprotein hormone which shares a common α subunit GPH α 1, 
this novel α subunit does not form a heterodimer with any of the known β subunits (TSH-
β, LH-β, FSH-β, CG-β)144. They contain cysteine residues that form a cystine knot 
structure, which is common to all glycoprotein hormone subunits important for the 
formation of the disulphide bond
144,147,148
. However, the thyrostimulin is less stable than 
the other glycoprotein hormones during the SDS-PAGE analysis
144, because the β5 lacks 
the disulfide bond necessary for the seat belt formation
145
.  
 
This typical framework consists of four cysteine residues with a cysteine spacing of Cys-
(X) 3- Cys and Cys-X-Cys, important for a ring structure formed by eight amino acids. The 
cystine knot family members contain two additional cysteines (C1,C4) that form a third 
disulfide bond that penetrates the ring structure, thus forming a cystine knot with 10 amino 
acids of which six are cysteine residues
149
. Cysteines 2, 3, 5, and 6 form a ring by disulfide 
bonding between cysteines 2 and 5 as well as 3 and 6. The third disulfide bond, formed by 
cysteines 1 and 4, penetrates the ring, thus forming a knot
148
.  The arrangement of the 
cysteine knot folding of these domains in sequence motifs for GPHα2 forms a three-
dimensional structure and has been referred to as a “hand” containing two fingers and a 
middle heel (figure 1.9)
147
. Two of them, between cysteines 1 and 2, as well as 4 and 5, 
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consist of anti-parallel β-strands that form finger-like projections, whereas the third 
domain between cysteines 3 and 4 usually contains an α-helical structure147.  
 
 
 
Figure.1.9: Schematic diagram showing the cysteine knot structure of thyrostimulin 
(adapted from Okajima,Y.  et al,2008)
147
. (A) Consensus sequence for the 10-membered 
cysteine knot structure. Due to the arrangement of the domains, the three-dimensional 
structure of these proteins has been referred to as a “hand” containing two fingers and a 
middle heel. (B) Sequence motifs for GPHá2 showing oligosaccharide attachment sites
147
. 
 
 
 
Heel 
Finger1 Finger2
The cysteine knot motif 
A
B GPHα2
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1.8.3 Role of N-linked glycosylation motifs in thyrostimulin 
regulation  
 
The oligosaccharides of glycoprotein hormones have been reported to be significant for 
their bioactivities
101
. Loss of these oligosaccharides may cause disruption of protein 
folding and /or disulfide bond formation, consequently altering the peptide stability and 
increase the peptide sensitivity to proteases
101. The GPHα2 and GPHβ5 subunits of 
thyrostimulin have three N-linked glycosylation motifs, which play a crucial role in 
thyrostimulin regulation. They are located at positions (Asn14 and Asn 58) of GPHα2 and 
(Asn63) of GPHβ5147. 
 
Okajima and his colleague studied the role of thyrostimulin N-linked oligosaccharide 
subunit expression, secretion and assembly by using site directed mutagenesis (site 
specific disruption) which allows selective and complete inhibition of oligosaccharide 
attachment at each site
147
. Deletion of both oligosaccharide motifs in GPHα2 (α2n 14,58q) 
and deletion of the solitary oligosaccharide in GPHβ5 (β5n63q) significantly decreased the 
expression level, secretion and stability of both subunits in the conditioned medium and 
cell lysate
147
. This was consistent with the previous finding that removal of the 
oligosaccharide chain in GPHα1 of all glycoprotein hormones and TSH-β of the TSH 
significantly reduced the secretion and expression level to negligible amounts
150,151
. 
 
1.8.5 Tissue expression of Thyrostimulin  
 
Tissue expression of thyrostimulin is highly controversial. Expression profile analysis 
using RT-PCR and immuno-histochemistry showed that both Thyrostimulin subunits α2 
and β5 are expressed in the pituitary of different vertebrates also in different tissues 
outside the HPT axis
144,145
. In general, tissue analysis demonstrated that α2 showed wider 
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range of distribution than β5, immuno-histochemistry analysis showed both Thyrostimulin 
subunits were co-localized in the rat pituitary, central nervous system, adrenal gland, 
stomach, duodenum, pancreas and testis
145,146,152
. A further report by Nakabayashi and his 
colleagues, where by endpoint RT-PCR analysis of a panel of rat tissue mRNA found α2 
and β5 transcripts in diverse tissues outside the HPA and HPT axes. However, they 
reported that β5 expression was observed in the brain, pituitary, thyroid, oviduct and the 
heart and not in testis or adrenal gland
144
. In contrary, a different group used northern 
analysis and quantitative real-time PCR was able to detect expression of α2 and β5 in 
different set of human tissues
153
. The reason for the difference in the expression pattern of 
thyrostimulin subunits in various reports is unclear, it could be explained by antibody 
specificity (Anti- α2 vs. Anti- β5), the sensitivity of the methods used and, alternatively, 
species differences (rat vs. human) might also account for the variable results. 
 
Thyrostimulin is thought to be expressed in corticotroph cells of the human anterior 
pituitary
153
. Nakabayashi and his colleagues reported co-localization of α2 and β5 to the 
anterior pituitary cells using double fluorescent immuno-staining, they did not, however, 
identify the specific cell type co-expressing the two subunits .In this study,  the α2 positive 
cells did not show co-staining with adrenocorticotropic hormone (ACTH), growth 
hormone (GH), prolactin (PRL), LH-β or TSH-β secretory cells144.  
 
Furthermore, Okada et al further advocated this point and reported that Thyrostimulin is 
expressed in the anterior pituitary, in an attempt to specify the cells which secrete 
Thyrostimulin they used double immuno-histochemical methods to stain for the co-
localization of β5 with any of the markers for cell types in the anterior pituitary, including 
GH, PRL, LH-β, FSH-β, and ACTH. They reported co localization of β5 with ACTH 
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which, according to the author, strongly suggests that thyrostimulin is produced in human 
pituitary by corticotrophs which are known to secrete ACTH. This was an interesting 
observation because these cells were not thought to have a direct role in thyroid 
activation
153
. These results contradict with another study which reported that thyrostimulin 
α2 mRNA is diffusely expressed in the anterior lobe of rat pituitary by using in situ 
hybridization and, did not co-localize with any of the other anterior pituitary hormone 
mRNAs
146. The author suggested that α2 might be expressed in an unidentified cell type 
and, thyrostimulin β5 mRNA was not detected in rat anterior pituitary by using the same 
method. This divergence from the immunohistochemical data might be explained by: 
firstly, thyrostimulin β5 might be stored in the pituitary but its expression is undetected in 
normal conditions. Secondly, cross reactivity of antisera with other antigen
146
. 
 
1.9. Thesis Hypothesis & Aims 
Thyroid dysfunction is often accompanied by skin problems. We are hypothesizing that the 
changes that accompany thyroid dysfunction in the skin are not simply due to the changes 
in the thyroid hormone levels. We think that TSHR activation might also be important but 
we are suggesting that there might be a novel ligand which is the thyrostimulin which may 
be providing the TSHR activation. The signaling through TSHR may be important in skin 
biology as well as thyroid function, this would require a functional TSHR in skin.  
 
We will investigate this hypothesis and address the following aims  
1. Is there a functional TSHR in the skin 
2. Are α2 and β5 subunits of thyrostimulin expressed in the skin 
  
 
 
 
 
 
 
 
 
 
 
 
Chapter two 
  
Expression of TSHR and agonist 
(Thyrostimulin) 
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2. Chapter two 
 
2.1. Introduction 
Almost all people with thyroid dysfunction experience aberrant activation or increased 
signalling of the TSHR. This is either because of high TSH in hypothyroidism or from 
thyroid stimulating antibodies in Graves’ disease49; or due to rare cases of familial non –
auto-immune hyperthyroidism which is caused by germline activating TSHR mutations
154
. 
Since TSHR is expressed in the skin its activation might be the cause of skin disease 
associated with thyroid dysfunction rather than changes in thyroid hormone levels.  
 
 TSHR RNA has been clearly detected in extra-thyroidal tissues including the skin
132
, 
adipose tissue
155
, cultured human hair follicle keratinocytes, human dermal papilla 
fibroblasts
133
, human skin fibroblast, and melanoma cell lines
53
offering an alternative 
explanation for dermatopathology associated with thyroid disorders. TSHR 
immunoreactivity (using monoclonal TSHR antibodies) has been observed in the dermis of 
both patients with pretibial myxedema and unaffected individuals
61
. All of these data lead 
to the question of whether the TSHR is of functional importance in normal skin or not?  
 
The thyroid-stimulating hormone receptor (TSHR) belongs to the superfamily of G-
protein-coupled receptors, characterized by the presence of a large extracellular domain 
and an extracellular amino terminus, jointly comprising the ligand binding site; and a 
seven trans-membrane spanning domain plus the carboxyl terminus responsible for the G 
coupling and the signal transduction
45,109,111
. 
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The full length TSHR consists of two subunits generated by cleavage of a single gene 
product, linked by disulphide bridges
119
. The A subunit, corresponding to the extracellular 
domain (ECD) and B subunit, which is a trans-membrane domain region, important for 
signal transduction via cAMP
45,156
.  The TSHR gene is located on chromosome 14q31, and 
spread over 60 kb and it spans 10 exons. The ECD is encoded by first nine exons (exons 1-
9) and part of the last exon, whereas the transmembrane and the intracellular domains are 
encoded entirely by the last exon (exon10)
100
. 
 
A number of TSHR alternative splicing or truncated isoforms have been detected on 
Northern blot analysis of human thyroid cells. Different other variant forms has been 
described in the literature which were shorter and longer than the cloned 4.3kb variant 
these are; (1.7kb variant), (1.3kb variant)
134
. Moreover, another TSHR variant with 
deletion of exon3 has also been described
139
, amongst these 1.3kb is the most abundant 
form therefore, we will be focusing on this form in this project.   
 
The TSHRv1.3 transcript has been shown to be expressed in normal and Graves’ thyroid 
extra-ocular muscle, PBMC, and, to a lesser extent in fat and fibroblasts
141
. The major 
human TSHR variant transcript (TSHRv1.3) (NM_001018036.2) is 1.3 kb in human and is 
comprised of exons 1-8 of the major mRNA species plus a unique 3`-sequence of DNA 
tract, presumably an intron, predicted to encode further amino acids and a polyadenylated 
tail
134
.  This transcript variant not only lacks the trans-membrane domain or signalling 
capability but also if expressed it is not expected to couple to G-proteins
134
. The exact 
pathophysiologic importance of the variant isoforms is not known yet. However, a possible 
biological role of truncated isoforms in modulating TSH signals is suggested by their 
occurrence in other species, including mouse, dog and chicken
157
.  
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The TSHR variant isoforms are formed by alternative splicing of the full length TSHR 
mRNA. Alternative splicing of eukaryotic pre-mRNAs is a mechanism for generating 
potentially many transcript isoforms from a single gene; the exons of the RNA produced 
by transcription of a gene (a primary gene transcript or pre-mRNA) are reconnected in 
multiple ways during RNA splicing. The resulting different mRNAs may be translated into 
different protein isoforms; thus, a single gene may code for multiple protein products 
(figure 2.1). The alternative splicing was thought to be unimportant and maybe even an in-
vitro artefact
157
. Currently its importance in generating novel and different proteins is 
increasingly recognised
157
. 
 
 
 
 
 
Figure 2.1, Schematic diagram showing alternative splicing. A single gene can produce 
multiple related proteins, or isoforms by means of alternative splicing (Adapted from A 
Guttmacher,2002
158
 ). 
 
 
Alternative splicing 
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This process includes joining of different 5' and 3' splice sites where two or more 
alternative 5' splice sites compete for joining to two or more alternate 3' splice sites, other 
types of common gene splicing events includes exon skipping and intron retention
158
. 
Taking that into consideration, as the full length TSHR transcript comprises 10 exons and 
is 4.3Kb and a smaller variant transcript comprises exons 1-8 of 1.3 Kb of the receptor 
gene, then as a result of alternative splicing, a smaller part of intron 9 is removed leading 
to creation of an alternative exon that codes for 22 unique amino acids (aa) in hTSHR and 
15 unique amino acids (aa) in (mTSHR) before reaching an alternative STOP codon
134
 
(figure 2.2). 
 
 
 
 
Figure 2.2. Structure of Human TSHR gene and TSHR splice variants.  Blue boxes 
indicate exons1-10, Black horizontal line indicates introns, and light pink box represents 
unique sequence in TSHRV, dark pink box indicates alternative stop codon.  
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Several studies were undertaken to detect the expression and the localization of full length 
TSHR in the skin
53,132,133
. In 2002, Slominski et al, demonstrated TSHR transcripts in 
cultured keratinocytes, epidermal melanocytes and melanoma cells using an exon 6 
forward and exon10 reverse primers
53
. While,  Bodo et al, 2009
133
, used an exon 1 forward 
primer and an exon 2 reverse primer and found transcript in normal human scalp skin and 
human hair follicle mesenchyme. Furthermore, Cianfarani and his colleagues, 2010
132
, 
amplified the TSHR with forward primers located in exons 4/5 and reverse primer located 
in exons 7/8 in cultured keratinocytes and dermal fibroblast (figure 2.3).  
 
 
 
Figure 2.3: Primers used in different reports to study TSHR expression. Blue boxes 
indicate exons1-10; pink box represents unique sequence in TSHRV, dark pink box indicates 
alternative stop codon (F) Represents forward primer, (R) represents reverse primers. Black 
arrows represent primers used in different reports; Red arrows represent primers used in this study 
(Adapted from Paschke R,1994
141
). 
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Generally, attempts to detect a full-length TSHR by PCR should be undertaken with 
primers spanning exons 1-10.  For example, as shown in (figure 2. 3) Bodo et al, 2009 and 
Cianfarani et al, 2010 tried to detect the full length TSHR with primer pairs spanning 
shorter segments as this may carry a considerable risk of amplifying TSHR variants, 
instead of full-length TSHR.  
 
In this project we used RT-PCR technique for detection of full length and the variant 
isoform of TSHR in the skin, thyroid and different cell lines and we tried to minimize the 
risk of amplifying the wrong gene and, avoid false positive results, for that reason the 
amplification strategy we employed was to use specific primers which distinguish between 
the full length and variant isoform for TSHR.  Full length human TSHR primer pair were 
designed to amplify 254 bp product, exons (9 to 10) while, the variant isoform primer pair 
were designed to amplify 338 bp product, exons 4/5 to the initial part of exon 8/9 (figure 
2.3) primer positions are shown in TSHR & TSHR  variant sequences (see appendix).  
 
The biological role of thyroid-stimulating hormone (TSH; thyrotropin) as an agonist of the 
TSH receptor (TSHR) in the hypothalamic–pituitary–thyroid axis is well known132. 
However, this receptor can also be activated by other pathological elements; the TSHR is 
considered as a major primary autoantigen in autoimmune thyroid disease
111
.  In particular, 
the TSHR is the target of the immune response in patients with Graves’ disease in which 
thyroid stimulating antibodies mimic the action of TSH and cause hyperthyroidism and 
goitre. While, other autoantibodies can inhibit its activation by TSH in some cases of 
Hashimoto’s thyroditis159. Both germline and somatic mutations, commonly located in the 
transmembrane regions, may induce constitutive activation of the receptor, resulting in 
congenital hyperthyroidism or the development of actively secreting thyroid nodules 
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respectively
55,160
. Similarly, mutations leading to structural alterations may induce 
constitutive inactivation and congenital hypothyroidism
55,160
.   
 
Based on Genbank searches, a new TSH-like hormone was identified named thyrostimulin 
because of its ability to activate the TSH receptor in vivo and in vitro
144
. This hormone is 
comprised of two novel human glycoprotein hormone like genes named GPHα2 (α2) and 
GPH-β5 (β5) based on chronological order of discovery. The Genbank accession numbers 
for α2 and β5 are AF403384 and AF403430 respectively144. The two thyrostimulin 
subunits are characterized by the potential for, in vitro, heterodimerization by using a 
yeast-two hybrid assay. Immunological analysis confirmed that both subunits colocalize in 
anterior pituitary cells. Recombinant thyrostimulin activates human TSHR but not LH and 
FSH receptors with high affinity to TSHR in a radioligand receptor assay
144
. The two 
recombinant thyrostimulin subunits stimulate cAMP production, thymidine incorporation 
by cultured thyroid cells and have an in vivo thyrotropic activity by increasing serum 
thyroxin levels in TSH suppressed rats following intravenous administration
144
.  
 
The potential physio-pathological role of thyrostimulin hormone is still awaiting 
elucidation. However, it was suggested that this hormone may play a role in a paracrine –
signalling mechanism in the anterior pituitary and other extra-thyroidal tissues expressing 
TSHR
161,162
, suggesting that thyrostimulin could play a role as a locally acting factor in 
activating the TSHR.  
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2.1.1Aims of chapter two  
 
The aims of this chapter are:   
Firstly, to investigate the site of expression of full length signalling competent TSHR 
receptor in other tissues apart from the thyroid especially in the skin, if so, which cell type.  
Secondly, to explore the possibility of TSHR variant expression in the skin and its role as a 
potential TSH or thyrostimulin binding protein, and finally to investigate whether the 
transcripts for the α2 and β5 subunits of thyrostimulin are co-expressed with the TSHR as 
a first step in determining the likelihood of thyrostimulin to serve as an alternative ligand 
of TSH for activating TSHR or TSHRV in the skin and in a variety of mouse tissues. 
However, its exact role is still unknown.   
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2.2. Materials and Methods 
2.2.1 Tissues and cells used in this project 
 
 2.2.1.1 Human tissues 
Since ethical approval is extremely time consuming and would have delayed the start of 
this project, human thyroid tissue and normal human skin tissue was purchased from a 
commercial source, AMS Biotechnology (Europe) Ltd, UK. Some skin samples were from 
the Dermatology Department, Cardiff University and were collected for research purposes 
with patient consent prior to the 2004 human tissue act. 
 
2.2.1.2 Mouse tissues  
For easy access of different mouse tissues, mouse tissues were used collected from adult 
C57Bl/6 mice aged 2-10 weeks (males and females). Mice were sacrificed using CO2 
asphyxiation (schedule 1) and tissues were dissected and immediately, frozen on dry ice. 
Tissues were stored at -80ºC until required. Prior to RNA extraction the tissues were cut up 
finely using a surgical scalpel on dry ice. 
 
2.2.1.3 Cell culture 
As skin is a combination of lots of cell types we used different cell lines, each cell line 
representing one cell type and are in vitro equivalents of the cell types found in the skin 
(table 2.1). The cell lines used in this project were to extract RNA or proteins. They were 
kindly prepared and provided by colleagues in the Dermatology and Endocrinology 
laboratories.  
 
74 
 
Table 2. 1.  Summary of different cell lines used in this project. 
 
Cell 
line 
Cell Type Culture Medium Source Reference 
HaCaT Human 
keratinocyte 
cell line. 
Cell passage 
number was 
38-40. 
DMEM (high glucose) 
supplemented with L-
Glutamine, 10% fetal calf 
serum (FCS). Medium for 
differentiation 
experiments.  
Cell Lines Service 
(CLS), Germany. 
  
Boukamp et al, 
1988
163
. 
HCA2 Human dermal 
fibroblast cell 
line 
Same as HaCaT but used 
heat inactivated FCS.  
Dr David Kipling, 
Cardiff University  
Wyllie et al. 
2000
164
.  
3T3L1 Mouse 
preadipocyte 
cell line 
DMEM/F12 10% FCS 
(complete medium, CM). 
ATCC* 
(Atlanta,USA) 
Zhang et al, 
2006
165
. 
3T3 Mouse 
embryonic 
fibroblast cell 
line 
DMEM + 10% FCS  Dr Joachim 
Bugert, Cardiff 
University 
Todaro GJ, Green 
H,  1963
166
. 
*ATCC= American Type Culture Condition 
 
2.2.1.4 Cell culture conditions 
Specific culture medium and conditions for each cell type used is shown in the summary 
table above (table2.1). Generally, the cells were grown in 80 cm
2
 Nunclon™ delta surface 
flasks [Nunc, UK] containing 10 ml culture medium. The medium consisted of Dulbecco’s 
modified Eagle medium (DMEM) (with 4.5 g/L glucose, L-glutamine and without sodium 
pyruvate) supplemented with 10% heat-inactivated Fetal calf serum (FCS) (EU approved), 
50 U/ml penicillin, 50 µg/ml streptomycin and 2.5 µg/ml fungizone (amphotericin B) [all 
reagents from Cambrex, Berkshire, UK]. The cells were kept in a humidified 5% CO2 
atmosphere at 37°C, and the culture medium was routinely replaced every 2 days.  
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2.2.1.5 Trypsinisation of cells  
The cells were passaged when they reach 80% confluence. The culture medium was 
removed and the cells washed three times with 10 ml sterile PBS. Then 2ml of trypsin-
EDTA (Lonza, Slough,UK) was added and the flask incubated at 37 ºC until the majority 
of the cells were in suspension ( ~ 5-10 min). To aid the release of the cells the flask was 
lightly tapped every couple of minutes. Once in suspension, 20 ml DMEM with 10% FCS 
was added to inactivate the trypsin. The cells were then reseeded in a fresh flask, if split 
1:5 they were ready to passage again within 7 days (for HaCaT cell line). For other cell 
lines, this varies between 4-8 days.     
 
2.2.1.6 Cryo-preservation of cells 
The cells were trypsinised as described above and the resulting suspension of cells 
centrifuged at 1000 rpm for 5 minutes at room temperature. The cell pellet was then 
resuspended in 0.5 ml culture medium and 0.5 ml freezing mixture (FCS with 20% 
dimethyl sulfoxide (DMSO) [Sigma-Aldrich Company Ltd, Dorset, UK] and transferred to  
2 ml sterile cryotube. The cryotube was placed in an insulating polystyrene freezing box 
containing isopropanol [Fisher Scientific UK Ltd, Leicestershire, UK] (ensuring a cooling 
rate of 1°C/min) and placed in an -80°C freezer overnight. The next day the cryotube was 
transferred to liquid nitrogen (-190°C) for long-term storage. 
 
Experiment designs: to study the expression of TSHR and agonist (thyrostimulin) in 
HaCaT cell line we used two experimental designs. The first experiment was based on the 
use of calcium for cell differentiation
167
and, the cells were harvested before and after 
adding calcium and the second experiment was based on confluence for the stratification 
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and differentiation to be initiated and similarly the cells were harvested at different time 
points. 
 
2.2.1.7 Calcium-Shift Induced Differentiation of HaCaT 
The day that the cells were plated was designated day 0. Following trypsinisation of an 
80% confluent T75 flask, the resulting cell suspension was centrifuged at 1000 rpm for 5 
mins at room temperature. The cell pellet was resuspended in 20 ml KGM® (keratinocyte 
growth medium) KGM® SingleQuots® supplemented with (Bovine pituitary extract, 
human epidermal growth factor, insulin and hydrocortisone) [Cambrex, Berkshire, UK] 
and 0.06 mM CaCl2 [Sigma-Aldrich Company Ltd, Dorset, UK]. This was repeated to 
ensure all traces of the DMEM (Lonza, Slough, UK) and serum were removed. The 
volume of medium was then adjusted to give a cell density of 4.5×10
5
 cells per dish in 6 
ml of low calcium medium. The cells were plated in 10 cm wells at a cell density of 
4.5×10
5
 cells per dish. The cultures were maintained in a humidified 5% CO2 atmosphere 
at 37°C and the DMEM culture medium replaced every two days. When the cells reached 
80% confluency (usually around day 6) the medium used was switched to KGM
®
 
supplemented with KGM
®
 SingleQuots
®
 and 1.8 mM CaCl2, and the cells were maintained 
for a further 10 days in this high calcium medium (bovine pituitary extract, human 
epidermal growth factor, insulin and hydrocortisone) [Cambrex, Berkshire, UK]. The cells 
were plated into six dishes:  the first one which is in low Ca
+2
 and harvested around 3 days 
when the cells are about 30% confluent; the second one which is collected on the day of 
shift when the cells are 80 % confluent (usually day 6); and the third one which is kept in 
low Ca
+2
 for the whole experiment (16 days total), then 3 other dishes which are taken at 
(6 days + 3), (6 days + 6), and (6 days + 10) post shift in high Ca
+2
 as illustrated in (figure 
2.4). 
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2.2.1.8 Confluence induced differentiation of HaCaT 
Similarly, the day that the cells were plated was designated day 0. Following trypsinisation 
of an 80% confluent T75 flask, the resulting cell suspension was centrifuged at 1000 rpm 
for 5 mins at room temperature, The cell pellet was resuspended cells in a Dulbecco`s 
modified Eagle`s medium DMEM (Lanzo, Slough, UK) (high calcium) supplemented with  
a mix of 10% fetal calf serum (FCS) (Biosera, South America), 2mol/L l-glutamine, 20 
mmol/L HEPES buffer, 5g/ml insulin, 5g/ml transferrin, 0.4 g/ml hydrocortisone and 
5 ng/ml sodium selenite The cells were plated in 10 cm wells at a cell density of 4.5×10
5
 
cells per dish. Cells were grown at 37C in a humid condition with 5% CO2 and 95% air 
and the Fresh culture medium containing 10% FCS was replaced every two days until cells 
were fully confluent. The cells were harvested when pre-confluent state (usually day 1), on 
day 3 when the cells are about 30% confluent; and (3 day + 1), (3 days + 3) ,(3 days + 7), 
(3 days + 10) post confluent,  see (figure 2.4) 
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KGM  Low Ca2DMEM High Ca 2
4.5 105 cells  
Plating Day 0
80% confluent
Day 3
Day 6
Low Ca +2
0.06 mM CaCl 2
High Ca +2 
1.8 mM CaCl2
Day 6+3 
Post shift
Day 6 +10 
Post shift
Day 16
Day 0
Day 3 (confluent)
Day 3 +7 
post-confluence  
Day 3 +10 
post-confluence 
Day 3 + 3 
post confluence
30% confluent
Day 3 +1
post-confluence
Day 6 +6 
Post shift
Day 1Pre- confluentDay 1
 
 
 
 
Figure 2.4: Schematic diagram showing HaCaT differentiation experiment design. Showing 
where the cells were plated in KGM, DMEM medium and harvested at different time points.   
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Figure 2.5:  Calcium-Shift Induced Differentiation of HaCaT.  
Showing live images of HaCaT cells plated in KGM medium at different time points 
before and after adding calcium. 
 
 
 
Low Ca2+
Day 3 (30% confluent)
Day 6 (80% Confluent)
Day16
Day 6+3
Day 6+6
Day 6 +10
High Ca2+
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2.2.1.9 Isolation of Total RNA from HaCaT Cells 
RNA samples were collected on day 1 (pre confluent), day 3 (30% confluency), day 6 
(80% confluency), (day 6 + 3) post-shift, (day 6 + 6) post-shift and (day 6 + 10) post-shift. 
Additional samples were also collected for the other experiment on day 1 (pre confluent), 
day 3 (confluent), (3 days + 1), (3 days + 3), (3 days + 7) and (3 days + 10) post confluent.  
 
In each case, the culture medium was removed and the cells washed three times with 1 ml 
Phosphate Buffered Saline (PBS). Total RNA was isolated using Invitrogen’s Trizol 
reagent (Invitrogen, life technologies ltd, Paisley, UK) according to the manufacturer’s 
instructions. The cells were lysed by the addition of 1 ml Trizol reagent and passing the 
cell lysate several times through a pipette. Visual inspection was performed using light 
microscopy to ensure complete cell lysis. To allow the dissociation of nucleoprotein 
complexes the cell lysate was transferred to a nuclease-free 1.5 ml microtube, and left for 5 
minutes at room temperature (RT). The RNA was separated from DNA and protein by 
adding 200 l chloroform [Fisher] and mixing the solutions vigorously. This was followed 
by incubation for 3 minutes at RT and then centrifugation at 12,000g for 15 minutes at 
4°C. The upper aqueous phase (500l), containing the RNA, was transferred to a fresh 
nuclease-free 1.5 ml microtube and the RNA precipitated by adding 500 l isopropanol 
[Fisher]. The sample was vortexed briefly, incubated for 10 minutes at RT, and then 
centrifuged at 12,000g for 10 minutes at 4°C. The supernatant was removed and the RNA 
pellet washed with 1 ml 75% ethanol [Fisher]. The sample was vortexed and then 
centrifuged at 7,500g for 5 minutes at 4°C. The supernatant was removed, the RNA pellet 
air-dried and resuspended in 20 l nuclease-free water [Promega]. Total RNA quantity and 
integrity were assessed by spectrophotometer [GeneQuant, GE Healthcare] and 2 % 
agarose gel analysis. RNA samples were stored at -80°C until required. 
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2.2.2 Reverse Transcription Polymerase Chain Reaction (RT-
PCR) 
 
The messenger RNA is first reverse transcribed into its complementary DNA (cDNA) 
using the enzyme reverse transcriptase. By means of semi-quantitative PCR, the resulting 
cDNA was used to amplify the regions of TSHR, TSHRV, α2 and β5 subunits of 
thyrostimulin and a housekeeping gene.  
 
2.2.2.1 RNA extraction 
 The initial and key step is to obtain high quality, intact RNA. The total RNA from human 
skin, thyroid, and mouse tissues was isolated with Trizol reagent (Invitrogen, life 
technologies ltd, Paisley, UK) according to the manufacturer’s instructions as described 
earlier. 
 
2.2.2.2 Reverse-Transcription 
The reverse transcription reaction was carried out by adding 5 µl (1µg RNA in 5µl of 
sterile dH2O) of mRNA to 1µl of Oligo-(dT) primers (Promega). The reaction was 
transferred to a thermocycler (GeneAmp9700, Applied Biosystem) and heated to 70°C for 
10 minutes to denature the RNA secondary structure. Reactions were cooled to 42°C and 
then 14 µl of a mixture of pre-prepared RT mix was added to each tube: 1 µl of reverse 
transcriptase AMV-RT (50 units/reaction) (Promega, Southampton, UK), together with 1 
µl of the RNAase inhibitor (Promega, Southampton, UK), 4 µl x5 Buffer (QIAGEN), 4 µl 
dH2O, 4 µl of deoxynucleotide triphosphate mixture (10Mm stock) (dNTP, Roche 
Diagnostics GmbH, Germany). The reaction was then incubated at 42°C for 60 minutes to 
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synthesise the cDNA and then at 70°C for 10 minutes to stop the reaction. The resulting 
cDNA was stored at -20°C until required. 
 
2.2.2.3 Polymerase Chain Reaction PCR  
PCR amplification was performed in a standard reaction volume of 50 µl with the use of 
Taq DNA polymerase (Qiagen, Crawley,UK) For each reaction 1 µl of cDNA template 
was added on ice to a microcentrifuge tube containing 49 µl of a master mix comprising 
the following reagents:  
 
Table 2.2: Constituents of PCR mix.  
PCR Mix Volume 
X 10 PCR amplification buffer 5 µl 
dNTPs mixture (10 mM)                                         1 µl 
Forward primers (0.1µg/µl )  2 µl 
Reverse primers (0.1µg/µl ) 2 µl 
MgCl2 (see MgCl2 optimization) Variable  
Q Solution Variable 
Taq DNA polymerase (5units/µl) 0 .25 µl 
Nuclease free water  Up to 50µl 
 
All the primers were synthesised by Sigma Genosys (Sigma-Aldrich, Dorset, UK) and 
designed from sequences obtained from NCBI Genbank. A summary of the primers used 
are shown in the (table 2.3) below.  The PCR tubes containing the PCR mix were capped 
and briefly centrifuged to collect the contents then transferred to MJ Research PTC-200 
Peltier thermal cycler. The Thermal cycling conditions for PCR: Denaturation for 5 
minutes at 95ºC was followed by 40 cycles of PCR amplification as follows: denaturation 
at 94ºC for 30 seconds, annealing at a temperature specific to each primer pair (table2.3) 
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for 30 seconds, extension at 72ºC for 30 seconds. The reaction products were maintained at 
4ºC after completion of cycles. 
 
2.2.2.4 MgCl2 optimization 
The MgCl2 concentration was optimized for each set of primers used in this project to get 
the maximum efficacy of the PCR.  In summary, in addition to the MgCl2 in the PCR 
buffer (15mM); 0 μl, 2μl, 4 μl, or 6 µl of MgCl2 (25mM) stock solution was added to the 
PCR mix to give final concentrations of 1.5mM minimum and 6.5 mM maximum. PCRs 
were run on an agarose gel and the intensity and purity of the amplicon compared. The 
PCR conditions giving the most intense single amplicon of the correct molecular weight 
was used for the same set of primers throughout the project.  
 
2.2.2.5 Calculating approximate annealing temp 
The annealing temperature of each set of primers was calculated according to the 
following equation:   (4xGC) + (2xAT) – 5 = º C  
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Table 2. 3: Summary of primers for genes of interest and housekeeping genes used in this project 
 
Species Gene 
NCBI Reference 
Sequence 
Amplicon 
size 
Sequence 
direction 
Primers 
Exon 
 
Annealing 
Temp  
 
MgCl2  
cycles 
 
Human 
 
HTSHR NM_000369 254bp 
Forward primer 
5’-GTGTCACTGCCCTTCCATCCA 
 
 
Exon 9 
 
 
60ºC 
 
       
    40 cycles 
Reverse primer 
 
5’-GGGGCTATTCAAGGCATTCACAGA 
 
 
Exon10 
   HTSHRV2 
 
NM_001018036.2 
 
338bp 
 
Forward primer 
 
5’-CCTCCTAAAGTTCCTTGGCATT  
 
  Exon 4/5 
  
 
 
     60ºC 
 
 
 
40 cycles 
Reverse primer 
5’-AGGACTTTCTTCCAAGAGGTAG 
 
Unique 
sequence in 
intron  
between 
exons 8/9 
 
  Mouse 
 
mTSHR 
 
 
NM_011648 
 
 
540bp 
 
 
166bp 
   
Forward  primer   
 
5’-ACGCATTCCAGGGCCTATGC  
 
5’-TCTTACCCGAGCCACTGC 
   Exon 6 
 
 Exon9 
 
 
     60 ºC 
 
 
 40 cycles 
Reverse primer 
5’-AGTTGCTTGGGCTCTCCTGG 
 
5’-TGTCACCCGGATCTTCTTCATA 
   Exon10 
 
  Exon10 
mTSHRV2 NM_001113404 232bp 
 
Forward primer 
 
5’-ACGCATTCCAGGGCCTATGC  
 
   Exon 6 
 
 
 
55 ºC 
 
 
 
      40 
cycles 
 
 
Reverse primer 
 
 
5’-TCCTAGATTTGTGCCTGGTGG  
 
 
   Exon 8 
 
Human 
 
APRT NM_000485 245bp 
 
Forward primer 
APRT (F1) 
       5’-GCTGCGTGCTCATCCGAAAG 
 
   Exon3 
 
 
   
     60ºC 
 
 
  
    35 cycles 
Reverse primer 
APRT (R1) 
 
5’-GTGGCCAGCAGATCATCCAC 
 
    
   Exon4 
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Mouse 
 
 
    β- Actin 
 
NM-007393 458bp 
 Forward primer  5’-GGTGGGAATGGGTCAGAAGG   Exon3 
 
    55 ºC 
 
30 cycles 
 
 
   Reverse primer 
 
5’-CACGCTCGGTCAGGATCTTC 
 
      
   Exon4 
     ARP 
 
 
NM_007475 347bp 
Forward primer, 
F2 
 
5`CTCGCTTTCTGGAGGGTGTC 
 
 
   Exon5 
 
 
55 ºC 
 
 
30 cycles 
Reverse primer, 
R1 
5`AAGCAGGCTGACTTGGTTGC 
   Exon7 
 
 
 
Human 
 
         α2 
 
 
BC093960 
400bp 
 
Forward primer 
 
5’-CTCGGAAGTGATGCCTATGGC 
  
 
 
60ºC 
 
 
 
40 cycles  
Reverse primer 
 
 
5’-CTAGTAGCGAGAGAGGCGACA 
 
 
           β5 
 
AF403430 
296bp 
 
Forward primer 
 
5’-ATGAAGCTGGCATTCCTCTTC 
 
  
 
 
60ºC 
 
 
 
40 cycles 
Reverse primer 
 
5’-CAGTTGGGCAGCTTGACAGTC 
 
 
Mouse 
 
        α2 
 
NM_130453 
 
355bp  
 
Forward primer 
 
5’-GAGTCTTGCTCCTTTGCCTGC 
 
 
   Exon2 
 
 
    
     60ºC 
 
 
 
 
 
40 cycles 
 
Reverse primer 
 
5’-CGGCACATATCACACTGGCAG 
 
 
    Exon4 
          β5 
 
 
NM_175644 
 
447bp 
Forward primer 
 
5’-TGAAGCCAGCGTTGTCACAGC 
   
  
 
60ºC 
Reverse primer 
 
      5’-ATGGGCATCCTTGTGAGCCAG 
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2.2.2.6 DNA (Agarose) gel electrophoresis 
The products of the PCR were analysed by size fractionation using agarose gel 
electrophoresis. To prepare an agarose gel an appropriate amount of agarose (Sigma-Aldrich, 
Dorset, UK) (2%) was dissolved in x2 Tris-acetate-EDTA (TAE) buffer (table 2.4) by 
heating the solution in a microwave oven for one minute until boiling. When the agarose had 
cooled sufficiently to touch, 5µl of Ethidium bromide (10mg/ml) (Sigma-Aldrich, Dorset, 
UK) was added and, the gel cast into a AGT1 gel tank (VWR International, UK) with a comb 
inserted at either end and left to set for around 30 min on a level surface. When set, the 
agarose gel was immersed in x2 TAE buffer. DNA samples were loaded (the Qiagen PCR 
buffer already contains gel-tracking dyes, ready for loading) into the wells of the 2% agarose 
gel together with a well containing standard size DNA ladder marker (New England Biolabs 
100 bp or 1 kb ladder). A constant voltage of 50V (approximately 120 mAmps) was applied 
until the tracking dye had migrated to the desired distance towards the positive electrode 
(about half an hour). The DNA was then visualised on an UV transilluminator, and 
photographed using Alpha Innotech Multi Image II, Alpha Imager HP, and wave length of 
365 nm.  The molecular weight was compared with the DNA ladder markers. 
 
Table 2. 4: X 50TAE (Tris-acetate-EDTA) buffer (stock solution) 
 
Tris  242g 
Acetic acid  57.1 g 
0.5 M EDTA PH 8 100 ml 
 
X 2 TAE was prepared by mixing 20 Parts stock with 480 parts H2O. 
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2.2.2.7 Sequencing of PCR products 
The identity of the PCR products and specificity of the primers for thyrostimulin and 
different types of TSHR in both species (human and mouse) were verified by DNA 
sequencing carried out by the Central Biotechnology Services (CBS) 
http://medicine.cf.ac.uk/cbs/, Cardiff University, Wales, and analyzed using A/B Applied 
Biosystem by life technology Software to confirm that they were 100% identical to their 
relevant cDNA sequences.  
 
The Modified Automated Sequencing Method using Big Dye v 3.1 & ABI 310 was applied. 
The forward and the reverse primer used for sequencing are listed in primer (table 2.3).  
Briefly, the PCR product was run in 2% Agarose gel to check that the bands were strong and 
clear and with the appropriate size. The following components were added to a nuclease-free 
500 l microtube: 20 µL of PCR product was mixed with 24 µL of PEG (Polyethylene 
glycol) (26% PEG 8000, 6.6 Mm MgCl2, 0.6 M NaOAc, pH5.2), the mixture was allowed to 
precipitate at room temp for 10 minutes then centrifuged at 13.000 rpm for 25 minutes at 
room temperature, the supernatant was carefully pipetted out (invisible pellets) The pellets 
were washed twice with 200 µL of ice cold 70% ethanol then centrifuged for 2 minutes at 
15.000 rpm. The supernatant was carefully removed and the samples were left to dry at room 
temperature for 5 minutes max. At this time point the sequencing oligonucleotide dilutions 
were made up (7µL primer + 13 µL of nuclease free water) and kept on ice and the master 
mix was prepared (2 µL of x5 Big Dye buffer, 2 µL Big Dye (v3.1), 1 µL of nuclease free 
water). The reaction mix was prepared on ice by mixing 4 µL of the DNA sample, 1 µL of 
primer, and 5 µL of master mix. The reaction mix was transferred to the PE Applied 
Biosystems 9700 thermocycler.  
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2.2.2.7.1 Thermocycler protocol for sequencing 
28 cycles of   Denaturation:   96C  for 10 sec  
    Annealing:       50C for 5 sec  
    Extension:        60C for 4min  
                                                              4C    
 
DNA samples were precipitated by the addition of 1 µL 3M Na
+
 Acetate (NaOAc) and 25 µL 
ice-cold 95% ethanol, then left at -20C for 15 minutes. Samples were centrifuged (15,000 
rpm at 4C for 30 minutes), and DNA pellets washed twice with 180 µL ice-cold 70% 
ethanol. Finally, the pellets were re-suspended in 10 µL ice-cold 70% ethanol for subsequent 
analysis on ABI 310 DNA sequencer, (Life Technologies Ltd, Paisley, UK). 
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2.3. Results 
2. .1. TSHR and agonist (α2 and β5) expression in human skin 
and human cell lines 
 
A number of tissues outside the thyroid express the TSHR including the skin suggesting that 
its activation might be the cause of skin diseases associated with thyroid dysfunction rather 
than changes in thyroid hormone levels. The aim of this experiment was to investigate 
whether TSHR, α2 and β5 thyrostimulin subunits are co-expressed in the skin and if yes, to 
determine in which cells type (s) they are expressed using appropriate cell lines.  
 
  
 
 
Figure 2.6: Transcript Expression of TSHR and thyrostimulin in human skin and human cell 
lines. Ethidium bromide stain of PCR amplification products separated on 2% agarose gel analysis of 
α 2 (410 bp), β 5 subunits (296 bp) of thyrostimulin and the thyrotropin receptor (TSHR) (254 bp) 
Lane 1) negative control (H2O) lane 2) Human skin, lane 3) HaCaT keratinocyte cell line, lane 4) 
HCA2 fibroblast cell line, + C) positive control (Human thyroid) for TSHR, APRT (251bp) = 
Housekeeping gene. The first lane contains the 100bp DNA ladder. 
 
Alpha 2 Beta5 TSHR 
1       2       3       4      1      2       3      4      1      2      3      4      +C
251bpAPRT
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As shown in figure 2.6, H2O was used as a negative control while human thyroid was used as 
a positive control for the TSHR. The ideal positive control for thyrostimulin would have been 
the human pituitary but this was difficult to obtain, and so not used in these experiments. 
APRT was used as a house keeping gene and the presence of the expected 251bp product 
shows that the RNA of all the samples tested was of reasonable quality and was reverse 
transcribed efficiently. The full length TSHR, of the correct amplicon size, is expressed in 
human skin, but it is not expressed in HaCaT keratinocyte and HCA2 fibroblast cell lines. On 
the other hand, both α2 and β5 subunits of thyrostimulin of the correct amplicon size are 
expressed in human skin, HaCaT keratinocyte and HCA2 fibroblast cell lines. No additional 
bands were observed. 
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2. .2. TSHR and agonist (α2 and β5) expression in mouse skin and 
mouse cell lines  
 
 
The aim of this experiment was to investigate whether TSHR, alpha2 and beta5 are co-
expressed in mouse skin and in which relevant mouse cell lines they are expressed.  
 
 
 
 
 
 
Figure 2.7: Transcript Expression of TSHR and thyrostimulin in mouse skin and mouse cell 
lines. Ethidium bromide stain of PCR amplification products separated on 2% agarose gel analysis of 
α 2 (313bp) and β 5 subunits (447bp) of  thyrostimulin and the thyrotropin receptor (TSHR) (166bp) 
from mouse skin and mouse cell lines:  Lane 1) negative control (H2O)   lane 2) Mouse skin (1), lane 
3) Mouse skin (2), lane 4) Mouse embryonic fibroblast cell line (3T3), lane 5) Pre-adipocyte cell line 
(3T3L1),  Actin (458bp) = Mouse housekeeping gene. The first lane contains the 100bp DNA ladder. 
 
 
 
 
Actin
(458bp)
1 2 3 54
Alpha2 Beta5 TSHR
1 2 3 54 1 2 3 54
500bp
500bp
166bp
100bp
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As shown in figure 2.7, H2O was used as a negative control (lane 1). The ideal positive 
control for the TSHR would be the mouse thyroid and, mouse pituitary gland for 
thyrostimulin. Mouse thyroid was used in most experiments. However, we were not able to 
isolate the mouse pituitary due to technical reasons. A parallel PCR analysis of β-actin 
provided a quality check for RNA integrity and RT efficiency for all samples. The TSHR and 
α2, (but not β5) are expressed in mouse skin of the correct amplicon size. Whereas, TSHR 
was not expressed in the mouse embryonic fibroblast cell line (3T3) nor in pre-adipocyte cell 
line (3T3L1). On the other hand, α2 was expressed in mouse skin and embryonic fibroblast 
cell lines (3T3) but not in the pre-adipocyte cell line (3T3L1). An additional band was seen in 
lane 5 α2 (740bp) which is most likely due to amplification of genomic DNA.  
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2. . . TSHR and agonist (α2 & β5) expression in different mouse 
tissues 
To facilitate our investigation of possible TSHR expressing tissues which might also be 
targets of thyrostimulin we applied ex vivo analyses of murine tissue aiming to investigate 
the expression of TSHR, α2 and β5 subunits of thyrostimulin as well.  
 
Alpha2
Beta5
TSHR
β-Actin
1        2        3        4        5        6        7       8       9      10     11      12100bp
355bp
447bp
540bp
458bp
166bp
 
 
 
Figure 2.8:  Transcript expression of TSHR and thyrostimulin in different mouse tissues.  
Ethidium bromide stain of PCR amplification products separated on 2% agarose gel analysis of alpha 
2 (355bp) and beta 5 (447bp) subunits of thyrostimulin and the thyrotropin receptor (TSHR) (540bp & 
166bp), β-actin (458bp) = Mouse housekeeping gene. :  Lane 1) negative control (H2O), Lane 2) 
heart, Lane 3) lung, Lane 4) kidney, Lane 5) spleen, Lane 6) stomach, Lane 7) small Intestine, Lane 
8) eye, Lane 9) brain, Lane 10) thyroid, Lane 11) ovary, Lane 12) testis, the first lane contains the 
100bp DNA ladder. 
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As shown in figure 2.8, H2O was used as a negative control. A parallel PCR analysis of β-
actin provided a quality check for RNA integrity and RT efficiency for all samples. The 
TSHR transcript is expressed in lung, eye, kidney, thyroid, ovary and testis, TSHR in lane 8 
(amplicon size 166 bp) was amplified using different set of primers. The α2 subunit (355bp) 
is only expressed in eye, ovary and testis. On the other hand, β5 subunit is expressed in most 
of the tissues tested of the expected size (447bp) such as heart, lung, kidney, small intestine, 
eye, brain, ovary and testis.  However, all three transcripts were only co-expressed in the eye 
and testis. Additional bands were amplified by TSHR primers in particular in heart, kidney, 
and testis samples. The additional band amplified by β actin primers in kidney and brain 
samples (872bp) is most likely due to amplification of genomic DNA.  
 
 
2.3.4. TSHR expression in mouse hair cycle 
 
This experiment was conducted to try to identify the skin component responsible for the 
observed TSHR transcript expression in mouse skin. RT-PCR was carried out at different 
stages of mouse hair cycle. In the mouse, the hair cycle is synchronised making the different 
stages of the hair cycle easy to analyse
29
. Utilizing this we compared the expression levels of 
the TSHR during mouse hair cycle including; early anagen (4 weeks), late anagen (5 weeks), 
and telogen (7-10 weeks) in C57B1/6 mice.  
 
Due to certain circumstances this experiment was conducted in different laboratory and 
different setting from where the experiment was originally started. Therefore, optimization of 
different PCR conditions (annealing temp and MgCl2) was essential at this stage as shown 
below (table 2.5).  
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2.3.4.1 Optimization of PCR annealing Temp in a different laboratory  
The annealing temperature of genes of interest was optimized using TC-512 Techne PCR 
machine, Barloworld scientific Ltd, Stone Staffordshire, UK. 
 
Table 2.5: Optimization of annealing temperature in a different laboratory.  
Gene Annealing Temp Delta Best result 
H.TSHR 58.5C 15C 60C 
M.TSHR 50.0C 15C 55.9C 
Human α2 58.0C 15C 61.9C 
Human  β5 58.0C 15C 53.9C 
 
2.3.4.2 Optimization of MgCl2 level in a different laboratory 
 As described earlier in the materials and methods, the MgCl2 concentration was optimized 
by using a range of the MgCl2 concentration, between 0 μl and 2.5 μl of MgCl2 (25mM) stock 
solution was added to the PCR mix to get the maximum efficacy of the PCR. The PCR 
conditions giving the most intense single amplicon of the correct molecular weight was used. 
 96 
 
 
 
 
Figure 2.9.Transcript Expression of TSHR during mouse hair cycle.   
Ethidium bromide stain of PCR amplification products separated on 2% agarose gel analysis of mouse 
TSHR (540bp).  ARP (347bp) = mouse housekeeping gene. Lane (1&2) 4 weeks (early anagen), lane 
(3&4) 5 weeks (late anagen), lane (5-9) 7-10 weeks (telogen), lane (10-12) positive control (mouse 
thyroid), lane (13) negative control (H2O). The first lane contains the 100bp DNA ladder. 
  
 
As shown in figure 2.9, H2O was used as negative control; three different samples of mouse 
thyroid were used as positive control. A parallel PCR analysis of ARP housekeeping gene 
provided a quality check for RNA integrity and RT efficiency for all samples. The levels of 
TSHR were higher in early anagen than in late anagen and relatively low in telogen. Please 
note that at the lower part of the ARP gel, the DNA marker and the negative control were 
loaded in different gels.  
 
1     2      3     4     5     6     7     8     9    10   11   12   13 
540bpTSHR
ARP 347bp
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2.3.5 TSHR and TSHR variant expression in 3T3L1 during 
adipogenesis 
In the mouse, the hair cycle is synchronised making the different stages of the hair cycle easy 
to analyse
29
. Due to adipogenesis, the thickness of both dermis and the subcutaneous layer 
increase during anagen to accommodate the hair follicle
29
, as shown in (figure 2.10). 
Recently, Festa et al, 2011 reported that de novo adipogenesis parallels follicular stem cell 
activity which leads to anagen
168
. The mouse 3T3L1 preadipocyte cell line is capable of 
undergoing adipogenesis and provides a useful model for the process in primary depots. 
 
 
 
 
Figure 2.10: Subcutaneous layer changes during the mouse hair cycle. 
Schematic diagram to showing the increase in the thickness of the subcutaneous layer to 
accommodate the hair follicles during the synchronised anagen phase of mouse hair cycle. 
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The aim of this experiment is to compare the levels of gene expression of both TSHR and 
TSHRV in 3T3L1 during adipogenesis. This experiment was carried out by others in the 
laboratory (figure 2.11).  
 
Figure 2.11: TSHR and TSHR variant expression in 3T3L1 during adipogenesis.  
 Ethidium bromide stain of PCR amplification products separated on 2% agarose gel analysis of: lane 
1) ARP housekeeping gene, lane 2) TSHR (540bp), lane 3) TSHRV (232bp). D1 = day 1, D3= day 3, 
D7= day 7, D10= day10. The first lane contains the 100bp DNA ladder 
 
As shown in figure 2.11, H2O, was used as negative control, a parallel PCR analysis of ARP 
housekeeping gene provided a quality check for RNA integrity and RT efficiency for all 
samples. The RT-PCR showed TSHR transcript was not expressed in 3T3L1 at early stages 
of differentiation but on day 7 when adipogenesis is clearly apparent in these cells the TSHR 
expression appears to be strongly expressed (switched on). TSHRV expression occurs earlier 
at day 3 and persists until day 10, longer than TSHR.  
 
 
1    2    3 1    2    3 1   2   3 1    2   3 
H2O Day 1 Day 3
1   2   3 
Day 7 Day 10
500bp
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2.3.6 TSHRV expression in human skin  
 
To our knowledge, TSHRV expression has not been explored in skin before.  The few studies 
that have investigated the role of TSHR in the skin present conflicting results and show 
evidence of signalling using unnaturally high levels of TSH
132,133
. These studies do not 
distinguish between full length and truncated variant. The aim of this experiment was to 
clarify the abundance of TSHR variant isoforms in the skin by using unique sequence primers 
in intron between 8/9 of the isoforms that are not present in full length TSHR in order to 
distinguish between transcripts coding for signalling competent TSHR and TSHRV. If 
TSHRV is expressed in the skin, it has the potential for binding TSH or thyrostimulin.   
 
 
Figure 2.12. Expression of TSHR and TSHR variant in human skin.  
Ethidium bromide stain of PCR amplification products separated on 2% agarose gel analysis of TSHR 
(254 bp) and TSHRV (338 bp) of human skin and human thyroid.  APRT (245 bp) = human 
housekeeping gene. Lane 1) negative control (H2O), lane 2) human skin, lane (3& 4) human thyroid. 
The first lane contains the 100bp DNA ladder. 
TSHR (254bp)
APRT (245bp)
TSHRV (338bp)
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500bp
500bp
500bp
744bp
100bp
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As shown in figure 2.12, H2O was used as negative control; two different samples of human 
thyroid were used as positive control. A parallel PCR analysis of APRT housekeeping gene 
provided a quality check for RNA integrity and RT efficiency for all samples. RT-PCR 
revealed high levels of TSHRV in some of human thyroid samples but not in human skin. 
Additional band was seen in APRT, lane 3 (744bp) which is most likely due to amplification 
of genomic DNA.  
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2.3.7 TSHRV expression in mouse skin 
 
This experiment was conducted to determine which TSHR variant isoform is expressed in 
mouse skin and whether its expression varies with the hair cycle. We investigated the 
TSHRV expression in hairy mouse skin at different time points of the hair cycle, and 
compared it with hairless skin (foot sole) (figure 2.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13.  Expression of  TSHR variant in mouse skin.  
Ethidium bromide stain of PCR amplification products separated on 2% agarose gel analysis of mouse 
TSHRV (232 bp) in mouse skin, β-Actin (458 bp) = mouse housekeeping gene. Lane 1) negative 
control (H2O), Lane 2) 2 weeks (anagen), Lane 3) 3.5 weeks (telogen), Lane 4) 7 weeks (telogen),  
Lane 5) 8 weeks (telogen),  Lane 6 ) Paw (hairless foot sole skin). The first lane contains the 100bp 
DNA ladder. 
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As shown in figure 2.13, H2O was used as negative control. A parallel PCR analysis of β-
Actin housekeeping gene reveals a variable quality for RNA integrity for all the samples.  
The RT-PCR revealed TSHRV transcript expression in dorsal skin (hairless foot sole skin) of 
variable degree at various ages of mouse skin corresponding to different stages of the hair 
cycle.  
2.3.8 TSHRV expression in different mouse tissues 
 
Further to the previous mouse tissue expression experiment, we asked whether the TSHRV is 
also expressed in mouse tissues other than the skin which might also be a potential target of 
TSH and thyrostimulin. We applied ex vivo analyses of representative samples of murine 
tissues (figure 2.14). 
 
Figure 2.14. TSHR variant transcript expression in mouse tissues.  
Ethidium bromide stain of PCR amplification products separated on 2% agarose gel analysis of 
TSHRV (232bp) in different mouse tissues, β-Actin (458bp) = mouse housekeeping gene.  Lane 1) 
Negative control (H2O), lane 2) heart, lane 3) kidney, lane 4) spleen, lane 5) stomach, lane 6) 
pancreas, lane 7) brain, lane 8) small Intestine, lane 9) testis, lane 10) positive control(mouse 
thyroid). The first lane contains the 100bp DNA ladder.  
500bp
232bp
458bp
TSHRV
β-Actin
100bp 1    2          3          4         5         6          7         8         9         10           
500bp
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As shown in figure 2.14, H2O was used as negative control, mouse thyroid used as positive 
control. A parallel PCR analysis of β-Actin housekeeping gene provided a quality check for 
RNA integrity and RT efficiency for all samples. The TSHR transcript variant was expressed 
in most of mouse tissues of the expected size (232bp) by RT-PCR analysis.  Primer dimers 
appear in the TSHRV gel. Additional bands were seen in some of β actin of lane 3 (kidney) 
and lane 6 (pancreas) samples (872bp) which is most likely due to amplification of genomic 
DNA. 
 
2.3.9 TSHR, agonist (α2 and β5) expression HaCaT cell line 
 
 
Cells of the human HaCaT keratinocyte line and primary keratinocyte cell line have been 
reported to express TSHR in culture.  We asked the question whether TSHR, α2 and β5 
subunits of thyrostimulin and TSHRV are expressed in human HaCaT cell line or not? 
 
Expression was investigated in two in vitro models for examining keratinocyte 
differentiation. The HaCaT lines were grown at different concentrations of calcium, which is 
known to affect differentiation and stratification of keratinocytes in culture
167
. The 
experiments were carried out in either Dulbecco’s Modified Eagle’s Medium (DMEM) with 
10% fetal calf serum (high calcium throughout) and harvested at different stages before and 
after confluence or in serum-free keratinocyte growth medium (KGM; low calcium) and 
harvested at different stages before (low calcium) and after shift or the addition of calcium 
(high calcium) when the cells are about 80% confluency usually at day 6.  
 
This experiment was done in a different laboratory where the initial work was conducted 
hence; optimization of the RT-PCR conditions was required. In all experiments we included 
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amplification of a housekeeping gene to provide a quality control on the integrity of the 
mRNA and efficiency of the RT step. We selected APRT and the first step in these HaCaT 
differentiation experiments was to evaluate APRT transcripts in three different cDNA sets 
(A, B and C) of HaCaT cells at various time points since its expression may also be regulated 
by the in vitro induced differentiation. 
 
 
2.3.9.1 Expression of APRT in HaCaT cell line in KGM   
 
 
Figure 2.15:  Expression of APRT housekeeping gene of three different sets of HaCaT cDNA in 
KGM (Calcium shift). Ethidium bromide stain of PCR amplification products separated on 2% 
agarose gel of housekeeping gene (APRT, 251bp) of different groups of HaCaT in KGM. Lane 1) 
Negative control (H2O), Lane 2) Day1 (Pre-confluent), lane 3) Day 3 (30% confluent), lane 4) day 6 
(80% confluent), lane 5) (Day 6 + 3) post-shift, lane 6) (day 6 + 6) post-shift, lane 7) (day 6 +10) 
post-shift. The first lane contains the 100bp DNA ladder 
Group A Group B
Group C
251bp
500bp
251bp
1    2    3   4     5    6    7 1    2    3   4     5    6    7 100bp
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As shown in the figure 2.15, H2O was used as negative control. Amplification of the APRT 
house keeping gene provide a quality check for RNA integrity and reverse transcription 
efficiency for all samples.  APRT was detected in all the three set of samples, but at variable 
levels in group B and C, being highest in group A with a similar strength of the signal in all 
lanes. 
 
2.3.9.2. Expression of TSHR in HaCaT cell line in KGM  
 
 
 
 
Figure 2.16: TSHR expression in different groups of HaCaT in KGM (Calcium shift) 
Ethidium bromide stain of PCR amplification products separated on 2% agarose gel analysis of 
(TSHR, 254bp) of different groups of HaCaT in KGM. Lane 1) Negative control (H2O), Lane 2) 
Day1 (Pre-confluent), lane 3) Day 3 (30% confluent), lane 4) day 6 (80% confluent), lane 5) (Day 6 
+ 3) post-shift, lane 6) (day 6 + 6) post-shift, lane 7) (day 10 + 6) post-shift. The first lane contains 
the 100bp DNA ladder. 
 
 
 
 
Group A Group B
Group C
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As shown in the figure 2.16, H2O was used as negative control. Due to some technical 
reasons at the time of doing this experiment the positive control of TSHR (human thyroid) 
was not used. The TSHR transcript was amplified at the same conditions in the three groups. 
However, only in group B a single band of relatively low strength post HaCaT differentiation 
at (day 6 + 3) post-shift of expected amplicon size (254bp) was seen.  No other bands were 
seen in group A or group C.  
 
2.3.9.3. Expression of TSHR in HaCaT cell line in DMEM 
100bp
251bp
254bp
APRT
1       2        3       4       5       6      7      8        9     
500bp
TSHR
500bp
 
 
 
Figure 2.17: Expression of TSHR in HaCaT cell line in DMEM. 
Ethidium bromide stain of PCR amplification products separated on 2% agarose gel analysis of PCR 
products of (TSHR, 254bp) and housekeeping gene (APRT, 251bp) of different groups of HaCaT in 
DMEM. Lane 1) Negative control (H2O),  Lane 2) day 1 (Pre-confluent), lane 3)  day 3 (confluent), 
lane 4) (day 3 + 1) (Post-confluence), lane 5) (day 3 + 3) (Post-confluence), lane 6) (day 3 + 7) (Post-
confluence), lane 7) (day3 + 10) (Post-confluence),  lane 8) Human skin and  lane 9) Human thyroid 
used as positive controls. The first lane contains the 100bp DNA ladder.  
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As shown in the figure 2.17, H2O was used as negative control; human skin and human 
thyroid were used as positive control. Amplification of the APRT house keeping gene 
provided a quality check for RNA integrity and reverse transcription efficiency for all 
samples (the APRT gel was loaded in different occasions). The TSHR transcript is not 
expressed in HaCaT cell line in DMEM in all the time points investigated pre- and post 
confluence. Please note that at the lower part of the gel (the APRT) gel results were loaded in 
different gels.  
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2.3.10 Expression of Thyrostimulin (α2&β5) in HaCaT cell line  
 
2.3.10.1 Expression of Thyrostimulin (α2 & β5) in HaCaT cell line in DMEM  
 
 
 
 
 
Figure 2.18: Expression of α2 and β5 subunits of thyrostiumulin in HaCaT in DMEM.  
 Ethidium bromide stain of PCR amplification products separated on 2% agarose gel analysis of α 2 
(410bp) and β 5 (296bp) subunits of thyrostimulin in HaCaT in DMEM.  Lane 1) Negative control 
(H2O),  Lane 2) day 1 (Pre-confluent), lane 3)  day 3 (confluent), lane 4) (day 3 + 1) (Post-
confluence), lane 5) (day3 + 3) (Post-confluence), lane 6) (day 3 + 7) (Post-confluence), lane 7) 
(day3+ 10) (Post-confluence),  lane 8) Human skin and  lane 9) Human thyroid used as positive 
controls. The first lane contains the 100bp DNA ladder.  
 
 
As shown in the figure 2.18, H2O was used as negative control; the ideal positive control for 
thyrostimulin is human pituitary which is difficult to obtain. Hence, in this experiment the 
human skin and human thyroid were used as positive control. Amplification of the APRT 
house keeping gene provided a quality check for RNA integrity and reverse transcription 
α2
β5
1        2        3       4       5        6       7       8       9100bp
500bp
500bp
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efficiency for all samples (as shown in previous experiment). The initial result showed that 
alpha2 and beta 5 were not expressed in the HaCaT cell line in DMEM in all the time points 
tested. Both subunits of thyrostimulin showed negative bands, at this stage it was difficult to 
proceed any further without a positive control since the human thyroid used here is not the 
ideal positive control of thyrostimulin and the ideal positive control would be human pituitary 
which is practically difficult to get.  
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2.3.10 TSHRV expression in HaCaT cell line 
 
2.3.10.1 TSHRV expression in HaCaT cell line in KGM  
 
Figure 2.19:  Expression of TSHRV in HaCaT cell line in KGM. 
 Ethidium bromide stain of PCR amplification products separated on 2% agarose gel analysis of 2% 
agarose gel analysis of PCR product of (TSHRV, 337 bp) and for housekeeping gene (APRT, 251bp) 
of HaCaT in KGM.  Lane 1) Negative control (H2O), Lane 2) Day1 (Pre-confluent), lane 3) Day 3 
(30% confluent), lane 4) day 6 (80% confluent), lane 5) (day 6 + 3) post-shift, lane 6) (day 6 + 6) 
post-shift,  lane 7) ( day 6 + 10) post-shift. The first lane contains the 100bp DNA ladder. 
 
 
 
As shown in the figure 2.19, H2O was used as negative control; Human thyroid used as 
positive control. Amplification of the APRT house keeping gene provided a quality check for 
RNA integrity and reverse transcription efficiency for all samples. The TSHRV transcript 
was not expressed in HaCaT cell line in KGM in all time points investigated. 
1       2       3       4      5       6      7     8    
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 2.3.10.2 TSHRV expression in HaCaT cell line in DMEM 
 
 
 
Figure 2.20.  Expression of TSHRV in HaCaT cell line in DMEM.  
Ethidium bromide stain of PCR amplification products separated on 2% agarose gel analysis of 
(TSHRV, 337 bp) and housekeeping gene (APRT, 251bp) of HaCaT in DMEM. Lane 1) Negative 
control (H2O), Lane 2) day 1 (Pre-confluent), lane 3) day 3 (confluent), lane 4) (day 3 + 1) (Post-
confluence), lane 5) (day 3 + 3) (Post-confluence), lane 6) (day 3 + 7) (Post-confluence), lane 7) 
Human thyroid used as positive control. The first lane contains the 100bp DNA ladder.  
 
 
As shown in the figure 2.20, H2O was used as negative control; Human thyroid used as 
positive control. Amplification of the APRT house keeping gene provided a quality check for 
RNA integrity and reverse transcription efficiency for all samples. The TSHRV transcript 
was not expressed in HaCaT cell line in DMEM in all time points investigated. 
TSHRV
APRT
337 bp
251bp
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 Discussion  
Expression of functional TSHR in the skin may have significant physiological and 
pathological implications particularly in autoimmune conditions associated with the 
production of stimulating antibodies against TSHR. Studies by Slominski and this team, 2002 
revealed mRNA transcripts for full-length (has the potential to be functional) TSHR in 
cultured keratinocytes, epidermal melanocytes, and melanoma cells by RT-PCR and this was 
confirmed by northern analysis
53
. In addition, others have used highly sensitive methods to 
confirm TSHR protein expression in  HaCaT this cell line
169
.  
 
In this chapter we were able to show the expression of the full length TSHR transcript in 
human skin and mouse skin (hairy and hairless skin). However, we were unable to detect 
noticeable levels of TSHR in HaCaT keratinocytes. The HaCaT cell line was either grown to 
different stages of confluency or at different concentrations of calcium, to induce 
differentiation and stratification of keratinocytes in culture
167
. These methods are known to 
induce early differentiation markers such as K1 and K10 but not later markers such as 
filaggrin
170. In the first experiment, the cells were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM) with 10% fetal calf serum and high calcium all the way through. Here, 
cells were harvested at different stages before and after confluence. In the other culture 
condition, cells were grown in serum-free keratinocyte growth medium (KGM) and low 
calcium. In this case cells were harvested at different stages; before (low calcium) and after 
adding high calcium.  
 
The occasional faint band shown in our data suggests that it might be related to HaCaT 
differentiation. The culture system employed was not completely in-vivo like since the cells 
were not fully differentiated and the later stages of differentiation were probably not 
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represented.  It is well known that there are other more complicated methods of culture which 
induce further differentiation (like in vivo) which could have been tried, such as growing the 
keratinocytes on a fibroblast collagen matrix and at the air/liquid interface
171,172
.  The TSHR 
transcript was not demonstrated in the undifferentiated mouse pre-adipocyte cell line 
(3T3L1). However, as 3T3L1 differentiate and the adipogenesis is clearly apparent, the 
TSHR appears to be strongly expressed (figures 2.10).  
  
Studies by Bodo et al, 2009 
133
 and Cianfarani et al, 2010
132
 investigating the role of TSHR in 
the skin present conflicting results and showed evidence of signalling using unnaturally high 
levels of TSH (In the UK, guidelines issued by the Association for Clinical Biochemistry 
suggest a reference range of 0.4-4.5 mIU/L)
173
 . In addition, these studies did not distinguish 
between full length and truncated variant. In our work, despite the use of unique sequence 
primers of the isoforms that are not present in full length TSHR in order to distinguish 
between transcripts coding for signalling competent TSHR and TSHRV, we were unable to 
detect the TSHR variant isoform transcript in human skin or HaCaT cell line by RT-PCR. 
However, a high level of TSHRV transcript expression was detected in mouse skin and at 
various ages of mouse skin corresponding to different stages of the hair cycle by the same 
method. The discrepancy between the human and mouse TSHRV results might be explained 
by differences in the hair cycle between species. The other possible explanation is the 
absence of hair follicles in the human skin samples used.  
  
Semi-quantitative RT-PCR showed higher levels in TSHR expression observed in early 
anagen hair follicles in mouse pelage skin, than in late anagen and relatively low in telogen 
which is consistent with predominant expression in the human anagen hair follicle as 
observed by Bodo et al ,2009
133
. However, more accurate information about the level of 
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TSHR expression in hair follicles at different stages of mouse hair cycle could have been 
gained using a quantitative method such as a real-time q-PCR technique.  
 
The α2 and β5 subunits of thyrostimulin were however readily expressed in human skin 
samples (α2 subunit in mouse skin) as well as in HaCaT keratinocyte and HCA2 fibroblast 
cell lines (figures 2.6 and 2.7). However, some experiments, failed to detect expression of 
thyrostimulin subunits in HaCaT. The inconsistency in thyrostimulin expression in HaCaT 
keratinocyte results could be related to the PCR conditions of each experiment as the RNA 
and the reverse transcription reaction used in these experiments were different in each 
experiment. It is known that RNA is very labile, and because the RNA extracted in different 
batches it might be of varying quality. In addition, the RT reaction will also vary from batch 
to batch, hence, housekeeper was included to provide some assurance of the quality RNA and 
that the RT reaction has worked.  The main challenge with this experiment is the lack of 
positive control required for confirming the expression of thyrostimulin as the ideal positive 
control would be the pituitary which is practically difficult to obtain.  
 
The results in this chapter showed TSHR transcript expression in a wide range of mouse 
tissues including lung, eye, kidney, thyroid, ovary and testis. The α2 subunit is only 
expressed in eye, ovary and testis. On the other hand, β5 subunit is expressed in most of the 
tissues tested as heart, lung, kidney, small intestine, eye, brain, ovary and testis. However, all 
three transcripts were only co-expressed the in eye and testis.  
  
The results showed more expression of β5 transcript in different mouse tissues then α2 
transcript. These results contradict with other reports where they showed α2 is more abundant 
than β5144,145,153. In this context, it is difficult to compare the relative levels of expression by 
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semiquantitative techniques and there may be differences in efficiency causing problems. 
Therefore, a real time qPCR would be a better technique for investigating the expression of 
thyrostimulin in these tissues.
  
 
 
 
 
 
 
 
 
 
 
 
Chapter three 
Immunodetection of the TSHR protein  
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3. Chapter three 
 
3.1 Introduction 
As described in the general introduction, the TSHR has two main forms; the full length 
TSHR and the TSHR variant isoform. The full length TSHR contains two subunits; A 
subunit, corresponding to the extracellular domain (ECD) (residues 21-415) encoded by 
exons 1-9 and, the B subunit, is mainly the transmembrane domain (TMD) (residues 416-
764) encoded by exon 10
111-114
.  Post translation proteolysis splits the TSHR into two A 
subunits and B subunit  linked to each other by disulfide bonds
115
. The TSHR variant is a 1.3 
kb and comprise exons 1-8 and a new “tail sequence” and lack the transmembrane domain134 
(figure 3.1).   
 
Figure 3.1:  Schematic diagram showing structure of TSHR holoreceptor, TSHR 
isoform  
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Reports revealed TSHR is expressed in extra thyroidal locations including lymphocytes, extra 
ocular tissues
174
, fibroblasts
61,175
; fat
165
, human skin
132
 and human scalp hair follicle
133
. 
Immunoreactivity to TSHR antibodies has been observed in the dermis of both patients with 
pretibial myxoedema and unaffected individuals. However, in the skin, it is not clear the 
exact site of this expression or the type of cell which expresses the TSHR. 
 
Literature review revealed that different studies used different TSHR antibodies to study 
TSHR expression in skin, These studies mainly used antibodies which recognizes  different 
parts of the extracellular domain of the TSHR
132,133,176-180
 (figure 3.2). Furthermore, the two 
recently published papers utilised two different antibodies to the extracellular domain of 
TSHR showing contradictory results
132,133
. By using the (BA8) antibody which recognises the 
conformation of the whole extracellular domain, Bodo et al showed that TSHR was 
immunolocalized to the mesynchymal dermal component of the hair follicle, as well as  the 
myoepithelial cells surrounding the sweat gland, the sebaceous glands, nerves and blood 
vessel endothelium . On the other hand, Cianfarani et al used an antibody A9, raised to a 
peptide corresponding to amino acid residues 147-228 of the extracellular domain, that 
immunolocalised to the epidermis and some cells in the dermis
132
.   
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Figure 3.2: Schematic diagram showing different binding sites of different TSHR 
antibodies used in immunohistochemical studies. 
 
As well as being inconsistent these results may not actually be immunolocalising the 
holoreceptor (TSHR), since these antibodies only detect the extra cellular domain and could 
also be detecting the truncated isoforms of the TSHR or the A subunit of the TSHR which 
can be shed by enzyme catalysed reduction of the disulphide bonds at the cell surface . As 
described in chapter two, we were able to amplify full length TSHR transcript from whole 
human skin, however, our RT-PCR revealed high levels of TSHRV transcript expression in 
human thyroid and mouse skin but not in human skin. 
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3.1.1 Aim of chapter three 
 
The aim of this chapter is to determine the localisation of the signalling competent TSHR 
expression in the skin. Immunolocalisation of TSHR was carried out with two different 
monoclonal antibodies; the A9 antibody recognises amino acids 147-228 of the extracellular 
A subunit and, the A7 antibody recognises amino acids 402-415 of the last bit of ECD of 
TSHR or the initial part of B subunit. The thyroid tissue was used as a positive control.  
 
NCBI Entrez Gene describes two alternatively splice variants, TSHR isoform 2 precursor 
(NM_001018036.1)
134
, TSHR isoform 3 precursor (NM_001142626.1)
139
. As illustrated in 
(figure 3.1) the TSHRV (isoform2) spans (residues 21-253) which is the extreme carboxyl 
terminal of the ECD that doesn’t include the A7 epitope and presumably after the bit coded 
for by the variant, therefore A7 cannot bind to TSHRV. Consequently, using these two 
antibodies could distinguish between the full length and the variant isoforms in order to 
determine whether there is a signalling competent TSHR in the skin (figure 3.1). These two 
antibodies can also distinguish between the A and B subunits generated by enzymatic 
cleavage of the holoreceptor. 
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3.2 Materials and Methods 
3.2.1 Immunohistochemistry (IHC) 
 
3.2.1.1 Tissues used in the project 
Human thyroid tissue and normal skin tissue was purchased from a commercial source (AMS 
Biotechnology, UK). Some skin samples were from the Dermatology department, Cardiff 
University and were collected for research purposes with patient consent prior to the 2004 
human tissue act. To avoid problems of antigen preservations, accessibility of antibodies 
encountered in paraffin or plastic-embedded material and for simple and rapid processing of 
the biopsies
181
 frozen section techniques were employed.  
 
Serial sections (5-8 µm) were obtained from the frozen tissue blocks using a Thermo 
Scientific Cryotome FSE cryostat. The sections were then mounted on SuperFrost® Plus 
glass slides (Menzel-Glaser GmbH, Braunschweig, Germany). The SuperFrost® is 
characterized by a process in which a permanent positive charge exists on standard 
microscope slides, which ensures firm electrostatic attraction of frozen tissue sections to the 
slide. These slides were left to air dry for 30 minutes. After drying, they were labelled and 
wrapped back to back in aluminium foil and then stored in the freezer at -80˚C until the time 
of staining. 
 
3.2.1.2 TSHR antibodies used 
Cryostat sections from human thyroid and human skin were analysed by 
immunohistochemistry using two different monoclonal TSHR antibodies .These antibodies 
are; A9 monoclonal antibody (Santa Cruz Biotechnology, Inc)
176
 and A7 monoclonal 
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antibody (AbCam)
177
. The individual antibodies were selected on the basis of their 
recognition of specific epitopes in the TSHR protein where each antibody recognises certain 
peptide in the TSHR. A thyroid tissue was used as positive control (table 3.1).  
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Table 3.1: Summary of antibodies and immunostaining conditions used in this study 
 
1º ab 
 
Host 
 
Corresponding 
aa 
 
Source 
 
Block 
 
Diluent 
 
All washes  
Dilution & 
incubation 
period 
 
2º ab 
 
Tertiary 
 
A9 
 
Mouse 
monoclonal 
antibody  
 
147-228 
 (ECD)  
 
Santa Cruz 
Biotechnology, 
Inc 
 
Hydrogen peroxide for 
10minutes 
5% normal sheep serum + 0.1% 
BSA in PBS-T for 30 minutes 
 
Avidin/Biotin blocking.  
 
0.1% BSA in PBS-T  
 
 
PBS-T  
 
1:100 
over night 
 
1:200 
Anti-mouse 
biotinylated 
(from sheep) 
 
ABC Kit 
 
 A7 
 
Mouse 
monoclonal 
antibody 
 
 
 
 
402-415  
last bit of (ECD) 
 
AbCam 
 
Hydrogen peroxide for 
10minutes 
5% normal sheep serum + 0.1% 
BSA in PBS-T for 30 minutes 
  
Avidin/Biotin blocking.  
 
 
0.1% BSA in PBS-T  
 
 
PBS-T 
 
1:50   
over night 
 
1:200 
Anti-mouse 
biotinylated 
 (from 
sheep)  
 
ABC Kit 
 123 
 
3.2.1.3 The Buffer solution 
Five litres stock of x10 PBS solution (phosphate buffered saline, pH 7.2) was prepared and 
 stored in bottles and used as stock for x1PBS (table 3.2) 
 
Table 3.2: Constituents for preparation of x10 Phosphate Buffered Saline solution 
 
Constituents  
Amount (in grams) 
required for 1 Litre (L) 
Amount (in grams) 
required for 5L 
Sodium chloride, NaCl 80 400 
 
Disodium hydrogen 
phosphate (dodecahydrate), 
Na2HPO4.12H2O 
35.8 179 
 
Potassium dihydrogen 
phosphate (anhydrous), 
KH2PO4 
 
2.4 12 
 
Potassium chloride, KCl 2 10 
 
Distilled water To make up to 1L To make up to 5L 
 
  
X1 PBS with 0.05% Tween 20 (PBS-T) (Sigma-Aldrich, Dorset, UK) was used as the buffer 
solution which helps in washing steps to reduce non-specific binding (for washes and for 
preparing the diluents). The diluents (intended for dilution of the primary antibody, secondary 
antibody and the tertiary reagent, and also used as a negative control), was prepared by 
adding 0.25 g of BSA (bovine serum albumin) (Sigma-Aldrich, Dorset, UK) and/or 0.25 g of 
Marvel (non-fat milk protein) to 25 ml of the PBS-T.  BSA and Marvel were added to prevent 
non-specific binding of the primary antibody, reducing the background by minimising non-
specific interactions between the primary antibody and non-target cellular proteins. 
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3.2.1.4 IHC methods 
Generally, the immunohistochemical methods are divided into direct and indirect methods. 
The direct method is a simple one-step staining procedure that involves direct interaction of 
the antigen with a specific labelled primary antibody (eg FITC conjugated, HRP 
conjugated)
182
. Whilst this method is quick to perform, since it utilises only one antibody, it is 
less sensitive giving little signal amplification. Indirect methods involve using a labelled 
secondary antibody (must be raised against an immunoglobulin of the same type and species 
as the primary antibody) or a secondary antibody and labelled tertiary compound, that binds 
to the unlabelled primary antibody-antigen complex. This indirect approach is more sensitive 
as it generates an amplified signal. To further amplify the signal, various three-step methods 
have been developed such as the peroxidase anti-peroxidase, alkaline phosphatase-anti-
alkaline phosphatase and avidin-biotin based methods
182
. In this project the avidin-biotin 
based method has been employed (ABC method)
133
 . In this method, the first layer is an 
unlabelled primary antibody, the second layer is a biotinylated secondary antibody and the 
third layer is either a complex of avidin-biotin peroxidase (ABC method) or an enzyme-
streptavidin conjugate (Streptavidin method) 
 
Slides were taken out of the freezer and allowed to reach room temperature, before removing 
the foil. Slides were labelled and fixed in acetone (Fisher Scientific, UK) for 15 minutes. The 
acetone-fixed slides were then air dried for 15 minutes to allow evaporation of excess acetone 
followed by three five-minute washes in PBS-T and than treated for 10-20 minutes with 3/% 
hydrogen peroxide (Fisher Scientific, UK). Each section on the slides were encircled with a 
water-repelling wax pen (Dako Pen, Glostrup, Denmark) and placed in a humidified chamber 
(a shallow plastic box with a moistened paper towel placed at the bottom). To reduce non-
specific binding of the secondary antibody, the slides were incubated with 5% normal serum 
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(from the same species in which the secondary antibody was raised) for 30 minutes at room 
temperature. This was followed by three five-minute washes PBS/tween. To suppress 
endogenous biotin activity it is necessary to block it with avidin and then block the 
unoccupied biotin binding-sites of avidin with biotin. Therefore, an avidin/biotin blocking kit 
(Vector Laboratories, Burlingame, CA) was used. The slides were incubated with avidin for 
fifteen minutes followed by fifteen minutes incubation with biotin with brief rinses (x 3) in 
the buffer solution in between. The sections were incubated with an optimum dilution of the 
primary antibody (table 3.1) overnight at 4˚C. Slides incubated with diluent (without any 
primary antibody) were run in parallel as a negative control for each experiment. This was 
followed by three five-minute washes in the buffer solution. 
 
The sections were then incubated with a relevant biotinylated secondary antibody for 30 
minutes at room temprature, and then washed by PBS/tween three times five minutes each, 
followed by incubation with reagents of the avidin-biotinylated enzyme complex kit 
(Vectastain ABC kit, Vector Laboratories Inc.) for a further 30 minutes. The ABC reagent 
was prepared at least thirty minutes before being used by adding 1 drop of reagent A and 1 
drop of reagent B to 2.5 ml of the diluent. The sections were then washed in the buffer 
solution three times and developed with (5mgs in 5ml of PBS) of horse radish peroxidase 
substrate solution (0.5 ml of 3, 3’ Diaminobenzidine (DAB), 4.5 ml of PBS and 6 µl of H202) 
(Fisher Scientific UK)  for 10 minutes at room temprature to produce colorimetric 
immunoprecipitates. 
The sections were then rinsed in tap water and counterstained with haematoxylin (Sigma 
Aldrich, UK) for 5 minutes and washed again in tap water. Finally, all sections were 
dehydrated through a graded series of alcohol solutions (1 x 70%, 1 x 90%, and 3 x 100% 
industrial methylated spirit; Genta Medica, York, UK) for 5 minutes each, and cleared in 
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three changes of xylene (Genta Medica, York, UK) for 5 minutes each. The slides were then 
carefully mounted with a cover slip using DPX mounting medium (a mixture of distyrene, a 
plasticizer, and xylene; RA Lamb, East Sussex, UK) and then left to dry overnight. 
 
3.2.1.5 Photography 
The following day, the slides were observed under a Nikon optiphot microscope for detection 
of positive staining. Positive staining (or antibody binding) was visualised as brown staining. 
Digital images were captured with Axiocam camera system (Zeiss) and Axiovision software 
(Zeiss) under different magnifications using three objectives (x10, x20, and x40). 
Standardised settings were used on the microscope and image capturing software to allow 
accurate comparisons. 
 
3.2.1.6 Optimization of the IHC protocol 
The protocols used in these experiments were optimized until good positive staining was 
detected and all the non-specific staining and background were minimised. Additional 
blocking step was required to block endogenous peroxidise by treating the sections with 
hydrogen peroxide for variable duration (10-20 minutes) before  the standard blocking step 
with 5% normal serum.   
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3.3 Results 
The immunohistochemical analysis of the TSHR protein was performed using commercial 
monoclonal antibodies A9 and A7 that recognise specific peptides of TSHR (figure 3.2), 
thyroid tissue was analysed as positive control.  
 
3.3.1 The A9 Antibody 
 
The standard ABC method was utilized first then a protocol modification was required where 
the Avidin and Biotin blocking steps were replaced by an additional blocking method by 
using hydrogen peroxide
133
. Although, hydrogen peroxide blocks the endogenous peroxidise, 
it could have a negative effect on the architecture of the tissue (because of the effervescence); 
this might explain why some of the sections look a bit ‘ragged.  The sections where treated 
with hydrogen peroxide for variable duration (10-20 minutes) before blocking with 5% 
normal serum (table 3.3).  
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Table 3.3:  Optimization conditions for A9 TSHR antibody  
A9 primary 
Ab 
Secondary 
Ab 
Blocking method  Tissue Comment 
 
 
1:100 O/N 
 
1:200 anti-
mouse 
biotinylated  
 
 
Endogenous 
peroxidase blocked 
for 20 minutes. 
  
 5% sheep serum in 
BSA in PBS-T for 30 
minutes 
 
Normal 
thyroid 
sections 
 
Strong immunoreactivity. 
Strong background staining  
 
1:200 O/N 
1:500 O/N 
 
1:200 anti-
mouse 
biotinylated  
 
 
 
Endogenous 
peroxidase blocked 
20 minutes  
 
5% sheep serum in 
BSA in PBS-T for 30 
minutes 
 
Normal 
thyroid 
sections 
 
  Good, positive  
immunoreactivity  with 
1:200 O/N 
 
 
1:200 O/N 
 
 
1:200 anti-
mouse 
biotinylated  
 
 
 
Endogenous 
peroxidase blocked 
10 minutes  
 
5% sheep serum in 
BSA in PBS-T for 30 
minutes 
 
Normal 
thyroid,  
Human 
skin 
sections 
 
 
Good staining of thyroid,  
Positive staining of dermal 
fibroblasts in some skin 
sections but most showed 
no immunoreactivity. 
 
 
1:100 O/N 
 
1:200 anti-
mouse 
biotinylated  
  
 
 
Endogenous 
peroxidase blocked 
10 minutes  
 
5% sheep serum in 
BSA in PBS-T for 30 
minutes 
 
Normal 
thyroid,  
Human 
skin 
sections 
 
 
Strong positive staining of 
thyroid. 
No epidermal staining. 
Positive dermal fibroblast  
 & sweat gland staining.   
Borderline staining of 
sebaceous gland. 
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Figure 3.3: Immunostaining of TSHR in human thyroid using A9 monoclonal antibody 
during the process of optimization. Negative controls (panels a, b and c) are sections 
incubated with secondary antibody only. Panels d, e and f are thyroid follicles sections 
incubated with A9 antibody at 1:200 dilutions. (Panels g, h and i) are thyroid follicles 
sections incubated with A9 antibody at 1:500 dilution. Scale bar x10=100µm, x20=50 µm, 
x40=20 µm. 
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Figure 3.4: Immunostaining of TSHR in normal thyroid, normal skin and skin 
appendages using A9 monoclonal antibody at dilution of 1:200 during the process of 
optimization. Negative controls (panels a, c, e, g, i) are sections incubated with secondary 
antibody. Thyroid and skin section (panels b, d, f, h, j) are sections incubated overnight with 
A9 antibody at dilution of 1:200. Scale bar x10=100µm. 
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Figure 3.5: Immunostaining of TSHR in normal thyroid, normal human skin, sebaceous 
gland and sweat gland using A9 monoclonal antibody. Negative controls (panels a, c, e 
and g) are sections incubated with secondary antibody only. In contrast, thyroid and skin 
section (panels b, d, f, h) are sections incubated overnight with A9 antibody at dilution of 
1:100. Scale bar x10=100µm. 
 
As shown in figures 3.3 to figure 3.5, the A9 monoclonal TSHR antibody was optimized 
using two dilutions of the primary antibody. The TSHR A9 antibody at 1:100 dilution seems 
1:100
1:100
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to be the optimal dilution in the thyroid tissue. Positive TSHR immunoreactivity is shown on 
the basolateral surface of the thyroid follicles.  A9 antibody at 1:200 dilution, the epidermis 
shows no immunoreactivity. However, the dermis shows positive fibroblast-like 
immunstaining, this staining is also obvious in the dermis surrounding the hair follicle and 
the sebaceous gland. Borderline staining is seen in the sebaceous glands and a borderline 
staining is shown in the periglandular myoepithelial cells of sweat gland. Similarly, at 1:100 
dilution the A9 antibody showed no immunoreactivity of epidermis while the dermis shows 
positive fibroblast-like immunorstaining with borderline staining of sebaceous glands. 
Interestingly the periglandular myoepithelial cells surrounding the sweat gland showed 
prominent TSHR immunoreactivity.  
 
3.3.2 The A7 antibody 
 As mentioned in A9 experiment, the standard ABC method was utilized
133
, then the protocol 
was modified by replacing the Avidin and Biotin blocking steps with an additional blocking 
step to block endogenous peroxidise (table 3.4).  
 
Table 3.4:  Optimization conditions for A7 TSHR antibody  
A7 Ab Secondary Ab Blocking Method Tissue Comment 
 
1:50 O/N 
 
1:200 anti-
mouse 
biotinylated  
 
Hydrogen peroxide 
for 10minutes 
5% normal sheep 
serum + 0.1% BSA 
in PBS-T for 30 
minutes 
 
Normal thyroid, 
Human skin  
 
Strong background (skin)  
 
Immunoreactivity in the 
thyroid, non specific 
staining of the epidermis, 
sebaceous glands and 
sweat glands.  
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Figure 3.6: Immunostaining of TSHR in normal thyroid using A7 monoclonal antibody. 
Negative controls (panels a, c) are sections incubated with secondary antibody only. Panels b, 
d are thyroid follicles incubated with A7 antibody at dilution (1:50). Scale bar x10=100µm, 
x20=50 µm. 
 
 
 134 
 
 
1:50
-C -C
1:50
-C
a
ed
b c
1:50
f
x10
Human skin Sebaceous gland Sweat gland
 
 
Figure 3.7: Immunostaining of TSHR in normal skin, sebaceous gland and sweat gland 
using A7 monoclonal antibody.  Negative controls (panels a, b and c) are sections incubated 
with secondary antibody only and reveal non-specific background staining. In panels d and e, 
staining is present but mainly non-specific, apart from some regions of the dermis and 
sebaceous gland with borderline positive staining. Periglandular myoepithelial cells are 
positively stained (f). Scale bar x10=100µm. 
 
 
As shown in figure 3.6 and figure 3.7, The A7 antibody dilution of 1:50 on normal thyroid 
sections (as a positive control), using an overnight incubation at 4ºC and with endogenous 
peroxidise blocking for 10 minutes was determined to be the best condition for clear positive 
thyroid staining. However, applying the same conditions on skin tissues reveals strong non-
specific immune staining of skin, apart from some regions of the dermis and the outer rim of 
sebaceous gland with borderline positive staining. There was much less clear cut immuno- 
staining of TSHR expressing fibroblast with A7 antibody. Periglandular myoepithelial cells 
of sweat glands show positive staining.  
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3.4 Discussion 
TSH operates by activating the TSHR expressed mainly on the thyroid epithelial cells
43,97
. 
However, several reports suggested that there are extra-thyroidal target cells for TSH and, 
therefore extra-thyroid TSHR expression including; adipose tissue
155
, cultured human hair 
follicle keratinocyte, human dermal papilla fibroblast
133
, human skin fibroblasts
132
, and 
melanoma cell lines
53
. 
 
The immunolocalization of TSHR at protein level in human skin was investigated by using 
A9 and A7 monoclonal antibodies. The pattern of staining obtained with both antibodies, on 
thyroid tissues was similar; i.e. dense staining at the basolateral surface of the thyroid 
follicular cells, in keeping with the known localization of the TSHR in the thyroid gland. 
However, the immunohistological results on human skin showed non-convincing TSHR 
immunoreactivity in human epidermis with both antibodies. Interstingly, when A9 antibody 
was used, the dermis showed a positive spindle-like or fibroblast-like immunostaining most 
probably of dermal fibroblast and a similar staining is observed in the dermal tissue 
surrounding the sebaceous gland and the infundibulum. However, there was much less clear 
cut immunostaining of TSHR expressing fibroblast with A7 antibody. This suggests that the 
A9 antibody might be detecting the TSHRV isoform or might be detecting the full length 
TSHR. Further details will be discussed in the general discussion.  Additionally, border line 
immunoreactivity is shown in the thin rim of cytoplasm surrounding the classic “honey 
comb” morphology of the sebaceous gland. 
 
 Furthermore, positive TSHR immunostaining was observed in periglandular myoepithelial 
cells of sweat glands in sections treated with both A7 and A9 monoclonal antibodies.  Our 
results are in agreement with the results obtained by Rapoport and his team where they used 
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A9 monoclonal antibody to compare the expression of TSHR in frozen skin sections obtained 
from severe case of pretibial myxedems patient and from sections obtained from normal 
individual, they found a positive elongated fibroblast-like staining in the dermis, although 
perhaps less intense, in normal individuals similar to that of the pretibial myxedema patient
61
. 
In this context, it is worth mention that the positive elongated fibroblast-like staining in the 
dermis was not detected in all the skin sections used. This could be related to the type of skin 
used (healthy vs adjacent to diseased skin).  
 
 More recently, Cianfarani et al, 2010 studied the expression of TSHR at protein level by 
immunohistchemistry using A9 antibody and showed immunoreactivity of TSHR in human 
epidermis and sparse cells in the dermis. They also used an antibody against prolyl 4-
hydroxylase, a fibroblast marker and proved that the cells in the dermis were fibroblasts
132
. 
Moreover,  a previous study by Slominski et al.2002 described TSHR mRNA expression in 
epidermal, hair follicle HaCaT keratinocytes and melanocytes, also in dermal and hair follicle 
fibroblast and melanoma cell line
53
. 
 
The absence of TSHR immunoreactivity in human epidermis and the positive sweat glands 
immunostaining is in agreement with that of the work done recently by Eniko Bodo and her 
team
133
 where they immunolocalized the TSHR in human scalp skin and hair follicle using 
BA8 monoclonal antibody, they reported the expression of TSHR in the mesenchymal cells 
of the pilosebaceous unit including the follicular dermal papilla (DP), the connective tissue 
sheath (CTS), and the arrector pili muscle and sebaceous gland whereas TSHR was not 
observed in interfollicular dermal fibrobalsts and keratinocyte in female scalp skin
133
. The 
conceivable reasons for the discrepancy between their finding and ours might be related to 
the lack of hair follicles in our sections (non scalp skin), different skin locations scalp vs  non 
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scalp, terminal hair vs. villous hair and/ or reagents used (anti-TSHR antibodies) may give an 
explanation for such discrepant data. 
  
In conclusion, our results are in agreement with others
61,132,133
 showed TSHR expression in 
the skin and this might provide evidence to support the idea that TSHR signalling could be an 
alternative mechanisim of extrathyroidal manifestations of thyroid disease rather than 
disturbance in thyroid hormone levels. Furthermore, that the isolated fibroblast-like cells 
shown in this chapter might be the fibrocytes which will be further discussed later.  If we had 
enough time we would have carried further experiment to confirm the fibroblast 
immunostaining in the demis by using antibody against  proly 4-hydroxylase fibroblast 
marker antibody
132
.
  
 
 
 
 
 
 
 
 
 
 
Chapter four 
Characterization of thyrostimulin 
antibodies 
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4. Chapter four 
 
4.1 Introduction 
As mentioned in the general introduction, thyrostimulin is a noncovalent heterodimer 
composed of a unique beta subunit (β5) and a novel alpha subunit (α2) which is different 
from the common α subunit (α1 subunit) shared by the other members of the glycoprotein 
family
153
. Thyrostimulin has three N-linked glycosylation sites, two in the α2 subunit and one 
in the β5 subunit which are important for secretion and receptor activation147. The human 
glycoprotein hormone α2 (GPHα2) gene (accession no. AF403384) has an open reading 
frame that codes for a precursor of 129 –amino acids with a 23-amino acid signal peptide at 
the N-terminus (figure 4.1), and two N-linked glycosylation sites. The putative 106- amino 
acid mature protein has a calculated molecular mass of 11.68 kDa. Whereas, the glycosylated 
human glycoprotein hormone α2 protein has a calculated molecular mass 13 kDa145.  
 
 
Figure 4.1 Nucleotide and deduced protein sequences of human GPHα2. Amino acid 
numbers are on the right, and the stop codon is marked with an asterisk. Putative N-linked 
glycosylation residues are circled. (Adapted from Hus et al, 2002
145
) 
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The human glycoprotein β5 (GPHβ5) gene (accession no. AF403430) has an open reading 
frame that codes for a precursor of 130 amino acids with a 24-amino acid signal peptide at 
the N-terminus (figure 4.2), and a single N-linked glycosylation site. The unglycosylated 
human glycoprotein hormone β5 protein has a molecular mass of 11.74 kDa. Whereas, the 
glycosylated β5 protein is 16 kDa145. 
 
 
Figure 4.2 Nucleotide and deduced protein sequences of human GPHβ5. Amino acid 
numbers are on the right, and the stop codon is marked with an asterisk. The putative N-
linlked glycosylation residue is circled (Adapted from Hus et al, 2002
145
). 
 
4.1.1Aim of chapter four  
 
To characterise new α2 and β5 thyrostimulin polyclonal antibodies using a fibroblast cell line 
transiently transfected with α2 or β5 expression vectors and then to study the expression and 
immunolocalisation of thyrostimulin subunits in human skin. 
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4.2 Materials & Methods 
4.2.1 Thyrostimulin antibodies    
 
Both α2 and β5 thyrostimulin antibodies are guinea pig polyclonal antibodies (Moravian 
Biotechnology, BRNO, Czech Republic) raised to specific peptides as shown in figures 4.3 
and 4.4 below. 
 
Figure 4.  Beta5 (β5) thyrostimulin antibody peptide. 
The sequence of β5 thyrostimulin subunit, NCBI reference sequence (NP_660154.3) is 
shown with the peptide used as antigen in green. 
 
 
 
Figure 4.4 Alpha2 (α2) thyrostimulin antibody peptide. 
The sequence of α2 thyrostimulin subunit, NCBI reference sequence (BC093960) is shown 
with the peptide used as antigen in red. 
 
4.2.2 Western blotting (Immunoblotting) 
 
Western blotting (also called immunoblotting) is a method for detecting specific proteins in a 
given sample of tissue homogenate or extract. It uses gel electrophoresis to separate 
denatured proteins according to molecular weight. The proteins are then transferred to a 
MKLAFLFLGPMALLLLAGYGCV
LGASSGNLRTFVGCAVREFTFL
AKKPGCRGLRITTDACWGRCET
WQKPILEPPYIEAHHRVCTYNE
TKQVTVKLPNCAPGVDPFYTYP
VPSAVTAEPAPLATTECETI 
MPMASPQTLVLYLLVLAVTEAW
GQEAVIPGCHLHPFNVTVRSDR
QGTCQGSHVAQACVGHCESSAF
PSRYSVLVASGYRHNITSVSQC
CTISGLKKVKVQLQCVGSRREE
LEIFTARACQCDM  
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nitrocellulose membrane, where they are detected using antibodies specific to the target 
protein. The amount of protein can be examined and compared between samples. The term 
“blotting” refers to the transfer of biological samples from a gel to a membrane and their 
subsequent detection on the surface of the membrane.  
 
4.2.2.1. Electroporation of HCA2  
 The tissue culture and electroporation were done by other colleagues in the Dermatology 
laboratory. HCA2 fibroblasts were transfected with α2 or β5 cDNA cloned into pcDNA3 by 
electroporation. Proteins were extracted from α2 and β5 transfected cells. Because 
thyrostimulin is secreted we assumed it would be in the cell condition medium therefore, the 
conditioned medium was also collected. Untransfected cell lysate and medium were used as 
negative controls. The GFP vector control contained cDNA for green fluorescent protein 
which was used as a positive control to prove successful transfection. 
 
The HCA2 cells were transfected with pcDNA3 vector containing α2, β5 and the GFP control 
vector by electroporation using Amaxa
® 
Cell line Necleofector
®
 Kit V (Lonza). In summary, 
cells were trypsinized, and seeded, the day before transfection and grown on 6-well plates in 
serum containing medium (FCS) at a density such that they were 70-80% confluent on the 
day when they were transfected. Cells were grown in DMEM with 10 % heat inactivated fetal 
calf serum. 
 
For transfection, the cells were trypsinised and the cell pellet was resuspended in 100µl 
electroporation solution (Nucleofector
®
 Solution V (Lonza) at room temperature.  The cell 
suspension (100µl) was combined with 1µg of vector (i.e.: pcDNA3 containing α2, or β5 and 
the GFP vector). The cell/ DNA suspension was transferred into a cuvette and then 
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electroporated on programme U012 optimised for HCA2 in the Amaxa nucleofector machine. 
Once the programme had finished, ~ 500 µl of pre-equilibrated culture medium was added to 
the electroporation cuvette and the cells were transferred into a 6-well plate (final volume 1.5 
ml medium per well). The cells were incubated in humidified 37ºC/ 5% CO2 incubator 
overnight. At 24 hours the cells were visualised using an inverted microscope (Nikon Eclipse 
TS100) to check for cell viability (~70-80%) and using a UV lamp (Nikon Intensilight C-
HGFI) to check that at least 50% viable cells remaining were positive for GFP expression. 
The medium was changed to DMEM alone in wells prepared for the collection of conditioned 
medium or DMEM plus 10% FCS in wells for cell lysate preparation. After 24 hours the 
serum-free medium was harvested and replaced and then harvested again after another 24 
hours. The medium was frozen for concentration later. The cell lysates were prepared 72 
hours after electroporation. 
 
4.2.2.1.1 Preparation of protein cell lysates from electroporated 
fibroblasts  
The culture medium was removed; the cells washed gently three times with 2 ml chilled PBS, 
then 300 µl x2 sample buffer added (table 4.1). The surface of the well was rubbed 
vigorously with the plunger from a plastic syringe to aid cell lysis. To ensure complete 
homogenization of the cells and removal of cellular contaminants, the cell homogenate was 
boiled for 5 minutes at 95C. The proteins were then transferred to a clean Eppendorf tube 
and used directly or frozen at -20°C until needed.  
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4.2.2.1.2 Preparation of proteins from Conditioned medium from 
transfected cells 
The conditioned medium was thawed until it reached room temperature and then 
concentrated using Amicon Ultra-4 Centrifugal Filter columns, (Millipore, USA) by spinning 
in the centrifuge for 40 minutes at 4250 rpm. The flow-through was discarded and then an 
equal volume of x2 sample buffer was added (table 4.1) to the solution remaining in the tube 
and transferred to a clean Eppendorf tube and used directly or frozen at -20°C until needed. 
 
Table 4.1:  Constituents of x2 Sample buffer 
Name  Amount  
0.5 Tris PH6.8 1 ml 
Glycerol 0.8 ml 
10% SDS (Sodium Dodecyl 
Sulphate) 
1.6 ml 
IM DTT (Dithiothreitol) 0.08 ml 
BPB( Bromophenol Blue) 
0.05%(Sigma) 
0.2 ml 
 
4.2.2.2 Electrophoretic separation of the proteins  
The initial step in a western blotting procedure is to separate the proteins using Sodium 
Dodecyl Sulfate polyacrylamide gel electrophoresis (SDS-PAGE), therefore, a running gel 
(also known as resolving or separating gel) has to be prepared first. The percentage of 
acrylamide to be used in the running gel depends on the size of the protein of interest, large 
proteins require a less concentrated gel and small proteins require a more concentrated gel. 
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The estimated molecular size of α2 and β5 subunits is 13 kDa and 16 kDa respectively, so the 
proteins were separated on 15 % polyacrylamide gel.   
  
   4.2.2.2.1 Gel preparation  
The Sodium Dodecyl Sulfate Polyacrylamide gels (SDS-PAGE) were prepared from the 
reagents listed in (tables 4.2, 4.3) and loaded into two Novex disposable (8cm X 6cm) 
cassettes (Invitrogen, Paisley, UK) up to a level of about 2 cm below the top of the cassette. 
The running gel was then carefully layered with water to ensure a flat top surface. Whilst, 
waiting for the running gel to set, the solution for the stacking gel was prepared. Both 
stacking and running gels are parts of the SDS-gel. However, the stacking gel is usually 4% 
and it is the portion in which the wells are formed and the protein samples are loaded.  
 
Table 4.2 Constituents of the running gel 
Constituent Running gel (15%) 
1.5M Tris pH8.8 3.75ml 
30% Acrylamide/bis- acrylamide gel solution (Sigma) 7.5ml 
10% SDS 150µl 
H2O 3.6 ml 
10% Ammonium  per sulphate (sigma)* 75 µl 
TEMED (N,N,N,N tetramethyl ethylene diamine) 99% sigma  7.5 µl 
*Should be added just prior to pouring the gel into the cassette. 
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Table 4.3 Constituents of the stacking gel  
Constituent Stacking gel (4%) 
0.5 Tris PH 6.8 1.25 ml 
30% Acrylamide/bis- acrylamide gel solution (Sigma) 0.65 ml 
10% SDS 50 µl 
H2O 3.05 ml 
10% Ammonium per sulphate (sigma)* 50 µl 
TEMED 10 µl 
*Should be added just prior to pouring the gel into the cassette. 
 
Once the running gel was set, the water from the top was drained off and the stacking gel was 
loaded on to the cassettes. A plastic comb was immediately inserted into the liquid stacking 
gel before it sets. Once set, the comb was carefully removed and the wells are rinsed with 
distilled water. The white strip at the lower end of the cassettes was removed and the 
cassettes were placed in the electrophoresis cell (XCell SureLock™ Mini-Cell 
Electrophoresis System, Invitrogen, Paisley, UK) with the wells facing inwards and locked in 
place. 
 
Following this step, x1 running buffer prepared from the x10 stock running buffer (as 
described in table 4.4) was loaded into the wells. Low-range prestained SDS-PAGE 
molecular weight marker (about 5 μl) (Precision plus, Catalogue no. 161-0373,  Bio-Rad 
Laboratories, Richmond, CA)  was loaded into the assigned wells, and then (5 μl)  samples of 
protein of interest (α2, β5, GFP transfected cell lysate, untreated cell lysate, conditioned 
medium of transfected cells, GFP conditioned medium) were also loaded in to the assigned 
wells. The chamber between the gels and the outer chamber of the apparatus were then filled 
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with the x1 running buffer. The electrophoresis apparatus was then connected to a power 
pack and run at a starting voltage of 150V and a constant current of 50 mA (25mA per gel) 
until the tracking dye reached the bottom of the gel. The cassettes were unlocked and 
removed from the apparatus, after which they were carefully dismantled by breaking the seal 
around them using the supplied Novex spatula. The stacking gel and the lower portion of the 
running gel were cut off. 
 
 Table 4.4 Composition of x10 running buffer 
Constituent Volume 
Tris (Mw121.1) 30g 
Glycine 144g 
SDS (Sodium dodecyl sulphate) 10g 
Distilled  Water  To make up to 1L 
 
 The x1 running buffer was made from a readymade stock of x10 running buffer (1:10). 
 
4.2.2.2.2 Transfer of proteins to the membrane  
After the electrophoresis step, the proteins are transferred from the electrophoresis gel to 
Immobilon membrane. For this purpose, western blotting buffer was prepared using a stock  
x 25 blotting buffer (table 4.5).  
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 Table 4.5 Composition of x25 blotting buffer 
Constituent Volume 
Tris (Mw121.1) 18.2g 
Glycine 90g 
H2O Up to 500ml 
 
The 500 ml x1 blotting buffer was made by mixing 20ml x25 blotting buffer, 100ml methanol 
and 380 ml H2O. 
 
Four pieces of filter paper and two pieces of polyvinylidene difluoride (PVDF) membrane 
(Immobilon-P Transfer Membrane, Watford, UK) were cut according to the dimensions of 
the gel (8 cm x 6 cm). The filter paper and the four pads were soaked in the western blotting 
buffer. Before soaking in the western blotting buffer, the hydrophobic membrane was made 
hydrophilic by immersing it in methanol for 10 seconds followed by two five minute washes 
in distilled water. The gel membrane sandwich for two gels was assembled on the cathode 
plate of the blotting apparatus in the following order:  sponge pad, filter paper, gel, 
membrane, filter paper, sponge pad, filter paper, gel, membrane, filter paper and the 
remaining two pads (figure 4.5). 
 
The other plate of the module was placed on top and closed. The assembled module (X Cell 
II Blot Module; Invitrogen, Paisley, UK) was then inserted into the tank of the blotting 
Apparatus (figure 4.6). The inner blotting chamber was filled with 1x western blotting buffer 
and the outer chamber of the blotting apparatus was filled with distilled water for cooling 
during the electrophoresis. It was then run at 25 V constant voltage (around 100 mA starting 
current) for 2 hours. 
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Figure 4.5 Illustration of a gel-membrane sandwich for two gels.  
 
 
 
Figure 4.6 Illustration of Electroblotting Apparatus  
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 4.2.2.2.3 Blocking and antibody incubation 
After 2 hours, the membranes were carefully removed and placed in a Petri dish and washed 
once in PBS-T (table 4.6) for 5 minutes. All the washing, blocking, and primary and 
secondary antibody incubation steps were performed on an orbital shaker to ensure proper 
contact with the membrane. 
 
Table 4.6 Constituents for preparation of PBS-T20 
Constituents Amount required to make up  500 ml 
            PBS (x10) 50 ml 
Tween-20 0.5 ml 
Distilled water 449.5 ml 
 
The PVDF membrane used in western blotting has a high affinity for proteins. Therefore, 
after the transfer of the proteins from the gel, it is important to block the remaining surface of 
the membrane to prevent any nonspecific binding of the antibodies to the membrane surface 
in subsequent steps. Therefore, the membranes were then placed in blocking buffer (5 g of 
Marvel in 100 ml of PBS-T), protein side down for an hour.  
 
Following this, the membranes were placed in primary (α2, β5) thyrostimulin antibodies 
diluted in 5% Marvel in PBS-T, overnight at 4° C on the rocker (table 4.7) The next day the 
membranes were washed in PBS-T (3 times for 5 minutes) to remove unbound reagents and 
reduce background. The membranes were placed in 10 ml of 1:500 dilution (diluted with 2% 
Marvel in PBS-T) of the anti-guinea pig secondary antibody (species corresponding to the 
primary anti body) conjugated to horse radish peroxidase (Dako UK Ltd, Ely, UK) for 30 
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minutes. This was followed by washes in 2% Marvel in PBS-T five times for two minutes 
each and, finally washed with PBS for one minute.   
 
Table 4.7 α2 & β5 thyrostimulin antibodies protocol used for western blotting 
Primary  
ab 
Host  Source  Dilution  Blocking 
Buffer 
Secondary 
labelled HRP 
ab  
Gel % 
 
    β5  
 
Guinea 
pig 
Moravian 
Biotechnology, 
BRNO, Czech 
Republic 
1:500 O/N 5% Marvel in 
PBS-T  
Anti guinea pig  
1:500 
 
  15% 1:2000 O/N 
    
    α2 
1:500 O/N 5% Marvel in 
PBS-T 
Anti guinea pig  
1:500 
   
  15% 1:2000 O/N  
 
4.2.2.3. Chemiluminescent detection of proteins. 
To visualise the protein signals, an enhanced chemiluminescence (ECL) technique was 
employed, which has to be performed in a dark room. The membranes were placed on cling 
film with the protein side up and a 1:1 mixture of solution I (table 4.8) and solution II (table 
4.9) were added to the membranes (approximately 2 ml per membrane) and it was left for 5 
minutes. 
 
Table 4.8 Constituents for preparation of solution I 
 
Constituents  Amount required 
Luminol (250 mM in dimethyl sulfoxide, DMSO) 1 ml 
Coumaric acid (90 mM in DMSO)  0.44 ml 
Tris (pH 8.5)  10 ml 
Distilled water  To make up to 100 ml 
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Table 4.9 Constituents for preparation of solution II 
 
Constituents  
 
Amount required 
30 % Hydrogen peroxide  
 
64 μl 
Tris (pH 8.5)  
 
10 ml 
Distilled water  
 
To make up to 100 ml 
 
Following this the excess solution was drained off and the membranes were placed protein 
side down on fresh cling film, wrapped up and placed in an X-ray cassette with the protein 
side facing upwards. The lights in the dark room were switched off and an X-ray film 
(Amersham Hyperfilm ECL, catalogue number: 28-9068-35; GE Healthcare UK Limited, 
Buckinghamshire, UK) of appropriate dimension was placed over the wrapped membranes in 
the cassette.  The exposure time ranged from 30 seconds up to 5 minutes. The film was 
removed from the cassette and placed in the developer solution till clear bands appeared, 
following which it was briefly immersed in the stop solution (water) and then in the fixer for 
around 30 seconds. The films were washed in distilled water for 15 minutes and then allowed 
to dry. Once dried the size of the bands on the film were determined by comparing it with the 
prestained molecular weight marker.  
 
4.2.2.4. Coomassie Blue staining    
To visualize the proteins and to check for even loading of protein, the gels were stained for 
30 minutes with 0.05g Coomassie brilliant blue R250 (Sigma) dissolved in 40ml methanol, 
10ml acetic acid and 50ml water followed by destaining with a mixture of 50ml methanol, 
75ml Acetic acid and 875ml H2O for every 30 minutes until the background of the gel is 
clear. 
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  4.2.2.5. Silver staining 
 
 Silver staining detects proteins after electrophoretic separation on polyacrylamide gels. Its         
main advantages are its high sensitivity (in the very low ng range) and can be achieved with 
simple and cheap laboratory equipment and chemicals. The main phases of silver staining are  
 protein fixation followed by sensitization, then silver impregnation (infusion) and finally      
image development
183
.  Several variants of silver staining protocols described in the literature 
which can be completed in a time range from 2 h to 1 day after the end of the     
electrophoretic separation. Once completed, the stain is stable for several weeks
183
 .  The 
silver staining was performed using PlusOne Silver Staining Kit, Protein (Code No.17- 1150-
01, GE Healthcare Bio-Sciences AB, Sweden). The initial step is to prepare the reagent 
solutions described in (table 4.10) from the chemicals provided in PlusOne Silver Staining 
Kit which are; Ethanol, Glacial acetic acid and Glycerol (87%w/w) (1000ml). For each gel, 
250ml solution is needed per gel. All steps should be performed with gentle shaking of the 
staining tray. 
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 Table 4.10 Constituents of reagent solutions used in silver staining  
Reagent name Component and quantity 
Fixing solution 30% Ethanol Ethanol 75ml 
Glacial acetic acid 25ml 
Water up to 250ml 
Sensitizing solution Ethanol 75ml 
Sodium thiosulphate (15%w/v)10 ml 
Sodium acetate(17g) 1 packet 
Water up to 250ml 
*1.25ml Glutaraldehyde (25%w/v)  
Silver solution Silver nitrate solution(2.5% w/v) 25ml 
Water up to 250ml 
Developing solution Sodium carbonate (6.25g) 1 packet 
Water up to 250ml 
Sir vigorously to dissolve the Sodium carbonate 
*0.2 ml formaldehyde (37%w/v) 
Stop solution EDTA-Na2.2H2O(3.65g) ) 1 packet 
Water up to 250ml 
Washing solution Water 
Reserving solution Ethanol 75ml 
Glycerol(87%w/w) 
Water up to 250ml 
* Glutaraldehyde and formaldehyde should be added immediately before use 
 
To fix the proteins, the gels are soaked in fixing solution for 60 minutes, the fixing solution 
was removed and sensitization solution was added with continuous shaking for 60 minutes. 
After removing the sensitization solution the gels are washed four times for 15 minutes each 
with distilled water. Then the gels were soaked in silver solution for 60 minutes with 
continuous shaking to ensure proper infusion of proteins with the silver stain. The silver 
solution removed and the gels washed four times in distilled water for one minute each 
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followed by adding the developing solution and  continuous shaking for 4-6 minutes until the 
bands reach the desired intensity, then the gels were transferred to stopping solution for 60 
minutes with shaking. The gels were transferred to preserving solution for 60 minutes. 
Finally, the gels were placed between two wet gel drying membranes (Sigma Aldrich. Dorset, 
UK) sheets and allowed to dry at room temperature overnight.  
 
4.2. . Immunohistochemistry of β5 thyrostimulin antibody 
 
Despite different attempts, techniques used in western blotting experiment to detect the 
thyrostimulin α2 & β5 subunit proteins using thyrostimulin antibodies, results fail to show α2 
subunit expression whereas only β5 subunit was detected. Therefore, IHC was utilized to 
explore whether β5 is expressed in the skin or not. 
 
4.2.3.1 Tissues used  
Human thyroid tissue and normal skin tissue was purchased from a commercial source (AMS 
Biotechnology, UK). Normal human skin was also collected from the Dermatology 
Department, Cardiff University. Frozen section techniques were employed as described in 
chapter three, section (3.2.1.1).  
 
4.2.3.2 Antibody used 
 Only β5 polyclonal thyrostimulin antibody is used (as described above).  
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4.2.3.3 The protocol 
Two protocols were tried 1) ABC method as in chapter 3 section (3.2.1.4). 2) The 
streptavidin method as described below: 
 
4.2.3.3.1The streptavidin method 
Slides were taken out of the freezer and allowed to reach room temperature; foil was removed 
and the slides then labelled, fixed in acetone and air dried for 15 minutes each, followed by 
three five-minute washes in 1x PBS-T (table 3.2) with 0.05% Tween 20 buffer solution. To 
reduce non-specific binding, the slides were incubated with 5% goat normal serum in 1% 
BSA/PBS-T for 30 minutes at room temperature. After tapping off the excess, the slides were 
washed three times five-minute each in 1x PBS-T The sections were incubated with an 
optimum dilution of the β5 primary antibody overnight at 4˚C (table 4.11). Slides incubated 
with diluent without any primary antibody were run in parallel as a negative control. This was 
followed by three five-minute washes in the buffer solution. 
 
The sections were then incubated with anti guinea pig biotinylated secondary antibody at a 
dilution of 1:400 (table 4.11) for 30 minutes, Followed by three five-minute washes in 1x 
PBS-T. The sections were then incubated with streptavidin (GE Healthcare, UK) at a dilution 
of (1:200) for a further 30 minutes. The sections were then washed in the buffer solution 
three times and developed with (5mgs in 5ml of PBS) horse radish peroxidase substrate 
solution (0.5 ml of 3, 3’ Diaminobenzidine (DAB), 4.5 ml of PBS and 6 µl of H202) (Fisher 
Scientific UK) for 10 minutes to produce colorimetric immunoprecipitates. The sections were 
then rinsed in tap water and counterstained with haematoxylin for 5 minutes and washed 
again in tap water. Finally, all sections were dehydrated through a graded series of alcohol 
solutions (1 x 70%, 1 x 90%, and 3 x 100% industrial methylated spirit; Genta Medica, York, 
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UK) for 5 minutes each, and cleared in three changes of xylene (Genta Medica, York, UK) 
for 5 minutes each. The slides were then carefully mounted with a cover slip using DPX 
mounting medium (a mixture of distyrene, a plasticizer, and xylene; RA Lamb, East Sussex, 
UK) and then left to dry overnight. 
 
4.2. .4 Optimization of β5 thyrostimulin antibody 
The protocols used in these experiments were optimized until good positive staining was 
detected and all the non-specific staining and background were minimised.  
 
  4.2.3.5 Optimization of primary and secondary antibodies 
Frozen sections of human skin were used to optimize β5 thyrostimulin primary antibody and 
anti guinea pig biotinylated secondary antibody. The Streptavidin method was used initially, 
and later on the standard ABC method was employed as described in chapter three, section 
(3.2.1.4). A summary of the protocols used during the optimization process is shown in (table 
4.11).All sections were treated with diluent only without the primary antibody as a negative 
control. Another negative control experiment was carried out with the pre immune serum 
instead of the primary antibody. The pre-immune serum is basically the serum of the host 
animal before it was immunized with the peptide of interest.  
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 Table 4.11 Summary of primary and secondary antibody optimization conditions 
β5 
primar
y ab 
Secondary ab Tissue Blocking Tertiary  
(Method) 
1:200, 
1:500, 
1:1000 
O/N 
Anti guinea pig 
biotinylated  
1:400  O/N 
Normal 
skin  
Endogenous peroxidase for 10 
minutes  
5% goat serum in PBS-T for 30 
minutes 
 
Streptavidin  
 
(1:200) 
1:50 
O/N 
Anti guinea pig 
biotinylated 1:200 
O/N 
Normal 
skin  
 
Endogenous peroxidase for 10 
minutes 5% goat serum in 
BSA/Marvel in PBS-T for 30 
minutes 
  
ABC 
none Only anti guinea 
pig biotinylated 
secondary Ab is 
used (1:200, 
1:400, 1:800 O/N 
 
Normal 
skin  
 
Endogenous peroxidase for 10 
minutes 5% goat serum in 
BSA/Marvel in PBS- T for 30 
minutes 
  
ABC  
1:500, 
1:750, 
1:1000 
O/N 
Anti guinea pig 
biotinylated  
 1: 400 O/N 
Normal 
skin  
 
Endogenous peroxidase for 10 
minutes 
 
5% goat serum in BSA/Marvel in 
PBS- T for 30 minutes 
  
ABC  
 
  4.2.3.6 Testing the pre immune serum 
In this protocol,  frozen sections  of human skin were used,  immunoreactivity of skin 
sections treated with β5 thyrostimulin antibody were compared with immunoreactivity of  
skin sections treated with guinea pig pre-immune serum in the same conditions.  The standard 
ABC method was used as described in chapter three, section (3.2.1.4), in addition to the use 
of hydrogen peroxide to block the endogenous peroxidase. The different dilutions of β5 
antibody and the pre immune serum samples were prepared (table 4.12) using the same 
diluent (1% BSA/Marvel in PBS-T) at room temperature at the same time.  Equal volumes of 
the β5 antibody and the pre immune serum were added to diluent. A summary of pre-immune 
serum protocol is shown in (table 4.13). 
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Table 4.12 Dilutions of β5 and pre immune serum  
β5  antibody Guinea pig pre immune serum   
Blank (Diluent only) Blank (Diluent only) 
1:1000    1:1000  
1:2000  1:2000 
1:4000 1:4000 
  
Table 4.13 Summary of pre-immune serum experiment protocol 
Primary Ab Secondary ab Tissue Blocking Method  
Anti β5 Ab  
1:1000 
1:2000 
1:4000 
O/N 
 
Anti guinea pig 
biotinylated  
1: 400 
 
 
 
Normal 
skin 
sections 
 
Endogenous 
peroxidase blocked for 
10 minutes. 
 
 5% goat serum in 
BSA/Marvel in PBS- 
T for 30 minutes 
   
 
Avidin & Biotin for 15 
minutes each  
 
ABC Kit 
Guinea pig  β5 
pre-immune 
serum  
1:1000 
1:2000 
1:4000 
O/N 
 
4.2. .7 β5 Peptide neutralization  
Peptide neutralization or immunizing peptide blocking is a technique used to determine if the 
immunoreactivity is specific. The initial step in this approach is to neutralize (incubate) the 
primary antibody with an excess of peptide that was used to raise the primary antibody. The 
antibody that is bound to the blocking peptide is no longer available to bind to the peptide 
epitope present in the protein in the cell. The neutralized antibody is then used side-by-side 
with the antibody alone, and the results are compared. By comparing the staining from the 
blocked antibody versus the antibody alone, the specific staining can be observed in the IHC 
sections. Staining recognized by the antibody will be absent in the tissue/cells probed with 
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neutralized antibody. In this project we compared the immunoreactivity of skin sections 
treated with β5 thyrostimulin antibody alone with sections treated with a mixture of β5 
thyrostimulin antibody plus the β5-blocking peptide (the peptide that the β5 antibody was 
raised to) under the same conditions. All antibody and blocking peptide samples were 
prepared at room temperature with the same antibody diluent (1% BSA/Marvel in PBS-T) 
and then centrifuged for 15 minutes for at least two hours before the start of the experiment to 
allow interaction between the antibody and the peptide. After fixation and blocking steps, the 
antibody solutions were incubated with skin sections overnight at 4
o
C. The standard ABC 
staining method was continued as described in chapter three, section (3.2.1.4). A summary of 
the β5 Peptide neutralization protocol is shown in (table 4.14). 
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Table 4.14:  Summary of β5 Peptide neutralization protocol. 
Primary ab Diluent Secondary 
Ab 
Tissues Blocking method & 
duration 
Method 
 
 
β5 1:1000  O/N 
 
 
 1% 
BSA/Marv
el in PBS-T 
 
 
 
Anti 
Guinea   
 
pig Ab  
 
(1: 400) 
 
 
 
 
Normal 
skin 
sections 
 
 
Endogenous 
peroxidase , 10 
minutes 
 
 5% goat serum in 
BSA/Marvel in PBS-
T, for 30 minutes.  
 
 
Avidin & Biotin,  15 
minutes each 
 
 
 
ABC 
Kit 
β5 1:1000 + 
blocking Peptide 
1:1000 O/N 
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4.3 Results 
4.3.1 Western blotting results  
 
4. .1.1 β5 thyrostimulin antibody  
 
                                                                                                                                                 
Figure 4.7 Western blot for detection of β5 subunit protein in cultured fibroblast 
transfected with β5 vector. Lane 1) β5 cell lysate, Lane 2) unelectroporated cell lysate (-ve 
control), Lane 3) conditioned medium from β5 transfected cells, Lane 4) conditioned 
medium from GFP transfected cells, Marker = Precision plus marker in kilo-Dalton (kDa).   
  
 
As shown in figure 4.7, immunoblots of protein prepared from cells transiently transfected 
with β5 expression vector, using the β5 thyrostimulin antibody at dilutions of 1:500 & 1:2000 
detected a band in the β5 cell lysate of approximately 15 kDa. There was no band detected in 
the un-transfected cell lysate. There is a smear like band in the β5 conditioned medium. 
However, no band detected in GFP conditioned medium.  
 
 
1:500
1 2 3 4
1:2000
1 2 3 4
15
20
25
37
50
75 
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4. .1.2 α2 thyrostimulin antibody   
 
 
Figure 4.8 Western blot for detection of α2 subunit protein extract in cultured fibroblast 
transfected with α2 vector. Lane 1) α2 cell lysate, lane 2) unelectroporated cell lysate (-ve 
control), lane 3) α2 condition medium, lane 4) GFP condition medium, Marker = Precision 
plus marker in kilo Dalton ( kDa). 
 
 As shown in figure 4.8 immunoblots of proteins prepared from cells transiently transfected 
with α2 expression vector using α2 thyrostimulin antibody at dilutions of 1:500 & 1:2000 
showed no reactivity with the α2 subunit protein in the cell lysate or the conditioned medium. 
Two faint bands are visible in lanes 3, 4 at dilution of 1:2000 most probably due to non 
specific binding in the serum since they are in the control as well and are of a protein too large 
to be thyrostimulin.  
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4.3.1.3 Coomassie Brilliant Blue result 
Coomassie staining of condition medium and cell lysate of α 2 and β5, GFP was applied. 
 
Figure 4.9 Coomassie Brilliant Blue staining of proteins from cell lysate and culture 
medium of HCA2 cell line transfected with α2, β5 and GFP vectors. Lane 1) α2 
conditioned medium, lane 2) β5 condition medium, lane 3) GFP condition medium, lane 4)  
α2 cell lysate, lane 5) β5 cell lysate, lane 6) untreated cell lysate, lane 7) data used for a 
different experiment, lane 8) Precision Plus marker in kDa.  
 
 
Coomassie Brilliant Blue staining of a 15% gel (figure 4.9) used to separate proteins 
extracted from cell lysate and culture medium of HCA2 fibroblast cell line transfected with 
α2, β5 and GFP. Lanes 1, 2 and 3 are difficult to comment on due to the fact that the proteins 
are below the detection level of Coomassie Brilliant Blue staining. Lanes 4, 5 and 6 looks 
similar and evenly loaded. Lane 7 is data used for different experiment.   
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4.3.1.4 Silver stain result  
Despite concentration of the conditioned media the levels of proteins are mostly below the 
detection level for Coomassie Brilliant Blue (figure 4.9). Therefore, silver staining, a 
sensitive method to detect even low levels of protein expression, was undertaken.  
 
Figure 4.10 Silver staining of SDS-PAGE gel of concentrated conditioned media. Lane 1) 
HCA2 cells condition medium transfected with α2 expression vector, lane 2) HCA2 cells 
condition medium transfected with β5 expression vector, lane 3) HCA2 cells condition 
medium transfected with GFP vector and lane 4) precision plus marker in kilo Dalton (kDa).  
  
 
As shown in Figure 4.10, proteins in the concentrated conditioned media from HCA2 cells 
transfected with α2 expression vector, β5 expression vector and GFP vector were investigated 
using silver staining of 15 % SDS-PAGE gel. Even using this sensitive method there were no 
obvious bands present in the condition medium of the α2, β5-transfected cells that were not 
present in the GFP transfected cells at the expected molecular weights. The α2 and β5 
expression is probably too low to be detected even with silver stain.  
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4.3.2 IHC results 
 
4. .2.1 Optimization of β5 antibody using streptavidin method  
The streptavidin method as a less direct method was carried out 
 
Figure 4.11 Optimization of the β5 polyclonal thyrostimulin using the streptavidin 
method. a) Negative control is section incubated with secondary antibody (1:400). Skin 
sections treated with different dilutions of β5 thyrostimulin antibody b) 1:200, c) 1:500 and d) 
1:1000 respectively. Scale bar x10= 100μm. 
 
 
As shown in figures 4.11, the immunostaining of thyrostimulin in human skin using β5 
polyclonal thyrostimulin antibody using the streptavidin method, the negative control is skin 
section treated with no primary antibody and only secondary antibody (1:400) used, and was 
of similar pattern and intensity in the negative control (skin incubated with no primary 
antibody) and in sections treated with β5 antibody at a range of dilutions of 1:200, 1:500 and 
1:1000.  Therefore a more sensitive method was needed (such as ABC) but with more 
stringent blocking. 
-C
a
1:500
c
1:200
b
1:1000
d
100μm
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4.3.2.2 ABC method with higher concentration of primary and secondary antibodies 
1:50-C 
a b
100μm
 
Figure 4.12 Optimization of the β5 polyclonal thyrostimulin using higher concentration 
of primary and secondary. a) Negative control is section incubated with secondary antibody 
(1:200). b) Skin section treated with 1:50 dilution of β5 thyrostimulin antibody. Scale bar 
x10= 100μm. 
 
As shown in figures 4.12, images of immunostaining of thyrostimulin in human skin using β5 
polyclonal thyrostimulin antibody during the process of optimization using ABC method.  
Negative control is skin section incubated with no primary antibody and reveals no staining. 
Because, the streptavidin method showed no immunoreactivity, skin section treated with 
higher concentration of primary β5 antibody (1:50) and a high concentration of the secondary 
antibody (1:200) using ABC method was carried out. Higher concentrations were used just to 
get a signal as a start point for the optimization process. At 1:50 dilution B5 antibody showed 
strong non-specific background signals, thus optimization of secondary antibody was 
required.  
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4.3.2.3 Optimization of secondary antibody 
 
Figure 4.13: Optimization of the anti-guinea pig secondary antibody concentration. 
Sections incubated without primary antibody at dilutions of secondary of a) 1:200, b) 1:400, 
c) 1:800. Scale bar x10= 100μm. 
 
As shown in figure 4.13, images of immunohistological staining during the process of 
secondary antibody optimization using the ABC method. In all sections no primary antibody 
was used (diluent only was used instead), the secondary antibody used at a range of dilutions 
(1:200, 1:400, 1:800) respectively. The anti guinea pig secondary at dilution of 1:400 seemed 
to be the highest concentration that revealed a clear background with no nonspecific staining 
in skin sections, so this dilution was used in the next experiments. 
 
 
1:200 1:400
1:800
a b
c
100μm
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4. .2.4 Optimization of β5 antibody using ABC method 
 
 
Figure 4.14: Optimization of β5 polyclonal thyrostimulin antibody using ABC method. 
Negative control (panel a) is section incubated with secondary antibody (1:400). In contrast, 
panels (b, c and d) are skin sections treated with different dilutions of β5 antibody (1:500, 
1:750 and 1:1000) respectively. Scale bar x10= 100μm. 
 
 
As shown in figures 4.14, Images of immunostaining of thyrostimulin in human skin using β5 
polyclonal thyrostimulin antibody during the process of optimization using ABC method with 
extra blocking. Negative control section (blank) is incubated with no primary antibody 
(diluent used instead) and reveals no staining. Skin sections treated with β5 antibody at a 
range of dilutions of (1:500, 1:750 and 1:1000) showed strong staining and additional 
controls are required to confirm the specificity. 
 
-C
a
1:500
b
1:1000
d
1:750
c
100μm
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4. .2.5 β5 pre-immune serum control 
 
Figure 4.15:  Immunostaining of thyrostimulin in human skin treated with β5 antibody 
compared to the pre-immune serum. Negative controls (panel a and b) are sections 
incubated with no primary antibody. Skin sections treated with β5 antibody (panels d, f and 
h), and human skin sections treated with pre-immune serum (panels c, e and g) (as negative 
control). β5 antibody and pre-immune serum used in a range of dilutions (1:1000, 1:2000, 
1:4000). The two sets of sections were run in parallel to each other at the same time under the 
same conditions. Scale bar x10= 100μm. 
 
-C 
b
β5 1:1000
d
β5 1:4000 
h
β5 1:2000
f
Pre-immune 1:1000
c
Pre-immune1:2000
e
Pre-immune 1:4000
g
-C 
a
100μm
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Shown in figures 4.15, are images of immunostaining of thyrostimulin in serial sections of 
human skin treated with β5 antibody and human skin sections treated with pre-immune serum 
(as negative control) during the process of optimization of β5 polyclonal thyrostimulin 
antibody using a range of dilutions (1:1000,1:2000,1:4000). For comparison, the two sets of 
sections were analysed in the same time using the same dilutions and under the same 
conditions.  Negative controls are section incubated with no primary antibody (diluent used 
instead) and reveal no staining. Unexpectedly, the pre-immune skin sections, in the tested 
dilutions, show strong nonspecific staining. Furthermore, the skin sections treated with β5 
antibody under the same conditions show positive non-specific inconclusive staining. 
Therefore, an extra blocking method was added. 
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4. .2.6 Blocking with β5 immunizing peptide  
 
Figure 4.16:  β5 antibody characterisation using the neutralization peptide technique. 
Skin section treated with no primary antibody (panel a) (as negative control), β5+ peptide 
(panel b) (as additional negative control), β5 antibody (panel c). The sections were prepared 
at the same time under the same conditions with the same dilution (1:1000). Scale bar x10= 
100μm. 
 
The pattern of immunostaining obtained with β5 polyclonal thyrostimulin antibody, on serial 
sections of human skin during the process of characterisation using peptide neutralization is 
shown in figure 4.16. Three skin sections were used: the first skin section incubated with no 
primary antibody used as a negative control and reveals no staining.  The second skin section 
incubated with β5 plus the peptide (as an additional negative control) and the third skin 
section treated with β5 antibody. The sections were prepared at the same time under the same 
-C
a
β5+ peptide(1:1000)
b
β5(1:1000)
c
100μm
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conditions with the same dilution (1:1000). The last two sections show positive strong 
nonspecific immunoreactivity. Table 4.15 summarizes the optimization conditions for β5 
Thyrostimulin antibody.  
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Table 4.15 Summary of optimization conditions of β5 thyrostimulin antibody. 
β5 primary 
ab 
Secondary ab Tissue Blocking Tertiary  
(Method) 
Comment 
Streptavidin method, optimising the primary antibody 
 
1:200, 1:500, 
1:1000 O/N 
Anti guinea pig 
biotinylated  
1:400 
Normal skin  Endogenous peroxidase for 10 minutes,  
5% goat serum in PBS-T 
 
 
Streptavidin  
1:200 
         No signal obtained 
         More sensitive method 
required 
More stringent blocking   
ABC method with higher concentration of primary and secondary 
 
1:50 O/N Anti guinea pig 
biotinylated 1:200 
Normal skin  
 
Endogenous peroxidase for 10 minutes, 5% goat serum 
in BSA/Marvel in PBS-T 
ABC         Too strong signal 
 
 
ABC method, optimisation of secondary antibody  
 
none Anti guinea pig 
biotinylated 1:200, 
1:400, 1:800 O/N 
Normal skin  Endogenous peroxidase for 10 minutes, 5% goat serum 
in BSA/Marvel in PBS-T 
 
ABC  1:400  seems to be the optimal     
dilution for secondary antibody 
ABC method, optimising the primary antibody  
 
1:500, 1:750, 
1:1000 O/N 
Anti guinea pig 
biotinylated  
1:400 
Normal skin  
 
Endogenous peroxidase blocked 10 minutes, 
5% Goat serum in BSA/Marvel in PBS-T 
ABC  Strong background   
 
β5 pre-immune serum control  
 
1:1000, 
1:2000 
1:4000 O/N 
Anti guinea pig 
biotinylated  
1:400 
Normal skin  
 
Endogenous peroxidase blocked 10 minutes, 5% Goat 
serum in BSA/Marvel in PBS-T 
ABC Pre immune show stronger 
signal than β5 antibody 
Blocking with β5 immunizing peptide  
 
1:1000 O/N Anti guinea pig 
biotinylated  
1:400 
Normal skin  
 
Endogenous peroxidase blocked10 minutes, 5% Goat 
serum in BSA/Marvel in PBS-T 
ABC Positive strong nonspecific 
immunoreactivity. 
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4.3 Discussion 
In this study α2 and β5 thyrostimulin polyclonal antibodies were characterised. The β5 
polyclonal antibody detected the β5 thyrostimulin subunit in the HCA2 fibroblast cell line 
transfected with β5 expression vector at the expected molecular weight. However, α2 
thyrostimulin polyclonal antibody failed to recognize the α2 subunit in the same cell line 
transfected with α2 expression vector under the same conditions. Therefore, for the purpose 
of the study the analysis only focuses on the β5 thyrostimulin subunit. The western blotting 
result for β5 thyrostimulin antibody shows a positive band at the expected molecular weight 
and the fact that there was no band detected in the cell lysate of untransfected cells is another 
important result as it confirms that the detected band can only be due to the expression of 
protein derived by β5 expression vector therefore it to indicates specificity of this result.  
 
 Using the GFP expression vector suggests that plasmid has gone into the cells. However, that 
does not necessarily mean the transfection was successful and it is no guarantee that α2 and 
β5 proteins will be expressed. For β5, it seems that there is enough protein in the transfected 
cells and the β5 antibody was able to bind to it. To confirm if the α2 was transfected or not, it 
would be ideal to detect the transcript by RT-PCR, but this was not possible since this was a 
transient transfection and that would be contaminated with the expression vector.  
 
The inability of the α2 thyrostimulin antibody to detect the α2 subunit protein in cell lysates 
or conditioned medium of the α2 transfected cells may be due to the fact that the antibody 
was used at a dilution of 1:500 or 1:2000; this may be too dilute, since the manufacturer's dot 
blot obtained a signal using concentrations of 1:100 and 1:400. Hence, a higher concentration 
of antibody could have been tried.      
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The western blotting analysis using β5 thyrostimulin antibody showed a smear like band in 
the conditioned medium of the cells transfected with β5 expression vector; this suggests that 
the detected band could be the glycosylated heterodimer of α2 and β5 thyrostimulin. To 
confirm that we could have tried α2 thyrostimulin antibody at a lower dilution, to see if it can 
detect any protein. Another experiment we could have used is to treat the sample with a de-
glycosylation enzyme (for example; N-glycosidase F
144
) and run it alongside the glycosylated 
protein and compare the results. 
 
 The other possible explanation is that the β5 antibody could be detecting lots of β5 subunits 
binding together, and the reducing agent in the sample buffer was not enough. This 
possibility could be investigated further by adding more reducing agent or by trying a 
different reducing agent such as β-mercaptoethanol. 
 
The investigations were not able to detect the β5 subunit protein in conditioned medium of 
the transfected cells for the following possible reasons; the β5 subunit protein was below the 
detection level even by using the silver stain as a sensitive method for detection of low level 
proteins. The other possible reason is that during the preparations for the culture medium the 
fetal calf serum was taken out from the cells and was replaced with DMEM medium instead 
which lacks the nutrients and we could have starved the cells to the level that they were 
unable to synthesis the protein. However, this possibility seems unlikely since that will take 
longer than 24 hours to starve the cells.  
 
Because of the technical challenges and the lack of good positive control our investigations 
focused only on β5 thyrostimulin antibody. Because of the constraint of time we were not 
able to explore these possibilities since we already have positive results for β5 cell lysate.       
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Following the positive western blotting result with β5 antibody, the immunohistological 
analysis was conducted to investigate the expression of thyrostimulin β5 subunit at the level 
in human skin using this β5 thyrostimulin polyclonal antibody.  During this process, I faced 
several technical challenges to achieve clear visible specific staining. Therefore, multiple 
blocking methods were carried out.  None of the methods and techniques applied show 
positive clear immunoreactivity of β5 antibody in skin sections and we were unable to show 
any positive results in the skin.  
 
 Because, the thyrostimulin α2 subunit is expressed in human pituitary144, tissue extract from 
human pituitary could be used as a positive control to test if the α2 antibody is functional. If it 
worked, the α2 antibody could be used for immunohistochemistry using human pituitary. 
Because of the technical challenges and the lack of good positive controls it was not possible 
to continue any further in investigating the α2 thyrostimulin antibody. 
 
The unexpected positive signal stronger than the β5 antibody obtained with the pre immune 
serum could be explained by the fact that the pre immune serum was provided in small 
volume and probably evaporated over a period of time and just concentrated any antibodies 
that were there prior to immunisation with the β 5 peptide. The large number of antibodies in 
the pre immune serum would potentially mask any β5 immunoreactivity.  
 
The results indicate that β5 antibody is clearly a good antibody. However, it cannot be used 
in its current form for immunohistochemistry and needs to be cleaned. If we had enough time 
we could have affinity purified the β5 antibody. In its un-purified form the β5 antibody could 
be used for cell culture expression studies by western blotting.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Five   
 
General discussion  
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5. Chapter five 
 
5.1 General discussion  
The main aims of this work were to investigate the presence of functional TSHR in the skin 
and to investigate the expression of α2 and β5 subunits of thyrostimulin in the skin as a 
potential alternative ligand responsible for TSHR activation.  
 
The full length TSHR transcript was demonstrated by reverse transcription-PCR techniques 
in human skin and mouse skin but not in cultured cells including HaCaT, HCA2 fibroblast, 
3T3L1 pre-adipocyte and 3T3 cell lines. Although the TSHR transcript was expressed in 
human skin, the immunohistochemistry results failed to demonstrate the TSHR protein in the 
epidermis. The opposite was true for the TSHR expression in fibroblast. The RT-PCR of 
cultured fibroblasts did not show the TSHR transcript however, the immunohistochemistry 
showed TSHR protein expression in cells that are most probably fibroblasts. The reason for 
the diverse results could be explained by the following reasons; the culture fibroblasts are at 
an unnaturally high density and, in a monolayer culture instead of being in a 3D matrix of 
extracellular proteins so might show different expression patterns. Alternatively, the skin 
samples used in these IHC experiments were obtained from the Dermatology Department, 
they may be skin adjacent to a lesion and therefore might not entirely normal. 
 
The immunohistochemical data presented in this thesis demonstrated TSHR positive 
fibroblast-like immunostaining most probably of TSHR expressing dermal fibroblasts and a 
similar staining is observed in the dermal tissue surrounding the sebaceous gland and hair 
follicle. These results are in agreement with previous reports which demonstrated TSHR 
expression in dermal fibroblast
132
, cultured fibroblast
53
 and from patient with pretibial 
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myxedema
61
.  According to the immunohistochemistry results presented here , it is intriguing 
to ask whether the TSHR expression is present in the normal resident skin cells 
(keratinocytes, sweat gland, hair follicle or the dermal cells) or is the TSHR expressed in 
some other cells that is brought in to the skin in response to injury, inflammation or, 
autoimmune reaction. Douglas et al, 2010, revealed that the TSHR is expressed in the CD34
+
 
fibrocytes which are wandering stem cells and they showed evidence of the presence of these 
cells in cultured peripheral blood mononuclear cells (PBMC) in patient with Graves’s 
disease. Furthermore, they demonstrated that these cells express TSHR at a level similar to 
the levels found on thyroid epithelium. They showed evidence of CD34
+
 TSHR+ fibrocytes 
infiltrating orbital tissues in situ
184
. These findings may suggest the potential link of CD34+ 
TSHR+ fibrocyte infiltration and their potential participation in the pathogenesis of the 
Graves’ disease184.  In addition, our results and others may provide evidence to support the 
suggestion that the dermal fibroblasts may present the autoantigen against which TSHR 
autoantibodies are generated
53,61,126,133,185,43,132,184,186
. 
 
 
The chapter three results demonstrated positive immunostaining of the TSHR expressing 
fibroblast with A9 antibody. However, there was much less clear cut immunostaining with 
A7 antibody. It is of interest to mention that both Rapoport et al, 2000
61
 and Cianfarani  et al, 
2010
132
 have used A9 antibody which recognises the 147-228 residues of TSHR ECD to 
show the TSHR expression in dermal fibroblast, In addition,  Bell et al, 2000
187
  used “anti- 
TSHR (352-366) antibody” which recognises the ECD of the TSHR. Collectively, that could 
suggest that the TSHRV only is expressed in these fibroblast like cells rather than the full 
length TSHR, these results are further supported by a study by Paschke R and colleagues in 
1994 who reported that the TSHR variant transcript is expressed in skin fibroblast
141
. In this 
context, it is important to mention that the A7 antibody is able to detect the epitope very close 
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to the membrane spanning region and it might be difficult for antibodies to have access to an 
epitope which is within the membrane spanning region as it really could be on the inside of 
the cell.  Although it should be noted that the A7 epitope is predicted to be just outside the 
cell in the part of the membrane spanning region which forms the disulphide bonds with the 
extracellular domain of the TSHR, which in turn could prevent the antibody binding by a 
process known as steric hindrance.     
 
In addition, positive TSHR immunostaining was demonstrated in periglandular myoepithelial 
cells of sweat glands in human skin. This is in agreement with the report from Bodo et al, 
2009, who showed TSHR expression in the myoepithelial sweat gland
133
.  It is well known 
that patients with hyperthyroid status, whether due to TSHR binding to its natural ligand, 
TSH, or because of pathological autoimmune antibodies in Graves’ disease, experience 
excessive sweating (hyperhydrosis). There is no specific treatment for excessive sweating in 
Graves’ disease. This raises the question, is the excessive sweating due to increase in the 
overall metabolic rate or is it due to TSHR signalling (activation) in the skin which might 
explain the hyperhydrosis in autoimmune Graves’ disease. It is obvious that skin involvement 
in thyroid disease is very site specific and there are still many questions to be answered: Is 
there aberrant TSHR expression in all skin sites or is there something special about certain 
skin sites, which may explain why only particular areas are involved in Graves’ disease. Is 
there an elevated level of TSHR in these sites and, if so what triggers the increase in 
expression.  It would be interesting to investigate and compare the skin from different sites in 
the body for the expression of TSHR.  
 
The RT-PCR data in chapter two showed highest levels of TSHR gene expression associated 
with early anagen, reducing to low levels in late anagen when the hair follicles have achieved 
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their full length and reducing still further in telogen when adipogenesis is quiescent.  These 
results are in agreement with several other studies where TSHR transcript and protein are 
shown to be expressed in scalp hair follicle and hair follicle mesenchymal 
compartment
131,133,165,188
.  
 
The TSHR variant was only demonstrated in mouse skin and at different stages of the hair 
cycle but not in human skin or cultured cells (chapter two). This suggests that the TSHRV 
transcript expression could be involved in the hair cycle as the human skin samples used (non 
scalp skin) had few or no hair follicles compared with the dense pelage of mouse skin.  
 
Although TSHR expression was not observed in undifferentiated 3T3L1, RT-PCR of cells 
during adipogenesis showed TSHR transcript on day 7 when adipogenesis is clearly apparent 
in these cells. The TSHRV expression occurs earlier at day 3 and persists until day 10, longer 
than TSHR. Previous studies have also shown an increase in TSHR during 3T3L1 cell 
differentiation
155,189,190
. This may offer a potential alternative explanation for elevated TSHR 
in the mouse anagen stage; that it may be associated with adipogenesis. Other reports which 
support this interpretation include elevated TSHR expression in 3T3L1 differentiation, rat 
preadipocytes and orbital fibroblasts undergoing adipogenesis 
189,191,192,193
.  
 
With the generally elevated levels of TSHR and of TSHRV seen during 3T3L1 
differentiation there is clearly a need to investigate whether the relative levels of these two 
isoforms significantly controls the level of signalling through the TSHR. The synchronised 
hair cycle in mouse could explain why the levels of TSHRV are higher in mouse than human 
since the adipose tissue will need to be more dynamic.  
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These experiments have shown that TSHR expression is increased (transcript and protein 
levels) during lineage specific differentiation (adipogenesis), one would ask does this mean 
that TSH is important for helping cells going through differentiation decide which kind of 
differentiation route they want to follow or is it just an artefact of the fact that they are about 
to go through differentiation, because many other kinds of receptors are upregulated as well.  
Studies have suggested that TSHR is functional during adipogenesis
80,155,187
, but being 
functional in biochemical sense does not mean functional in biological sense for controlling 
cell differentiation.  The presence of functional TSHR in preadipocytes raises the possibility 
of a novel role for TSHR signalling in  cell differentiation but further analysis is required to 
investigate whether TSHR is functional in differentiating cells or not.   
 
Generally, patients with hyperthyroidism have TSHR activation and high levels of thyroid 
hormones, whereas, hypothyroid patients have TSHR activation and low levels of thyroid 
hormone levels. These two factors may contribute to the differences in the skin changes in 
each case. The TSHR expression shown here together with the findings of other 
studies
53,132,133
, suggest that the circulating TSHR auto-antibodies may participate together 
with the abnormal levels of thyroid hormones towards the skin and hair changes associated 
with Graves’ disease and this might suggest that some forms of this disease may be due to a 
direct autoimmune response towards cutaneous TSHR and increased signalling through the 
TSHR has to be considered as an intriguing possibility. TSHR expression in the hair follicle 
could be a direct target of the autoantibody and could explain the alopecia areata in patients 
with Graves’s disease133. The pretibial myxedema in Graves’ hyperthyroidism and a more 
generalised myxedema in Hashimoto’s hypo-thyroidism62,65,81, could also be partly due to 
direct effect of the autoimmune antibodies towards the TSHR in the dermal fibroblast and 
preadipocytes
61
. Pretibial myxedema is a relatively rare event and only occurs in some 
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patients with thyroid disease. Considering the elevation of TSHR in 3T3L1 differentiation, 
certain conditions such as wound healing may be required to elevate TSHR to critical levels 
in dermal fibroblasts to cause autoimmune driven disease. Furthermore, TSHR signalling 
could also explain some of the other skin symptoms associated with thyroid disorders for 
instance, the epidermal melanocyte could explain the pigmentation in Graves’ disease as an 
intercellular mediator, and it might also explain vitiligo as TSHR could turn melanocyte to a 
target for the autoimmune antibodies
53
.   
 
Studies demonstrated thyrostimulin expression in skin and, in vivo and in vitro data showed 
that this new hormone is capable of forming a dimer and may compete with TSH for 
TSHR
144,153
. The higher affinity of thyrostimulin to TSHR
144
 suggests the potential role for 
thyrostimulin as an alternative ligand rather than TSH in the normal functioning of TSHR 
signalling in the skin. In this study, the α2 & β5 thyrostimulin subunits transcripts were 
readily expressed in human and α2 subunit in mouse skin, cultured HaCaT, HCA2 fibroblast 
cell lines and in some mouse tissues.   
 
Since the data in chapter two confirms the expression of thyrostimulin in α2 subunit mouse 
skin, it would be interesting to study whether the thyrostimulin is expressed during the mouse 
hair cycle and to investigate if the level of expression varies in relation to 3T3L1 
differentiation which would support the suggestion of thyrostimulin might be the alternative 
ligand of TSHR signalling and illustrates the need for good thyrostimulin antibody. The β5 
antibody we produced is able to detect exogenous β5 in transfected fibroblasts and may be 
able to bind the endogenous subunit (if present). The RT-PCR data shown in chapter two 
confirms the expression of α2 thyrostimulin transcript in the skin. This underlines the need 
for α2 antibody to investigate the site of α2 expression in the skin.   
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The current modalities for treatment of Graves’ disease are anti-thyroid medications, 
radioactive iodine, or surgery, each treatment has shown to be effective and well tolerated by 
the patients
194
. However, there is a significant rate of relapse especially with anti-thyroid 
medications and radioactive iodine
195
. Recently, Neumann et al, 2011 suggested a small 
molecule antagonist which inhibits Graves’ disease antibody activation of the TSH 
Receptor
171,196
. If these antagonists were administered to those patients with hyper active 
autoimmune thyroid, the autoantibody would no longer bind to TSHR either in thyroid or in 
the extra thyroidal locations, such as orbital and dermal fibroblasts, sweat gland and hair 
follicle. It would not only make the patients euthyroid but would also improve the clinical 
outcome of the other extrathyroidal symptoms which are sometimes difficult to treat and may 
also improve the quality of life of those patients. 
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5.2 Recommendation and future work 
There are two important issues that need to be investigated in more detail. Firstly, the full 
length TSHR and the TSHR variant have completely opposite roles and the balance between 
these two isoforms is very important. When TSH, stimulating antibodies or thyrostimulin 
bind to the signalling competent full length TSHR receptor this will have an effect on the 
cell. However, when TSH, stimulating antibodies or the thyrostimulin bind the TSHR variant, 
as the TSHR variant is not attached to the cell there will be no signal and therefore its 
activation will have no effect on the cell. Thus, the balance between the two could be very 
important for how much TSHR activation happens even in the cell type where there is a lot of 
full length receptor such as the thyroid gland itself, and to our knowledge this area has not 
been explored before. It would be interesting to investigate and compare balance between 
these two isoform and probably the way to do that is to use the q-PCR method for full length 
TSHR and TSHR variant expression in well characterized cells like thyroid follicular cells or 
the 3T3L1 as a starting point.  
 
Secondly, the results in this work suggested that the TSHR and the TSHRV are expressed in 
mouse hair cycle and it would be interesting to investigate the gene expression of these two 
isoforms in more depth. Probably by studying the gene expression in different stages of hair 
cycle in TSHR knockout mouse and the hair cycle in mice model with mutated TSHR known 
as (hyt/hyt) mouse.  
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Appendix 
 
 
Full length human thyroid stimulating hormone receptor (TSHR), transcript variant 1, mRNA 
sequence showing  position of primers used in different studies including this study:  
 
NCBI Reference Sequence: NM_000369.2, Chr14:81421869-81612646 
    CCTCCTCCAC AGTGGTGAGG TCACAGCCCC TTGGAGCCCT CCCTCTTCCC  50 
ACCCCTCCCG CTCCCGGGTC TCCTTTGGCC TGGGGTAACC CGAGGTGCAG  100 
AGCTGAGAAT GAGGCGATTT CGGAGGATGG AGAAATAGCC CCGAGTCCCG  150 
TGGAAAATGA GGCCGGCGGA CTTGCTGCAG CTGGTGCTGC TGCTCGACCT  200 
GCCCAGGGAC CTGGGCGGAA TGGGGTGTTC GTCTCCACCC TGCGAGTGCC  250 
ATCAGGAGGA GGACTTCAGA GTCACCTGCA AGGATATTCA ACGCATCCCC  300 
AGCTTACCGC CCAGTACGCA GACTCTGAAG CTTATTGAGA CTCACCTGAG  350 
AACTATTCCA AGTCATGCAT TTTCTAATCT GCCCAATATT TCCAGAATCT  400 
ACGTATCTAT AGATGTGACT CTGCAGCAGC TGGAATCACA CTCCTTCTAC  450 
AATTTGAGTA AAGTGACTCA CATAGAAATT CGGAATACCA GGAACTTAAC  500 
TTACATAGAC CCTGATGCCC TCAAAGAGCT CCCCCTCCTA AAGTTCCTTG  550 
GCATTTTCAA CACTGGACTT AAAATGTTCC CTGACCTGAC CAAAGTTTAT  600 
TCCACTGATA TATTCTTTAT ACTTGAAATT ACAGACAACC CTTACATGAC  650 
GTCAATCCCT GTGAATGCTT TTCAGGGACT ATGCAATGAA ACCTTGACAC  700 
TGAAGCTGTA CAACAATGGC TTTACTTCAG TCCAAGGATA TGCTTTCAAT  750 
GGGACAAAGC TGGATGCTGT TTACCTAAAC AAGAATAAAT ACCTGACAGT  800 
TATTGACAAA GATGCATTTG GAGGAGTATA CAGTGGACCA AGCTTGCTGG  850 
ACGTGTCTCA AACCAGTGTC ACTGCCCTTC CATCCAAAGG CCTGGAGCAC  900 
CTGAAGGAAC TGATAGCAAG AAACACCTGG ACTCTTAAGA AACTTCCACT  950 
TTCCTTGAGT TTCCTTCACC TCACACGGGC TGACCTTTCT TACCCAAGCC  1000 
ACTGCTGTGC TTTTAAGAAT CAGAAGAAAA TCAGAGGAAT CCTTGAGTCC  1050 
TTGATGTGTA ATGAGAGCAG TATGCAGAGC TTGCGCCAGA GAAAATCTGT  1100 
GAATGCCTTG AATAGCCCCC TCCACCAGGA ATATGAAGAG AATCTGGGTG  1150 
ACAGCATTGT TGGGTACAAG GAAAAGTCCA AGTTCCAGGA TACTCATAAC  1200 
AACGCTCATT ATTACGTCTT CTTTGAAGAA CAAGAGGATG AGATCATTGG  1250 
TTTTGGCCAG GAGCTCAAAA ACCCCCAGGA AGAGACTCTA CAAGCTTTTG  1300 
ACAGCCATTA TGACTACACC ATATGTGGGG ACAGTGAAGA CATGGTGTGT  1350 
ACCCCCAAGT CCGATGAGTT CAACCCGTGT GAAGACATAA TGGGCTACAA  1400 
GTTCCTGAGA ATTGTGGTGT GGTTCGTTAG TCTGCTGGCT CTCCTGGGCA  1450 
ATGTCTTTGT CCTGCTTATT CTCCTCACCA GCCACTACAA ACTGAACGTC  1500 
CCCCGCTTTC TCATGTGCAA CCTGGCCTTT GCGGATTTCT GCATGGGGAT  1550 
GTACCTGCTC CTCATCGCCT CTGTAGACCT CTACACTCAC TCTGAGTACT  1600 
ACAACCATGC CATCGACTGG CAGACAGGCC CTGGGTGCAA CACGGCTGGT  1650 
TTCTTCACTG TCTTTGCAAG CGAGTTATCG GTGTATACGC TGACGGTCAT  1700 
CACCCTGGAG CGCTGGTATG CCATCACCTT CGCCATGCGC CTGGACCGGA  1750 
AGATCCGCCT CAGGCACGCA TGTGCCATCA TGGTTGGGGG CTGGGTTTGC  1800 
TGCTTCCTTC TCGCCCTGCT TCCTTTGGTG GGAATAAGTA GCTATGCCAA  1850 
AGTCAGTATC TGCCTGCCCA TGGACACCGA GACCCCTCTT GCTCTGGCAT  1900 
ATATTGTTTT TGTTCTGACG CTCAACATAG TTGCCTTCGT CATCGTCTGC  1950 
TGCTGTTATG TGAAGATCTA CATCACAGTC CGAAATCCGC AGTACAACCC  2000 
AGGGGACAAA GATACCAAAA TTGCCAAGAG GATGGCTGTG TTGATCTTCA  2050 
CCGACTTCAT ATGCATGGCC CCAATCTCAT TCTATGCTCT GTCAGCAATT  2100 
CTGAACAAGC CTCTCATCAC TGTTAGCAAC TCCAAAATCT TGCTGGTACT  2150 
CTTCTATCCA CTTAACTCCT GTGCCAATCC ATTCCTCTAT GCTATTTTCA  2200 
CCAAGGCCTT CCAGAGGGAT GTGTTCATCC TACTCAGCAA GTTTGGCATC  2250 
TGTAAACGCC AGGCTCAGGC ATACCGGGGG CAGAGGGTTC CTCCAAAGAA  2300 
CAGCACTGAT ATTCAGGTTC AAAAGGTTAC CCACGAGATG AGGCAGGGTC  2350 
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TCCACAACAT GGAAGATGTC TATGAACTGA TTGAAAACTC CCATCTAACC  2400 
CCAAAGAAGC AAGGCCAAAT CTCAGAAGAG TATATGCAAA CGGTTTTGTA  2450 
AGTTAACACT ACACTACTCA CAATGGTAGG GGAACTTACA AAATAATAGT  2500 
TTCTTGAATA TGCATTCCAA TCCCATGACA CCCCCAACAC ATAGCTGCCC  2550 
TCACTCTTGT GCAGGCGATG TTTCAATGTT TCATGGGGCA AGAGTTTATC  2600 
TCTGGAGAGT GATTAGTATT AACCTAATCA TTGCCCCCAA GAAGGAAGTT  2650 
AGGCTACCAG CATATTTGAA TGCCAGGTGA AATCAAAATA ATCTACACTA  2700 
TCTAGAAGAC TTTCTTGATG CCAAGTCCAG AGATGTCATT GTGTAGGATG  2750 
TTCAGTAAAT ATTAACTGAG CTATGTCAAT ATAGAGCTTC TCAGTTTTGT  2800 
ATAACATTTC ATACTAAAGA TTCAGCAAAT GGAAAATGCT ATTAATTTGG  2850 
TTGGTGACCA CAAGATAAAA TCAGTCCCAC GTTGGCTCAG TTCAACTAGA  2900 
TGTTCCCTGA TACAAAGAGA ACTTGATTTC CTTAAAACTG AAAAGCCAAA  2950 
CACAGCTAGC TGTCATACAA GAAACAGCTA TTATGAGACA TGAAGGAGGG  3000 
TAAGAATTAG CTTTAAGTTT TGTTTTGCTT TGTTTTGTTT TTTAACTCAA  3050 
CCTATTAATC ATCTCTTCAC AAGAATCCAC CTGATGTGAC CAAGCTATTA  3100 
TGTGTTGCCT GGAAAAACTG GCAAGATTTC AGCTTATGTG GCCTAGCAAA  3150 
CTAAGAATTG CTCTTCTTGG CCAGCCTCAT AGCATAAAAG ATGTGAACTC  3200 
TAGGAAGTCT TTCTGAGTAG CAATAAGTGG GAATTATGGG CAGAGCACAC  3250 
TCAATCCCCT GTTGATTAAT AAAACAGGCT GGACACTAAT TAACTATGGG  3300 
ACTTAAATCT GTAGAAATGA AGGAGTCCAA TAGCTTCTTC CAATTTTAAA  3350 
ACTCTAGTAC ATCCCTTTCC CTCAAATATA TATTTCTAAG ATAAAGAGAA  3400 
AGAAGAGCAC TAAGTAAGTA GAATCTGTTT TTCCTATTTT GTAGGGCTGC  3450 
TGACTCCTAG TCCTTGAAGC CTAGACACAT GACCCAGGAA ATTTTTCCTT  3500 
TGTTTCACTT TTGATTATGA TGTCTGAGCC AAAAATTCAA TTAAGTAAAC  3550 
ATACTCGCCT GGATCTGAAT CATTCATTTA ATTACTAGAT CTACCCAGCT  3600 
GTTATATCAG GCCAAAAACA GATTCGTGTT TATATAAAAG AGTAAACGAT  3650 
GGTTGCAAAT TTTGGCTATT TAGAGTTGCT ACTTCACTAT GAAGAGTCAC  3700 
TTCAAAACAC TTCGCTTGTC TTTAGGGATG ATTTTTGCCA TTTCCAGTCC  3750 
ACGGTATGAT ACTAAAGCTG TCAAGAGAGG TTTCTTCTTT TCTGAAACTG  3800 
CCAGCTCTTT CCAGCCCTGT TGATCACTGG ACATAAAGCT TCTTTTCCCC  3850 
AATAATTCTT CTTTACTTAA AATAGTCAGG ATCTTTATCT ACAGATGTAC  3900 
TCTCCAGGTT ACCTGTGATG ATAGCCCCCT AATGTCCTGC TAGAAAAGTC  3950 
TCCAAGCAGA GATGACATTA CTTCTGAATG CTCATAAACC ACACCATGAA  4000 
ATAAAAGCTC TTTGTTGTTT TAAGATTGTG AAGTGTCGTT AATGGGTCCC  4050 
CACAGATGGT CCCTGCTGGA CTCACCTGGA ATCTCTCCAC AGCCATACCC  4100 
ACTCATCACT ATCATTGAGA CCTGCACATC TTAATAGAAA TATTATAAAC  4150 
ATCGAAAATC ATGACTTACC TAGAAGTTCG CTTGTAACTA ATGAAATTAA  4200 
ACAAATGTGT TGCCTTTTGT CATGTGTTTC TCTCCTGTGA CATTTCAAAA  4250 
TATCACATCT TGATAAATAA TGTGTTTCAT CTTGAATAGC TGAACTAATT  4300 
GCTTTGGAAA CAGAGTCCTA GAAAAGTGAC TTCAACAGAA TTGTTACTAA  4350 
AATTTGCACT CACAACATGA AATAAATTTT CTTCCTATGG AATAATCGTG  4400 
    Aaaaaaaaaa 
 
 
 Figures 7.1 Human TSHR sequence gene showing the position of primers used in different 
syudies.  The  primers used in a various reports to amplify hTSHR  were colour coded,  Solminski et 
al,2002
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  (first pair of primers),  Solminski et al,2002
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Human thyroid stimulating hormone receptor variant (TSHRV), transcript variant 2, mRNA 
sequence showing position of primers used in study:  
 
NCBI Reference Sequence: NM_001018036.2, Chr14:81421869-81575286 
 
CCTCCTCCAC AGTGGTGAGG TCACAGCCCC TTGGAGCCCT CCCTCTTCCC  50 
ACCCCTCCCG CTCCCGGGTC TCCTTTGGCC TGGGGTAACC CGAGGTGCAG  100 
AGCTGAGAAT GAGGCGATTT CGGAGGATGG AGAAATAGCC CCGAGTCCCG  150 
TGGAAAATGA GGCCGGCGGA CTTGCTGCAG CTGGTGCTGC TGCTCGACCT  200 
GCCCAGGGAC CTGGGCGGAA TGGGGTGTTC GTCTCCACCC TGCGAGTGCC  250 
ATCAGGAGGA GGACTTCAGA GTCACCTGCA AGGATATTCA ACGCATCCCC  300 
AGCTTACCGC CCAGTACGCA GACTCTGAAG CTTATTGAGA CTCACCTGAG  350 
AACTATTCCA AGTCATGCAT TTTCTAATCT GCCCAATATT TCCAGAATCT  400 
ACGTATCTAT AGATGTGACT CTGCAGCAGC TGGAATCACA CTCCTTCTAC  450 
AATTTGAGTA AAGTGACTCA CATAGAAATT CGGAATACCA GGAACTTAAC  500 
TTACATAGAC CCTGATGCCC TCAAAGAGCT CCCCCTCCTA AAGTTCCTTG  550   
GCATTTTCAA CACTGGACTT AAAATGTTCC CTGACCTGAC CAAAGTTTAT  600 
TCCACTGATA TATTCTTTAT ACTTGAAATT ACAGACAACC CTTACATGAC  650 
GTCAATCCCT GTGAATGCTT TTCAGGGACT ATGCAATGAA ACCTTGACAC  700 
TGAAGCTGTA CAACAATGGC TTTACTTCAG TCCAAGGATA TGCTTTCAAT  750 
GGGACAAAGC TGGATGCTGT TTACCTAAAC AAGAATAAAT ACCTGACAGT  800  
TATTGACAAA GATGCATTTG GAGGAGTATA CAGTGGACCA AGCTTGCTGC  850  
TACCTCTTGG AAGAAAGTCC TTGTCCTTTG AGACTCAGAA GGCCCCACGC  900 
TCCAGTATGC CATCATGATG CCTGCTAAGG CAGCCACCTT GGTGTACATG  950 
CTCACAGAGG CTCTGTTCAT GGAGCAGCTG CTGTTTGAAA AATTTTGAAA  1000 
TGCAAGATCC ACAACTAGAT GGAAGGCACT CTAGTCTTTG CAGAAAAAAA  1050 
TGTACCTGAA TGTACATTGC ACAATGCCTG GCACAAAGAA GGAAGAATAT  1100 
AAATGATAGT TCGACTCGTC TGTGGAAGAA CTTACAATCA TGGGGAAAGA  1150 
TGGAATAAAA ACATTTTTTA AACAGCATGa aaa 
 
Figure 7.2: Human TSHR variant 2 sequence. TSHRV spans exons1-8 plus 22 amino 
acids in the beginning of exon 9, sparing the transmembrane part of full length TSHR. Red is 
untranslated region (intron), blue is transulated region (exons). Yellow highlight represents 
the primers used in this project, forward primer is in exons 4/5 and reverse primer is in the 
unique sequence in intron between exons 8/9 of 1.3 variant form.  
  
 
 
